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Overview 
Telomeres are non-coding TTAGGG repeats that complex with six key proteins to protect the 
ends of eukaryotic chromosomes (19, 42) (Figure 1). The number of telomeric repeats, 
known as the telomere length (TL), varies greatly between species, populations, individuals, 
and cell types (20, 43). This variation is due to many factors including genetic differences 
(146), cellular replicative history (60), inflammation (29), oxidative stress (157), and 
environmental factors, such as excess caloric intake (169) and alcohol consumption (120). 
Importantly, telomeres must remain above a certain length to prevent the triggering of 
senescence or apoptosis in all eukaryotic cells (21, 23). As a result of this central role in cell 
viability, telomere shortening is involved in developmental processes (134), aging (8), and 
the pathogenesis of age-related diseases (21). Most TL measurements are from circulating 
leukocytes (120, 155, 169) due, primarily, to the relative ease of acquiring blood samples (9). 
Emerging evidence, however, of tissue-specific TLs (43, 67, 86), high intra-individual 
variance in TL (43), and the substantial overlap of risk factors for many diseases and short 
leukocyte telomeres (52), highlights the need to measure TL in appropriate cell types. This 
Chapter focuses on TL in the heart and its relevance to heart development, function, and 
disease (particularly cardiac hypertrophy and heart failure). 
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Figure 1. A representation of the telomere sequence and key protective proteins. The 5’ 
vertebrate telomere sequence is TTAGGG and is around 1.5-15 kilo bases (kb) in length in 
humans and 20-40 kb in most rodents. This includes a single-stranded G-rich overhang of 
around 200 nucleotides (nt) (19, 20). Six key proteins also bind to the telomere sequence and 
two to the G-rich overhang to prevent linear ends from being recognised as damaged DNA 
(42). Image produced using motifolio. TRF1, telomere repeat-binding factor 1; TRF2, 
telomere repeat-binding factor 2; POT1, protection of telomeres 1; TIN2, TRF1 interacting 
nuclear factor 2; TPP1, tripeptidyl-peptidase 1; RAP1, repressor/activator protein 1. 
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Heart disease (also known as cardiovascular disease) is an umbrella term for all heart-
related disorders and the worldwide leading cause of death (99). A degenerative and 
irreversible form of heart disease, known as heart failure, occurs when the heart cannot 
adequately supply blood to the body (114). This increasingly common disease is caused by 
the gradual loss of cardiomyocytes (also known as cardiac myocytes, cardiocytes, or simply 
myocytes in the context of the heart), highly-specialised heart cells that produce the 
contractions (72, 84, 113, 115). Several other heart diseases, such as atherosclerosis (a 
hardening and narrowing of the arteries), myocardial infarction (MI) (inadequate blood 
supply to the heart), and hypertension (high blood pressure) can lead to heart failure through 
the development of cardiac hypertrophy (discussed below) (50, 155). Furthermore, heart 
failure can predispose to other heart diseases such as arrhythmias (disorders of impulse 
generation and conduction) and sudden cardiac death (the abrupt loss of heart function) (47, 
155). Therefore, despite this complex interplay, the loss of cardiomyocytes is an overarching 
pathogenic feature of heart disease and has prompted researchers to identify mechanisms 
involved in the survival and replication of these cells. As short telomeres lead to senescence 
and, ultimately, apoptosis (21), several studies have measured TL in cardiomyocytes and 
heart tissue (Table 1) as a way of providing insights into cardiac function and viability. In this 
regard, early research showed that TL reflected the replicative history and proliferative 
potential of rat hearts in vivo (71). A following study on human heart failure revealed that 
cardiomyocytes with telomeres less than 2.5kb in length expressed the senescent marker p16 
(also known as p16INK4a and tumour suppressor cyclin-dependent kinase inhibitor 2a) (35). In 
various strains of mice, the pro-apoptotic transcription factor and tumour suppressor protein, 
p53, was found to be up-regulated in cardiomyocytes with the shortest telomeres (81, 148). 
These findings demonstrate that telomere-induced senescence and apoptosis is associated 
with cardiomyocyte loss and heart disease. 
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Table 1. A summary of the available articles measuring TL in the heart. Animal studies 
are listed first and ordered by species, followed by human studies, which are ordered by 
sample type. The different methods for measuring TL are reviewed elsewhere (102). 
Animal models 
Species Principle findings 
Method of 
telomere 
measurement 
Lead author 
and year of 
publication 
Fischer 344 
rats 
Some cardiomyocytes divide throughout 
life to counteract cell loss. The percentage 
of cardiomyocytes with short telomeres 
increases with age. 
Confocal 
microscopy 
Kajstura, 
2000 (71) 
Female Fischer 
334 rats 
CSC transfusion promotes the 
regeneration of cardiomyocytes and 
improves the survival of rats exposed to 
the anti-cancer drug doxorubicin. 
qFISH 
De Angelis, 
2010 (41) 
Male Fischer 
334 rats 
Age shortens CSC telomeres but some 
functional CSCs remain in senescent heart 
and produce young cardiomyocytes.  
qFISH and 
confocal 
microscopy 
Gonzalez, 
2008 (57) 
Sprague-
Dawley rats 
Forced Tert expression increased cardiac 
TL and decreased apoptosis.  
Southern blot 
Oh, 2001 
(112) 
Sprague-
Dawley rats 
12-months of low-dose Staphylococcus 
aureus to promote inflammation 
decreased cardiac TL but did not affect 
heart function. 
qPCR 
Raymond, 
2014 (126) 
Male Sprague-
Dawley rats 
The antioxidants EGCG, quercetin, and 
carvedilol prevented cardiomyocyte 
telomere attrition and apoptosis after 
abdominal aortic constriction.  
Southern blot 
Sheng, 2011 
(138) 
Male Sprague-
Dawley rats 
Six months of daily beta adrenergic 
receptor activation decreased left ventricle 
function but did not change cardiac TL.  
qPCR 
Raymond, 
2013 (125) 
Male Sprague-
Dawley rats 
Ethanol in the drinking water caused 
cardiomyocyte apoptosis and LV dilation 
but did not affect cardiac TL. 
qPCR 
Raymond, 
2016 (124) 
Male Dahl salt-
sensitive rats 
Repetitive hyperthermia attenuates cardiac 
telomere attrition in salt-induced 
hypertension. 
Dot blot 
Oyama, 2012 
(117) 
DahlS.Z-
Leprfa/Leprfa 
rats 
TL in cardiomyocytes did not differ 
between lean and obese salt-sensitive rats.  
Southern blot 
Takahashi, 
2014 (144) 
Male Otsuka 
Long-Evans 
Tokushima 
fatty rats 
Insulin resistant rats present with 
increased cardiac fibrosis and decreased 
telomerase activity (which can be 
ameliorated with PPAR-ƴ activation) but 
no changes in cardiac TL. 
Dot blot 
Makino, 2009 
(88) 
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Male Wistar 
rats 
The anti-cancer drug doxorubicin induces 
oxidative stress and shortens 
cardiomyocyte TL. 
qFISH 
Maejima, 
2008 (87) 
Male Wistar 
rats 
Severe renal failure shortens cardiac 
telomeres similarly to myocardial 
infarction.  
qPCR 
Wong, 2009 
(164) 
Hypertrophic 
heart rats 
Cardiac and cardiomyocyte TL was 
shorter at the onset of hypertrophy but 
longer at birth and in the presence of 
established hypertrophy.  
qPCR 
Marques, 
2016 (91) 
H9c2 cells 
EGCG inhibited telomere shortening in 
H2O2-induced oxidative injury. 
Southern blot 
Sheng, 2010 
(139) 
Terc-/- mice 
Telomere shortening impaired cell 
division and increased cardiomyocyte 
apoptosis and hypertrophy. 
Confocal 
microscopy 
Leri, 2003 
(81) 
IGF-1 mice 
IGF-1 mice have longer cardiomyocyte 
telomeres, less CSC senescence, and 
increased cardiomyocyte replacement 
throughout life.   
qFISH and 
confocal 
microscopy 
Torella, 2004 
(148) 
C57Bl6 mice 
The young mouse heart contains 
cardiomyocytes with different TLs but the 
proportion of cells with short telomeres 
increases with age. 
Confocal 
microscopy 
Rota, 2007 
(131) 
C57/Bl6, 
eNOS-/-, and 
Tert-/- mice 
Cardiomyocyte TL was the same in 3-
week and 6-month old sedentary and 
exercised mice. 
Flow FISH 
Werner, 2008 
(160) 
H/M-SOD2−/− 
mice 
The superoxide dismutase and catalase 
mimetic EUK-8 inhibited changes typical 
of dilated cardiomyopathy but did not 
affect cardiac TL. 
Dot blot 
Makino, 2010 
(89) 
CAST/Ei mice 
Age-associated cardiac telomere 
shortening was attenuated after 44 weeks 
of voluntary exercise.  
qPCR and 
Southern blot 
Ludlow, 2012 
(86) 
friend leukemia 
virus B inbred 
strain mice 
Pim-1 overexpression transiently 
increases CSCs TL and proliferation. 
qFISH and 
confocal 
microscopy 
Cottege, 2012 
(38) 
Male C57BL/6, 
miR-34a-/-, and 
miR-34a-/+ 
mice 
The microRNA miR-34a causes 
cardiomyocyte telomere attrition and 
apoptosis.  
qPCR 
Boon, 2013 
(25) 
Mdx/Terc-/- 
mice 
Only mice with a genetic deficiency of 
dystrophin and Terc develop heart 
disease.  
qFISH 
Mourkioti, 
2013 (106) 
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FVB/N, 
C57/BL6,  
Tert-/-, and 
Tert+/- mice 
Overexpression of Tert in the heart 
rescues short telomeres and increases 
proliferation in mouse cardiomyocytes.  
qFISH 
Bär, 2014 
(12) 
Terc-/- and  
p21-/- mice 
Cardiomyocyte TL decreases rapidly in 
the first 15 days of life, pushing 
cardiomyocytes out of the cell cycle.  
qFISH Aix, 2016 (3) 
Male C57BL/6 
mice 
The senescent heart is characterised by 
quiescent CSCs with intact telomeres. 
Stem cell factor can stimulate CSC 
proliferation.  
qFISH and 
confocal 
microscopy 
Sanada, 2014 
(133) 
FoxO1+/- mice 
Cardiac TL was decreased in FoxO1+/- 
mice fed ad libitum compared to caloric 
restricted littermates.  
Dot blot 
Makino, 2015 
(90) 
H/M-SOD2−/− 
mice 
EGCG prevented cardiac telomere 
shortening and prolonged survival of 
H/M-SOD2−/− mice.  
Dot blot 
Oyama, 2016 
(118) 
Male Schlager 
BPH/2J and 
BPN/3J mice 
Telomere attrition in the heart occurs after 
the development of hypertension. 
qPCR 
Chiu, 2016 
(36) 
Bmal1-/- mice 
Antioxidant treatment protects cardiac 
telomeres from oxidation but does not 
significantly reduce telomere attrition. 
qPCR 
Hemmeryckx, 
2016 (62) 
Dogs 
TL did not change in cardiomyocytes that 
were paced to mimic dilated 
cardiomyopathy after 1, 3, and 4 weeks.  
Southern blot 
and qFISH 
Leri, 2001 
(80) 
Birds (zebra 
finches) 
TL in the heart is correlated with TL in 
red blood cells. 
qPCR 
Reichert, 
2013 (127) 
Birds (siskins) 
Malaria infection shortens cardiac TL in 
parallel with other major organs. 
qPCR 
Asghar, 2016 
(10)  
Zebrafish 
Telomerase activity and TL increase after 
cardiac injury but in telomerase-
knockouts cardiac cells do not proliferate 
and repair the heart after injury.  
qFISH and 
confocal 
microscopy 
Bednarek, 
2015 (14) 
Human studies 
Sample type Principle findings 
Method of 
telomere 
measurement 
Lead author 
and year of 
publication 
Fetuses 
TL is the same in the kidney, liver, and 
heart during early embryonic development 
but then significantly shortens in the heart. 
Modified 
Southern blot 
Ulaner, 2001 
(151) 
Fetal 
cardiomyocytes 
TL is not associated with the senescence 
of fetal cardiomyocytes in vitro.  
Southern blot 
Ball, 2005 
(11) 
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Biopsies 
Telomere shortening and subsequent 
senescence in CSCs characterises heart 
disease.  
Confocal 
microscopy 
Chimenti, 
2003 (35) 
Biopsies 
Average CSC TL was 7.5kb, more than 
three times longer than senescent cells. 
Autologous CSC infusion post MI 
decreased infarct area and improved heart 
function.  
qFISH and 
Flow FISH 
Bolli, 2011 
(24) 
Biopsies 
CSCs expressing only IGF-1R had longer 
telomeres and reduced apoptosis.  
Flow FISH 
D'Amario, 
2011 (39) 
Biopsies 
The growth properties of CSCs in heart 
failure are similar to those in the normal 
heart. 
Flow FISH 
D'Amario, 
2011 (40) 
Biopsies and 
cadavers 
Myogenic CSCs increased >13 fold in 
aortic stenosis. Cardiomyocyte 
hyperplasia contributes to increased 
cardiac mass. 
Southern blot 
Urbanek, 
2003 (152) 
Biopsies and 
cadavers 
Cardiomyocyte apoptosis is associated 
with short telomeres, defective TRF2, and 
Chk2 activation. Interference with TRF2 
shortens telomeres in nondividing 
cardiomyocytes.  
Southern blot 
Oh, 2003 
(113) 
Biopsies and 
cadavers 
CSC mitotic index increased 14-fold in 
chronic and 29-fold in acute infarcts. 
There were more CSCs with short 
telomeres in chronic and acute infarcts, 
reducing the number of functional CSCs. 
Confocal 
microscopy 
Urbanek, 
2005 (153) 
Biopsies and 
cadavers 
CSCs can be isolated and expanded in 
vitro with only a 130bp reduction in TL 
per population doubling. 
Confocal 
microscopy 
Bearzi, 2007 
(13) 
Cadavers 
CSCs with short telomeres produce 
senescent progeny. Females CSCs have 
longer telomeres and greater replicative 
potential than males. 
qFISH and 
confocal 
microscopy 
Kajstura, 
2010 (70) 
Cadavers 
TL is not correlated with tissue turnover 
in vivo. The heart typically has the longest 
telomeres of all major organs.  
Southern blot 
Takubo, 2002 
(146) 
Cadavers 
Average yearly telomere attrition rate in 
the myocardium is 20bp. TL decreased an 
average of 3bp for every one gram 
increase in cardiac mass.  
Southern blot 
Terai, 2013 
(147) 
Cadavers and 
live donors 
Cardiac TL is not significantly correlated 
with TL in other organs.  
qPCR 
Dlouha, 2014 
(43) 
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Explanted 
hearts 
Short telomeres in CSCs are biomarkers 
of heart failure. TL can be used to sort 
functional CSCs. 
Flow FISH 
Cesselli, 2011 
(31) 
Search terms included ‘telomeres in the heart’, ‘cardiac telomeres’, ‘telomere length and 
cardiac hypertrophy’, and ‘telomere length in heart disease’. Searchers were performed using 
PubMed in March 2017. TL, telomere length; Terc, telomerase reverse transcriptase RNA 
component; IGF-1 mice, insulin-like growth factor-1-overexpressing mice; Tert, telomerase 
reverse transcriptase catalytic subunit; eNOS, endothelial nitric oxide synthase; TRF2, 
telomere repeat-binding factor 2; qFISH, quantitative fluorescence in situ hybridization; flow 
FISH, flow fluorescence in situ hybridization; qPCR, quantitative polymerase chain reaction; 
H/M-SOD2−/− mice, heart/muscle-specific manganese superoxide dismutase-deficient mice; 
PPAR-ƴ, peroxisome proliferator-activated receptor-ƴ; Bmal1-/- mice, brain and muscle 
ARNT-like protein-1 deficient mice; ROS, reactive oxygen species; p21, cyclin-dependent 
kinase inhibitor 1; FoxO1, Forkhead transcription factors of O group 1; DahlS.Z-Leprfa/Leprfa 
rats, Dahl salt-sensitive rats crossed with leptin knockouts; H9c2 cells, immortalised rat 
embryonic cardiomyoblasts; CSCs, cardiac stem cells; IGF-1R insulin-like growth factor-1 
receptor.  
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Telomere length during heart development 
Telomeres can be elongated by telomerase, an enzyme comprised of a catalytic reverse 
transcriptase, Tert, and an RNA component, Terc (109). Telomerase is particularly active 
during embryonic development but decreases after birth in most tissues (21), including the 
heart (26, 112). In addition to being the primary maintenance mechanism of TL, telomerase is 
involved in many other cellular processes, including growth (141), proliferation (30, 140), 
and mitochondrial function (2). As such, some studies have focused on telomerase activity in 
the heart and neglected TL (26, 111, 129, 150). Nonetheless, several findings highlight the 
importance of TL in the heart as a stand-alone variable that should be directly measured. For 
instance, heart disease and other age-associated complications in Tert-/- and Terc-/- mice are 
due to short telomeres and not telomerase function (142); decreases in TL in heart cells 
resulting in apoptosis and heart disease can occur without changes in telomerase activity (41); 
and exercise training can maintain TL in the aging heart independently of telomerase (86). 
Changes in cardiac TL may also play an important role in normal cardiac development during 
embryogenesis. In this regard, TL in the human heart (and other major organs) is 15-17kb at 
8 weeks gestation but declines significantly by 17 weeks gestation, while in other organs, 
such as the kidney and liver, telomeres remain long (151). When grown in vitro, however, 
human fetal cardiomyocytes stop dividing independently of TL after 20-25 population 
doublings (11). Furthermore, lifespan of cultured human fetal cardiomyocytes remains 
unchanged even when telomeres are elongated via transduction of TERT (11). In contrast, 
TERT overexpression can immortalise many other primary human cells (79) and prolong the 
survival of adult rat cardiomyocytes (112) by increasing TL. In addition, Tert-overexpression 
specific to the myocardium in mice suppressed telomere attrition and prevented terminal 
differentiation of cardiomyocytes in the first month of life (112). Therefore, TL may play 
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important roles in early cardiac development but appears to be independent of the 
mechanisms controlling prenatal senescence and developmental apoptosis in the heart.  
In the first 15 days of life, mouse cardiomyocytes are pushed out of the cell cycle by a 
rapid decrease in TL, which activates the growth arrest protein p21 (also known as cyclin-
dependent kinase inhibitor 1 and p21Cip1). Neonatal cardiomyocyte senescence was prevented 
in p21 knockout mice indicating that TL in the heart may be directly involved in cardiac 
development after birth (3). These findings offer an explanation for the cardiomyocyte 
division that has been observed in the first (123) and third (110) weeks of life. Despite 
significant telomere attrition during prenatal and neonatal development, early findings on 
human cadavers revealed the heart typically has the longest TL of all the major organs (146). 
Also in contrast with results from fetal hearts (151), telomere attrition in the left ventricle is 
relatively slow after the neonatal period, losing only 13bp per year compared to other tissues 
and organs, such as the kidney, which decrease 30-60bp per year (146). A follow up study by 
these authors reported a similar telomere attrition of 20bp per year in the myocardium using 
530 autopsied human samples and regression analysis (147). In a more recent study on twelve 
cadavers aged 0-88 years, cardiac TL was non-significantly longer than in the liver, brain, 
triceps, and skin but was not correlated with TL in any of the eleven organs studied (43). 
Therefore, tissue-specific patterns of telomere attrition lead to intra-individual variations in 
TL that differ before and after birth.  
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Telomere length in cardiac hypertrophy 
In neonatal humans only around 0.016% of cardiomyocytes are in cytokinesis and this 
decreases to undetectable levels in the early twenties (101). Such limited proliferation 
restricts most cardiac growth after birth to cardiomyocyte hypertrophy (50). Overt 
cardiomyocyte growth, however, causes an increase in the contractile mass of the heart, 
known as cardiac hypertrophy (or left ventricular hypertrophy) (45), and is the biggest risk 
factor for heart failure and sudden cardiovascular death with the exception of old age (Figure 
2) (74). Cardiac hypertrophy is also directly linked to cardiomyocyte loss in the diseased 
heart where the remaining cells increase in size to compensate for the death of their 
neighbours (115). Interestingly, when cardiomyocytes from 12-week old mice were separated 
into three categories based on size (< 20 000, 20 000 – 40 000, and > 40 000µm3) TL 
significantly decreased (from 40±0.73 to 33±0.82 and then 25±0.36 kb [mean±SEM], 
respectively) with each increase in cell size (131). These findings demonstrate that 
cardiomyocyte TL is related to cell size (a necessary feature of development and a key 
predictor of heart disease) and that TL is not homogenous even within a specific cell type. In 
accordance with these findings on TL, smaller cardiomyocytes had no detectable senescent 
markers, while some of the larger, and all of the largest cells, had high levels of p16 
expression (131). Although these three categories of cardiomyocytes are present throughout 
life, the number of senescent and hypertrophied cells increases and the number of young and 
small cells decreases with age in mice (131) and humans (35). Indeed, telomere attrition in 
young and old cardiomyocytes leads to the same senescence program but the number of cells 
involved is significantly greater as age increases (148). Finally, contractile ability (130, 148) 
and intracellular calcium concentrations (131) also decrease in the presence of short 
telomeres and hypertrophy. Taken together, these findings suggest that cardiac aging is 
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characterised by short telomeres, hypertrophy, senescence, and decreased contractile 
performance all at the cardiomyocyte level. 
The inverse association between TL and both cardiomyocyte development and cardiac 
hypertrophy suggests that the loss of telomeric repeats may affect cardiomyocyte function 
before senescence or apoptosis is reached. Indeed, cardiac telomere attrition in utero (151) 
coincides with the heart becoming functional (5) in humans. Moreover, the rapid telomere 
attrition that occurs when cardiomyocytes withdraw from the cell cycle (3) heralds the switch 
from hyperplastic to hypertrophic growth (110, 123) in neonatal mice. In further support of 
this suggestion in humans, individuals of African descent have longer telomeres at birth (59), 
an increased rate of (leukocyte) telomere attrition in adulthood (66) and are more prone to 
heart disease than Caucasians (167). In addition, men have shorter telomeres in the heart (70) 
and other organs (55) as well as a greater incidence of heart disease than women (165). 
Furthermore, twin studies have estimated that 84% of changes in TL (in leukocytes) are 
attributable to genetic factors (69). Similarly, twin and family studies have estimated the 
heritability of cardiac mass to be 30–84% (28, 94, 137), with primary cardiac hypertrophy 
affecting up to 16% of European- and 43% of African-descendants (54). Collectively, this 
suggest that TL, rate of telomere attrition, cardiac hypertrophy, and heart disease are 
significantly determined by genetic factors.  
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Figure 2. The normal heart compared to the hypertrophic heart. Cardiac hypertrophy 
involves a thickening of the ventricular wall (compare red arrows) which causes a 
maladaptive decrease in chamber size (compare lower pink areas) and, consequently, cardiac 
output. As cardiac hypertrophy primarily affects the left ventricle, it is also known as left 
ventricular hypertrophy.  
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Cell-specific telomere length in the heart 
In addition to shorter telomeres, cardiac hypertrophy, senescence, and apoptosis, fibrosis is a 
hallmark of aged hearts in rodents (25, 88) and humans (44). Fibrosis occurs when cardiac 
fibroblasts, which synthesise the extracellular matrix to support cardiomyocyte contraction 
(158), deposit excess collagen in place of cardiomyocytes that have undergone cell death 
(35). Cardiac fibroblasts were originally believed to constitute 60-70% of all cardiac cells and 
30-40% of  the heart’s mass, with cardiomyocytes accounting for 70-80% of cardiac mass but 
only 30-40% of all heart cells (108). While estimates of the cardiomyocyte population have 
not changed (18), a recent report using cell-specific markers found that endothelial cells were 
the most numerous cell type in the heart and account for around 45% of all cardiac cells 
(122). Relatively small numbers of leukocytes, cardiac stem cells (CSCs), vascular smooth 
muscle cells, monocytes and macrophages have also been detected (40, 108, 122). 
Interestingly, TL in the heart has only been measured in isolated cardiomyocytes, CSCs 
(discussed below), and whole heart tissue; separated endothelial cells or fibroblasts, as far as 
the literature revealed, have not been studied. The consensus that heart disease is a result of 
cardiomyocyte insufficiency, has led some authors to argue that TL in whole heart tissue 
from non-infarcted areas (which contain less collagen than infarcted areas (76, 143)) reflects 
that of cardiomyocytes (164). This however remains to be shown and as TL significantly 
varies in cardiomyocytes from the same individual (131), cell specific TL measurements 
should be considered the most valid, followed by sorted cells, whole tissue, and lastly the use 
of circulating leukocytes as a proxy (the available research that measured TL in heart cells, 
along with the specific cells used, is summarised in Table 1). Nonetheless, the measurement 
of telomeres in cardiac fibroblasts and endothelial cells under different conditions could help 
elucidate the complex intra-individual variation in TL and how it affects the heart.  
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Telomere length in heart failure and function 
As with heart development, functional changes associated with cardiac injury are also 
accompanied by changes in telomeric variables. For instance, protein levels of TERT, the rate 
limiting step of telomerase (83), increased 8.6 fold during acute and 2.6 fold after chronic MI 
in humans (153). Similarly, in male Sprague-Dawley rats subjected to abdominal aortic 
constriction, there was an increase in Tert-mRNA positive cardiomyocytes during the 
development of pressure overload-induced cardiac hypertrophy but a decrease in the later 
stages of heart disease (138). Moreover, in dogs with dilated cardiomyopathy induced by 
pacing their hearts to 210 beats per minute, Tert protein levels increased in the first three 
weeks before significantly decreasing after four weeks (80). Interestingly, in each of these 
cases, cardiac TL either decreased or stayed the same, despite increases in Tert. This suggests 
that the heart responds to stress by upregulating Tert to maintain TL. An increase in Tert, but 
unchanged or decreased TL, could also be explained by the enhanced cardiomyocyte turnover 
that is often present in the diseased heart (80). For instance, two in every thousand 
cardiomyocytes in human cardiac hypertrophy induced by aortic stenosis were in mitosis and, 
like Tert levels, cardiomyocyte division was inversely correlated with the duration of the 
disease once it was present for more than one year (152). Moreover, total Akt is similar in 
both healthy and infarcted human hearts but active phosphorylated Akt increased 21-fold 
during acute myocardial infarction and 3.8-fold after chronic myocardial infarction. Finally, 
Akt also activates Tert (46) resulting in a transient increase in telomerase and proliferation at 
the onset of heart disease. Taken together, these findings demonstrate that acute stress on the 
heart induces compensatory mechanisms aimed at preserving TL. As the heart disease 
progresses, however, these mechanisms become attenuated and then exhausted leading to 
overt cardiac failure (35, 113).  
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In end-stage human heart failure, average cardiomyocyte TL is 25% shorter than age-
matched controls (7.8+-0.2 and 6.5+-0.2kb respectively) (113). In contrast with findings on 
mice (25, 131) and rats (91), significant telomere erosion only occurred in the presence of 
heart failure and not cardiac hypertrophy alone (113). Similar results were found by Terai and 
colleagues (147) with each one gram increase in heart weight corresponding to only a 3bp 
decrease in TL. Moreover, individuals who died of heart disease had the heaviest hearts and 
the shortest telomeres but this was not always significant (147). These modest changes, 
however, could be explained by the measurement of TL in whole heart tissue compared to 
isolated cardiomyocytes in the other studies discussed so far. In this regard, one study found 
that average cardiomyocyte TL was 39% shorter in diseased compared to normal aged human 
hearts (35). Furthermore, cardiomyocyte apoptosis increases 0.5-1% in end-stage human 
heart failure (72, 113). While such low percentages may seem insignificant, Wencker and 
colleagues (159) found that a rate of apoptosis of 0.023% was pathologically relevant and 
these findings could be explained by decreases in cardiac TL. Therefore, there may not be a 
net decrease in TL at the tissue level even if there is sufficient telomere-induced cell loss to 
cause heart failure and cell-specific TL measurements may be necessary to determine organ 
viability. Uncovering the role of telomeres in normal cardiac growth and in the transition to 
cardiac hypertrophy and failure could help to identify harmful factors that could be 
manipulated to treat heart disease.  
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Factors that exacerbate cardiac telomere attrition and heart disease 
Defective telomerase 
In the two most common models of telomere dysfunction, Tert and Terc knockout mice, a 
lack of telomerase activity causes cardiomyocyte TL to shorten 3-5kb per generation, with 
cardiac hypertrophy and heart failure presenting by the second and fifth generations 
respectively (22, 81). As early generations of these mice are healthy, this strongly suggests 
that short TL (which can also be viewed as ineffective telomere maintenance) and not 
defective Tert, Terc or telomerase expression, is the cause of the cardiac pathologies that 
occur in these animals. These (inter-generational) changes also parallel the stages of human 
heart disease and Terc knockout mice are considered a good model of human heart failure 
(163). Systemic telomere inhibition, however, creates several comorbidities that affect the 
heart making it impossible to determine the role of TL in heart function. For instance, 
telomere shortening in endothelial cells can cause atherosclerosis (100) and third generation 
Terc knockout mice have high blood pressure (121) before the onset of established cardiac 
dysfunction (20, 81). Importantly, these conditions can affect cardiac telomere attrition 
through pressure induced hypertrophy and heart failure (50, 161). Interestingly, 
haploinsufficency of both Tert and Terc in mice causes telomere erosion and limits tissue 
renewal to the same extent as Tert and Terc knockouts (142) (although other research 
suggests this is only true for Terc knockout mice (34)) indicating that the only critical 
function of telomerase is telomere elongation. Similarly, in humans, single mutant TERT and 
TERC alleles can cause heterogenous phenotypes within families (119). Moreover, these 
individuals are asymptomatic in early life, indicating once more that short TL, and not 
defective telomerase expression, determines disease.  
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Insufficient telomeric proteins 
There are six key proteins, collectively named shelterin, that directly bind to the telomeric 
DNA sequence to constitute a telomere (42) (Figure 1). As shelterin is needed to protect 
telomeres, a paucity of these proteins can cause rapid telomere erosion. For instance, Tert and 
Terc knockout mice are viable until the fifth generation (20), however many knockout mice 
deficient in a shelterin gene, such as telomere-repeat binding factor 2 (TRF2), are 
embryonically lethal (92). Indeed, a decrease in TRF2 expression has been suggested as the 
earliest event in some forms of telomere shortening (107). In human heart failure, telomere 
attrition is associated with decreased expression of TRF2 and an increase of the pro-apoptotic 
mediator Checkpoint kinase 2 (Chk2)  (113). In cultured noncycling mouse cardiomyocytes, 
suppression or antisense knockdown of Trf2 caused telomere erosion and apoptosis (113). 
Conversely, because shelterin proteins are subunits of telomeres (42), short TL may also 
reduce Trf2 levels. In support of this notion, decreased TL and Trf2 expression (and Chk2 
activation) is prevented in cardiac-specific Tert transgenic mice (113). Transcriptome 
changes that influence cardiac TL and Trf2 expression have also been traced back to 
microRNAs, noncoding RNA molecules that post-transcriptionally regulate gene expression 
(105). For instance, MicroRNA-34a-/- mice showed less cardiac aging, hypertrophy, and cell 
death compared to wild type controls (25). One target of microRNA-34a is protein 
phosphatase 1 regulatory subunit 10 (also known, and hereafter referred to, as Pnuts), which 
facilitates the binding of Trf2 to telomeric DNA (75). In line with the post-transcriptional 
action of microRNAs, Pnuts expression in microRNA-34a-/- mice was more down-regulated 
at the protein level (25). Furthermore, Pnuts overexpression in cultured mouse 
cardiomyocytes reduced apoptosis and telomere attrition without changing telomerase 
activity (25). This highlights the importance of telomeric regulators and their utility in 
preserving cardiac TL and function. 
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Biomechanical stress 
The most common cause of cardiac hypertrophy and heart failure is other heart diseases, 
particularly hypertension (50) and atherosclerosis (161), which place biomechanical stress on 
cardiomyocytes (74). In male BPH/2J mice, a genetic model of hypertension, cardiac TL was 
not different from normotensive controls at 4 weeks of age before the onset of hypertension 
but became significantly shorter at 12 and 20 weeks of age after the development of high 
blood pressure (36). In male Sprague-Dawley rats subjected to abdominal aortic constriction 
(to mimic atherosclerosis), heart weight, telomere attrition, p53 levels, and cardiomyocyte 
apoptosis increased progressively (138). In both these cases, which model the two most 
common causes of human heart failure, it appears that cardiac telomere shortening is a by-
product and not a cause of the disease. It is still possible, however, that telomeric factors, 
such as Trf2 insufficiency, are involved in the onset of the disease, before changes in TL are 
observed. For instance, it has been demonstrated that telomere uncapping in leukocytes 
influences hypertension status whereas mean TL does not (103). Uncapped telomeres present 
with DNA damage known as Telomere dysfunction-Induced Foci (TIFs) (145), which are 
identified by the colocalization of shelterin and DNA damage response proteins, such as Trf2 
and gamma-H2AX (98). Indeed, although telomeres must maintain a critical length to allow 
the formation of protective loops (Figure 3), telomere structure is the most important factor 
governing cell viability (19). In support of this, it has also been suggested that apoptosis 
caused by Trf2 insufficiency may be independent of TL (92). Perhaps studies of telomere 
structure, or the identification of novel telomeric proteins, could elucidate the link between 
heart function and TL.  
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Figure 3. A representation of the telomere structure. The formation of protective T and D 
loops prevents cellular machinery from recognising telomere ends as damaged DNA (42) 
(only one of four telomeres on the chromosome is shown). Image produced using motifolio. 
TRF1, telomere repeat-binding factor 1; TRF2, telomere repeat-binding factor 2; POT1, 
protection of telomeres 1; TIN2, TRF1 interacting nuclear factor 2; TPP1, tripeptidyl-peptidase 
1; RAP1, repressor/activator protein 1. 
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Renal Failure 
Renal failure is another common disease that often leads to adverse cardiac remodelling (4). 
Indeed, severe renal failure in rats shortened TL in the heart by around 20% and induced 
cardiac hypertrophy (164). A key pathophysiological feature of heart failure (149) is beta 
adrenergic receptor activation, which can be traced back to the well-studied Renin 
Angiotensin Aldosterone System (RAAS) (reviewed elsewhere (116)). Beta adrenergic 
receptor activation also induces cardiomyocyte hypertrophy (97) and adrenergic receptor 
activation with Angiotensin II (AngII) has been shown to decrease TL in the heart (39). In 
male Sprague Dawley rats, beta adrenergic receptor activation with isoproterenol for six 
months increased left ventricle dysfunction but did not affect cardiac TL or hypertrophy 
compared to saline-treated controls (125). Consequently, the authors concluded that beta 
adrenergic receptor activation is likely not responsible for the telomere attrition observed in 
heart failure. Although blood pressure was not measured in this study, Sheng and colleagues 
(138) also used male Sprague Dawley rats and found that the beta receptor blocker and anti-
hypertensive drug carvedilol reduced cardiac hypertrophy, telomere attrition, and Trf2 protein 
loss in these animals. Other research on rats, however, has also failed to associate cardiac 
dysfunction with hypertensive status (91, 124). Therefore, RAAS activation and interactions 
between the heart and kidney can influence both cardiac TL and function but this may occur 
independently of hypertension.  
Hypoxia 
MI also leads to heart failure, telomere attrition and cardiac hypertrophy. In rats, MI caused a 
similar reduction in TL as renal failure (around 20%), however, renal failure and MI in 
combination did not exacerbate telomere shortening (164). Hypoxia-induced cardiomyocyte 
necrosis is primary consequence of MI (32) and severe hypoxia (95% N2 and 5% CO2) 
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reduces cell number and alters morphology in cultured rat cardiomyocytes (68). Interestingly, 
necrosis is even more significantly associated with age than apoptosis in cardiomyocytes 
from wild-type (WT) and transgenic mice (148). As a corollary, necrosis is correlated with 
oxidative stress, hypertrophy, age, and p16 and p53 expression in normal mice and those with 
longer lifespans (148). Although necrosis is not considered telomere-dependent, this suggests 
that necrotic debris may affect TL and survivability of proximal cardiomyocytes and could be 
a mechanism of cell loss with age and particularly after MI. In this regard, MI can destroy up 
to 25% of the adult heart (77), however only 1% (17) to 1.9% (101) of cardiomyocytes are 
replaced annually in a 20 year old person, and less than half of cardiomyocytes present at 
birth are replaced in an average lifetime (17). This innate limitation highlights the importance 
of identifying the primary causes of cardiomyocyte loss to prevent and treat the many types 
of heart disease.  
Oxidative stress 
The slow turnover of cardiomyocytes means that telomere attrition must be due to 
mechanisms other than cell division. The most common explanation for this phenomenon is 
oxidative stress (2, 51, 81, 156) and several findings support this suggestion. For instance, 
oxidative stress and telomere attrition increase in the presence of heart disease in Sprague-
Dawley rats (138) and WT mice (148). In addition, more that 80% of apoptotic human 
cardiomyocytes exhibit oxidative damage (153). Oxidative stress also plays a particularly 
important role in the development and outcomes of diabetes and metabolic syndrome 
(obesity, insulin resistance, and hypertension) in humans (51, 156). Animal models of 
diabetes and metabolic syndrome, however, do not always exhibit increased cardiac telomere 
attrition. For instance, in Dahl salt-sensitive (DS) rats crossed with Zucker rats with a 
missense mutation for the leptin receptor gene (obese) (DS/obese rats) to mimic metabolic 
syndrome, oxidative stress accompanied cardiac hypertrophy and dysfunction at 18 weeks of 
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age (144). TL, however, did not differ between the DS/obese rats and lean homozygous 
controls despite the upregulation of Chk2, p21, and p53 (144). Similarly, although Tert and 
Trf2 protein levels were decreased, no changes in cardiac TL were found at 40 weeks of age 
in a rat model of type 2 diabetes (88). Nonetheless, these findings suggest that oxidative 
stress can cause telomere erosion in the heart by directly interacting with telomeres as well as 
decreasing telomerase activity and Trf2 protein levels.  
Inflammation 
Another potential factor to explain cardiac telomere attrition in the absence of significant cell 
division is inflammation (82, 93, 126, 156). In this regard, Sprague-Dawley rats exposed to a 
low-dose of Staphylococcus aureus for 12-months to promote inflammation had decreased 
cardiac TL but no change in heart function (126). Determining the effects of oxidative stress 
and inflammation in heart disease, however, is challenging as they often occur in conjunction 
(117, 144) and can induce one another (65). It has also been proposed that oxidative stress 
and inflammation are a result, and not a cause, of heart disease (168) although studies that 
have induced oxidative stress (62) and inflammation (126) suggest a causal involvement. 
Nevertheless, mitochondrial compromise can exacerbate oxidative stress (58) and decreases 
in (leukocyte) TL (132). As such, it has been suggested telomere attrition and cardiac 
dysfunction is a consequence of decreased cardiomyocyte mitochondrial biogenesis (104). 
While it is possible that a third confounding factor, such as mitochondrial compromise, could 
cause decreased cardiac function and TL, the most probable explanation is that several 
pathways interact with telomeres and collectively contribute to cellular dysfunction in the 
heart. Their relative importance and the causal agents likely depend on the specific type of 
disease as well as the genetic and environmental factors involved. 
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Environmental toxins and unhealthy lifestyle  
Several environmental toxins, including tobacco and alcohol, along with lifestyle factors, 
such as sedentary behaviours and mental stress, are also associated with heart disease and 
telomere erosion (52). Of these, however, only the effects of alcohol consumption on cardiac 
TL have been assessed. Ethanol administration (5% v/v in drinking water) to rats for four 
months increased cardiomyocyte apoptosis and LV dilation but there was no change in 
cardiac TL, blood pressure, heart weight, C reactive protein (a marker of inflammation), or 
fasting blood glucose (a marker of diabetes) (124). Although these results suggest that TL is 
not involved in the cardiac dysfunction observed in this model, it is also likely that four 
months may not be sufficient to cause a significant change in cardiac TL. Nonetheless, these 
diseases highlight the sensitivity of the heart to a myriad of stimuli and comorbidities that can 
damage cardiomyocytes and lead to heart disease. TL, however, has also been used as a 
proxy for systemic stress. For instance, malaria infection has been shown to decrease cardiac 
TL in parallel with other major organs in birds (10). Although intra-individual variations in 
TL are less pronounced in birds (127) than humans (43), these authors considered short TL in 
multiple organs (including the heart) a marker of systemic stress (10) and thus not necessarily 
of heart disease in particular. The primary stressor of cardiomyocytes is considered to be 
biomechanical stress (50) and aortic constriction to induce this significantly reduces TL in 
mice and humans (113). Collectively, this highlights the need to determine and control for 
‘stressors’ that exacerbate heart disease and telomere attrition so the exact involvement of 
telomeres in the heart can be uncovered.  
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Factors that protect cardiac telomeres and heart function  
Antioxidants 
Antioxidants can prevent the damaging effects of oxidative stress on telomeres and 
cardiomyocytes. For instance, Bmal1-/- mice (a model of premature aging due to increased 
ROS production) exposed to a high fat and high cholesterol diet, suffer from increased 
cardiac telomere attrition and oxidation (62). Ten weeks of treatment with the antioxidant 
TEMPOL, however, significantly decreased telomere oxidation and non-significantly 
attenuated telomere attrition (62). Similarly, Makino and colleagues (89) examined telomere 
biology in heart/muscle-specific manganese superoxide dismutase-deficient mice (H/M-
SOD2−/−), which develop premature heart failure. EUK-8, a superoxide dismutase and 
catalase mimetic with antioxidant properties, was administered to H/M-SOD2−/− mice for 
four weeks beginning at 8 weeks of age (89). At the end of the study, no shortening of TL 
was observed in heart tissues from all mice tested, but telomerase activity and Trf2 protein 
levels were downregulated in H/M-SOD2−/− mice and this could be inhibited by EUK-8 
treatment (89). The short duration of this study may explain why there were no changes in 
TL. Indeed, the administration of the powerful antioxidant epigallocatechin gallate (EGCG) 
to H/M-SOD2−/− mice for 8 weeks (as opposed to only 4 weeks (89)) prevented the dilated 
cardiomyopathy, increased inflammation, and decreased TL observed in the control group 
(118). EGCG and another antioxidant, quercetin, also inhibited oxidative stress, TRF2 protein 
decreases, and telomere attrition in male Sprague-Dawley rats subjected to abdominal aortic 
constriction (138). Similar results have also been found in cultured mouse cells with 
exogenous Trf2 (113) and Pnuts-overexpression (25) conferring protection form oxidative 
stress. Moreover, EGCG inhibited decreases in TL and protein expression of Trf2 in 
immortalised rat embryonic cardiomyoblasts (H9c2) cell line induced by oxidative stress 
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(139). Finally, activation of the mitochondrial regulator peroxisome proliferator-activated 
receptor-ƴ (PPAR-ƴ) was found to ameliorate cardiac oxidative stress, as well as Tert and 
Trf2 decreases without changes in TL at 40 weeks of age in diabetic rats (88). These ‘rescue’ 
studies provide further evidence that decreasing oxidative stress protects cardiac telomeres 
and function. 
Caloric intake 
Excess caloric intake is the cause of obesity and the primary risk factor for diabetes (7), both 
of which can lead to heart disease and (leukocyte) telomere attrition (73, 169). Early research 
showed that calorie restriction (CR) decreased the mortality rates of rats at 800 days of age 
from 50 to 80% (16). In this regard, cardiac TL was significantly shorter in heterozygous 
Forkhead transcription factors of O group 1 (Fox01+/) (homozygous knockouts are 
embryonically lethal) compared to WT mice at 35 weeks of age when fed ad libitum. 
However, CR (70% of ad libitum) for 20 weeks from 15 weeks of age prevents the 
accelerated TL in Fox01+/- mice (90). CR also reduced oxidative stress and cardiomyocyte 
apoptosis in WT mice (90). It should be noted, however, that heart to body weight ratio or 
blood glucose levels in CR and ad libitum WT and Fox01+/- mice did not change, limiting the 
applications of these findings to human obesity and diabetes (and the subsequent cardiac 
complications). Importantly, the most powerful preventative strategy for obesity, diabetes, 
and heart disease is simply a healthy diet (such as sufficient antioxidants and reduction of fat) 
combined with adequate exercise (162). In this regard, however, cardiomyocyte TL in mice 
did not change after 3 weeks or 6 months of exercise training. Interestingly, control animals 
over 18 months of age showed significant telomere shortening (160) suggesting that, as in 
models of heart disease (62, 89), exercise-induced effects on TL also take time to become 
significant. In support of this notion, age-associated cardiac telomere shortening was 
attenuated after a more prolonged 44 weeks of voluntary exercise in rats (86).  
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Exercise 
Despite a delay in changes to cardiac TL, many rapid responses to exercise involve telomeric 
pathways. For instance, Tert and Trf2 protein levels increase and p16, p53, and chk2 protein 
levels decrease in mice after three weeks of voluntary running (160). Interestingly, these 
exercise-induced changes were absent in Tert-/- mice (160). Similarly, WT mice supplied with 
running wheels are also immune from the cardiotoxic effects of the anti-cancer drug 
doxorubicin whereas Tert-/- mice are not (160). In addition, cardiac-specific overexpression of 
Tert promotes survival after myocardial infarction and protects against cardiomyocyte 
telomere attrition and apoptosis (112). Akt (130) and IGF-1 (148) overexpression in mice 
also causes an increase in the number of small cardiomyocytes with greater contractile 
performance and longer telomeres leading to increased LV function and delayed aging. 
Furthermore, intraperitoneal treatment with IGF-1 in mice increased telomerase activity and 
phosphorylated Akt protein levels (160), suggesting these pathways may be linked. 
Moreover, cardiomyocytes in stem cell factor (SCF)-treated mice were smaller with longer 
telomeres compared to saline-treated controls (133). Interestingly, SCF (48) as well as IGF-1 
and Akt (160) are upregulated following exercise and this could be one pathway that 
promotes exercise-induced cardioprotective adaptations. 
Physiological cardiac hypertrophy 
Although cardiac hypertrophy is a powerful predictor of heart failure, an increase in cardiac 
mass can also be an adaptive response to exercise (49) or pregnancy (1). This so-called 
physiological cardiac hypertrophy or athlete’s heart (reviewed elsewhere (45, 95)) is 
functionally and mechanically distinct from the pathological kind in that it is adaptive, 
reversible, and harmless. Interestingly, pathological hypertrophy is also reversible in its early 
stages (44) and this coincides with the upregulation of telomeric variables and unchanged TL 
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seen in the early stages of heart disease (80, 138, 153). In addition, TL is maintained (160) or 
even extended (86) with regular exercise, suggesting that telomere attrition may be a specific 
feature of pathological hypertrophy and thus a better marker of heart function than cardiac 
mass. Furthermore, Tert and IGF-1 overexpression in rodents is cardioprotective but also 
induces hypertrophy in cardiomyocytes (37, 64, 112). As only small cardiomyocytes are 
capable of undergoing replication (35, 81, 152), physiological cardiac hypertrophy may seem 
counter-intuitive but IGF-1 and Akt overexpressing mice also possess an increased number of 
small replicating cardiomyocytes (130, 148). Furthermore, Tert (112), as well as IGF-1 and 
Akt (128), is involved in cardiomyocyte proliferation, suggesting that adaptive cardiac 
growth includes hypertrophy and a relative increase in cell number (hyperplasia). Indeed, 
levels of cardiomyocyte death and replication are similar during aging in IGF-1 mice (148) 
but cell loss exceeds replication in the hearts of aged WT mice and rats (57). Therefore, it is 
tempting to speculate that pathways involved in physiological or ‘pre-pathological’ cardiac 
growth promote telomere elongation to protect against stress-induced (be it physiological or 
pathological) cardiomyocyte loss. 
Hyperthermia and combining treatments  
One final treatment shown to influence TL in the heart is repetitive hyperthermia. In this 
regard, Oyama and colleagues (117) found that 4 weeks of daily immersion for 10 min in 
40°C water prevented cardiac telomere attrition, oxidative stress, and hypertrophy in 10-week 
old salt-induced hypertensive rats. Interestingly, significant changes in cardiac TL occurred 
relatively quickly in this study whereas most research suggests that factors regulating TL, 
such as Tert and Trf2, are likely more relevant in medium- and short-term treatments. 
Nonetheless, when taken together, these findings highlight the ability of endogenous and 
exogenous factors to increase cardiomyocyte survival through telomeric pathways. 
Identifying the molecular mechanisms responsible for the adaptive cardiac changes following 
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antioxidant treatment, CR, exercise, and hyperthermia could help develop novel treatments 
for heart disease. In this regard, the effects of regular mild hyperthermia may be similar to 
those of regular exercise. Furthermore, improved anti-oxidant capacity is also an adaptive 
response to exercise (78) and physical activity reduces fibrosis in injured rat hearts (82). 
Given the beneficial effects of exercise on TL and several measures of heart function, 
identifying the precise mechanisms distinguishing pathological from physiological growth 
provide promise of shifting pathological cardiac hypertrophy to the physiological end of the 
spectrum. This could not only rescue TL but also degenerative cardiomyocyte loss. Despite 
the importance of diet and exercise in preventing and treating heart disease, however, little 
research has determined the effects of these variables on cardiac TL.  
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Telomere length in cardiac stem cells 
The mammalian heart contains cardiac stem cells (CSCs) that divide throughout the lifespan 
to replenish old and damaged cardiomyocytes (6). Since this discovery, much research has 
focused on understanding replication and senescence in these cells to potentiate cardiac repair 
with age and after injury. Ex vivo endomyocardial biopsies obtained from the apex of the left 
ventricle in humans have revealed two types of CSCs; myogenic CSCs, which constitute 97% 
of CSCs and mainly form cardiomyocytes, and vascular CSCs, which constitute only 3% of 
CSCs and mainly form smooth muscle and endothelial cells (40). Like cardiomyocytes, TL 
regulates the life cycle of CSCs (13) with longer telomeres designating CSCs that are 
replicating and replacing old cardiomyocytes with short telomeres (35, 152). Telomerase 
activity in human CSCs attenuates telomere shortening (152) but an average of 130bp of 
telomeric DNA is still lost after each cell division (13). Telomere-induced senescence in 
CSCs occurs when TL reaches around 1.5kb (153). As such, one overarching theme in the 
literature is that short telomeres force CSCs to undergo senescence and apoptosis. This, in 
turn, prevents cardiomyocyte replacement in the aging heart and leads to heart disease (35, 
133, 148).  
This loss of proliferative potential questions the true stem cell-like qualities of CSCs 
and some studies (38, 41, 57) have referred to cardiac cells positive for c-kit (the receptor of 
SCF (133)) as cardiac progenitor cells. Regardless of this limitation, however, cardiac cells 
with stem cell like qualities exist and can be extracted from the aged human heart and rapidly 
expanded in culture. In one study, average CSC TL decreased from 9.3 to 8.2 then 6.9kb in 
vitro after approximately 12, 18, and 27 population doublings respectively (13). Furthermore, 
CSCs extracted from aged hearts had telomeres 5.3-7.7kb (40), indicating that there is 
considerable growth reserve in the human heart throughout life. In another study, average 
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CSC TL post-MI was 7.5kb, more than three times longer than senescent cells, highlighting 
that viable CSCs with huge replicative potential are present even in the diseased heart (24). 
Nonetheless, age is a major predictor of telomere shortening, decreased telomerase activity, 
increased TIFs, p16 and p21 expression, which are all considered biomarkers of hCSC 
senescence (31). Of these, TL may be the best biomarker to identify CSCs capable of 
producing functional cells. Indeed, human CSCs with shortened telomeres produce new cells 
that inherit this trait and quickly acquire the senescent phenotype (70). Identifying the 
mechanisms that elongate cardiac telomeres could facilitate rejuvenation of the heart by 
producing functional, long-living cells in vivo. This could be achieved by harnessing and 
compounding the replicative potential of CSCs demonstrated in culture.  
Enhancing cardiac stem cell proliferation 
Although cardiomyocyte renewal by CSCs with short telomeres is destined to result in a 
phenotypically old heart (70), growth factors promoting mitosis can disrupt cellular 
senescence (133). Indeed, CSCs increase 1.9-fold in mice between 4 and 22 months of age 
(148) and around 3-fold from 4 to 28 months of age in rats (57). Importantly, however, the 
number of senescent cells also increases, resulting in fewer functional CSCs with age (148). 
This suggests that delaying cellular senescence in the heart would suffice to prevent age-
associated cardiac decline. In this regard, the levels of cell death and replication are similar 
during aging in IGF-1 mice, which could explain the longer telomeres found in these animals 
throughout life (148). It was also demonstrated that IGF-1 activates telomerase in CSCs 
inducing them to divide via the P13K-Akt pathway, which provides an explanation for this 
increase in cardiomyocyte TL, proliferation, and lifespan (148). The phenotypic age of CSCs, 
like cardiomyocytes discussed above, can also be determined by the oxygen levels of the 
microenvironment. In this regard, hyperoxic CSCs do not suffer telomere attrition with age 
while normoxic CSCs and CMs suffered 46 and 43% decrease in TL respectively from three 
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to thirty months of age in mice (133). Once more, these differences in TL had functional 
consequences because 74% of hyperoxic CSCs could divide and replenish the heart whereas 
only 30% of normoxic CSCs could replicate (133). Importantly, however, exposure to 
hyperoxic conditions stimulated proliferation of CSCs, suggesting that improved oxygen 
supply could stimulate cardiomyocyte renewal (133). Similarly, overexpression of the 
cardioprotective kinase Pim-1 in primary 13-month old mouse CSCs, causes a transient 
increase in proliferation and TL (38). These factors provide possible mechanisms to 
temporarily increase CSC proliferation, which could allow sufficient repair after ischaemic 
death to prevent degenerative cardiac decline. Such treatments would also lower the risk of 
oncogenic complications that accompany the prevention of senescence and apoptosis (38).  
Another option to preserve cardiac function with age is to stimulate only functional 
CSCs to divide. Indeed, CSCs with long telomeres remain throughout life and can produce 
phenotypically young cardiomyocytes (57). One study found that SCF reversed cardiac aging 
in mice by stimulating phenotypically young CSCs in situ (133). Importantly, newly formed 
cardiomyocytes following SCF treatment had 75% longer telomeres (133). To identify CSCs 
with maximal growth reserve, D’Amario and colleagues (39) examined CSCs from patients 
undergoing elective cardiac surgery for coronary artery disease for the presence of IGF-1, 
insulin-like growth factor-2, and angiotensin II (Ang II) and their receptors (39). The authors 
found that older CSCs had shorter telomeres and increased AngII and apoptosis whereas 
CSCs with IGF-1 receptors (IGF-1R) had the longest telomeres and highest proliferative 
capacity (39). Moreover, the IGF-1/IGF-1R pathway was found to promote CSC growth and 
survival as well as preserve TL (39), consistent with the increased TL and number of dividing 
CSCs found in IGF-1 mice (148). As a result, CSCs expressing only IGF-1R had a young 
phenotype with long telomeres and reduced apoptosis making them the ideal cells for cardiac 
repair (39). Finally, IGF-1 also inhibited AngII-induced cell death by 40% in old CSCs (39). 
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Collectively, these findings highlight not only the importance of growth factors and oxygen 
levels to preserve functional CSCs and cardiomyocytes but also their ability to reverse 
cardiac aging and disease.   
CSCs can be isolated from human ventricle tissue, grown in vitro, and then injected 
back into the heart as a treatment for heart failure (13). This makes increasing CSC 
proliferation a promising way to facilitate cardiac regeneration after CSC infusion (38). 
Clinical trials on autologous CSC (one million cells) transplantation post-MI improved 
cardiac function and decreased infarct area by 30% one year after treatment (24) (CSC 
therapy is reviewed elsewhere (53)). To optimise CSC infusions, however, the transplanted 
cells will require a young phenotype of which the key molecular hallmark is long telomeres 
(70). Understanding CSC and cardiomyocyte preservation is also crucial to cancer therapies 
because cardiotoxicity is a side-effect of many antineoplastic drugs. The most notable of 
these are the anthracyclines such as doxorubicin (154), which causes telomere erosion 
through oxidative stress (87). In rats, doxorubicin administration caused heart disease and 
death and subsequent in vitro studies found this occurred through CSCs telomere erosion and 
apoptosis (41). Indeed, doxorubicin caused a 30% decrease in TL and the percentage of CSCs 
with telomeres <8kb increased more than four times despite the maintenance of telomerase 
activity (41). Another study found that Pim-1 decreased the toxic effects of doxorubicin in 
CSCs (38), highlighting the mechanistic involvement of telomeres in doxorubicin-induced 
heart failure. Interestingly, CSC transfusion can also promote the regeneration of 
cardiomyocytes in vivo and improve the survival of rats exposed to doxorubicin (41). This led 
to the suggestion of autologous CSCs being obtained and transfused before the administration 
of cardiotoxic drugs to prevent or manage subsequent heart failure (41). Interventions to 
maintain TL, however, may preserve heart function and obviate the need for dangerous, 
invasive, and costly surgical procedures. 
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In contrast to the body of research on CSCs, Senyo and colleagues (135) found that 
pre-existing cardiomyocytes are the primary source of new cells in both healthy and diseased 
mouse hearts. These researchers also discovered that cardiomyocyte proliferation increases 
adjacent injured myocardium despite an overall reduction in cardiomyocyte DNA synthesis 
with age (135). Similarly, Beltrami and colleagues (15) showed 4% of human 
cardiomyocytes were in proliferation (identified by Ki67 antigen expression) in areas 
adjacent infarcts and 1% at sites distant from injury. The notion of cardiomyocytes being 
responsible for the maintenance of the heart’s cell population (and losing this ability with 
age) is a simple and powerful explanation for heart disease. In support of this suggestion, 
cardiomyocytes have shorter TLs than CSCs in mice (133); human fetal cardiomyocytes 
undergo a maximum of 25 population doublings in vitro (11) whereas CSCs extracted from 
aged hearts have significant growth reserve even after 27 population doublings (13); and, 
based on the telomere attrition of cultured CSCs, 1x1015 cells can be produced by CSCs from 
one individual before senescence is reached (13). Nonetheless, the ability of CSCs (6), as 
well as cardiomyocytes without detectable stem-cell qualities (123, 135), to divide is clear 
but the inability of the heart to regenerate with age, and particularly after injury, is even more 
obvious. Given this replicative potential in vitro, it is also possible that cardiomyocyte 
replacement in vivo is hindered by other factors, such as the deposition of collagen, and not 
the poor replicative potential of CSCs and cardiomyocytes. Whether cardiac cells can be 
induced to divide following injury, and protected from senescence and apoptosis to prevent 
disease, is a promising area of future research. To accomplish this, however, the factors 
influencing telomere-induced senescence and apoptosis will likely need to be elucidated.  
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Cardiac telomere length in animal models  
The use of a mouse model with Tert-overexpression specific to the myocardium (12, 112) 
circumvents the limitations of systemic telomere dysfunction as seen in Tert and Terc 
knockout mice (discussed above). Nonetheless, all rodent models present with many crucial 
differences when compared to humans. For instance, cardiomyocytes isolated from mice have 
TLs varying from 14-58kb (131) compared to 1.5-15kb in humans (146). Furthermore, 
critical TL associated with cell senescence of human CSCs is around 1.5kb (153) whereas in 
mice it is approximately 14kb (131). The difference in TL between mice and humans could 
explain the development of the mdx/Terc-/- mouse as a model for the recessive 
cardiorespiratory disorder Duchenne Muscular Dystrophy (96). mdx mice have a nonsense 
mutation in the causal gene but are phenotypically healthy (27). When crossed with Terc 
knockouts, however, mdx mice exhibit cardiomyopathy and decreased lifespan as seen in 
human Duchenne Muscular Dystrophy (106). Interestingly, these phenotypes did not appear 
until the second generation, which again suggests that TL and not telomerase activity is 
responsible for the manifestation of the disease phenotype. In this regard, differences in 
cardiac telomere length or maintenance could explain the phenotypic heterogeneity of genetic 
cardiomyopathies in humans.  
Ludlow and colleagues (86) utilised the CAST/Ei mouse, which has relatively short 
telomeres, similar to those in humans (61), but the C57BL/6 mice strain, which has relatively 
long telomeres (85), has still been used to study human heart disease (25, 133). Interestingly, 
telomeres in zebrafish and humans are of similar size (63), which could make zebrafish a 
good model of human cardiac disease in regards to telomere biology. In addition, the 
zebrafish heart can completely regenerate after injury (56) and this is accompanied by a 
transient increase in cardiomyocyte TL and proliferation (14). Furthermore, Tert-/- zebrafish 
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are unable to elongate telomeres or replenish their cardiac cell population after injury (14). 
These results highlight the involvement of telomerase and the importance of cardiomyocyte 
replacement but leave unanswered questions regarding the exact role telomeres have in the 
heart. Perhaps if telomere elongation could be inhibited in WT and Tert-/- zebrafish, the role 
TL plays in cardiac rejuvenation could be elucidated in this model. Despite similarities in 
human and zebrafish TL, however, the longer lifespan of humans suggests that more stringent 
telomere maintenance is required, and such mechanisms may not be present in short-lived 
animals. These interspecies differences highlight the need to validate animal findings in 
human models of disease.  
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Cardiac telomere attrition as a potential cause of heart failure 
Another important question that has long been posited (136) but remains unknown (52) is 
whether telomere attrition is a cause or consequence of heart disease. As telomere length is 
cell-specific (43, 67, 86), the role of telomeres in disease development likely varies between 
different types of heart disease. Furthermore, uncovering these relationships will require the 
study of telomere regulation at the site/s of each specific cardiovascular pathology. 
Nevertheless, there are essentially only three possible explanations for the involvement of TL 
in any type of heart disease. Firstly, telomere attrition causes the disease; secondly, telomere 
shortening is a consequence of the disease; and thirdly, one or more confounding variables, 
such as oxidative stress and mitochondrial dysfunction, cause both telomere shortening and 
the disease. In the heart specifically, confounding variables pose particular challenges to 
demonstrating a cause and effect relationship between cardiac TL and function. For instance, 
as short TL is strongly associated with age (33, 60) and cardiac hypertrophy is a normal and 
necessary feature of development (50), cardiac TL and heart failure have the same primary 
risk factors. As discussed above, however, the dysregulated telomere maintenance observed 
in early-stage heart failure (80, 138, 153) and the propensity of telomerase-deficient mice to 
develop cardiac hypertrophy and subsequent heart failure (81), suggests insufficient telomere 
maintenance may cause cardiac hypertrophy and heart failure (Figure 4).  
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Figure 4. The possible causal involvement of telomeres in the pathophysiology of 
cardiac hypertrophy and heart failure. Trf2, telomere repeat-binding factor 2. 
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Conclusions  
In conclusion, telomere attrition (113, 131, 148), as well as telomere-induced senescence (35, 
148) and apoptosis (81, 166), is a consistent molecular feature of heart failure. Although it is 
possible that telomere shortening may only be associated with the onset and not the 
development of heart failure, this still implicates other telomeric variables, such as TERT and 
TRF2, in the early stages of disease. The interdependence and substantial redundancy of 
cellular activities has also made it difficult to identify causes of cardiac telomere attrition, 
aging, and disease. In this regard, cardiac hypertrophy could be used as a model of early-
stage heart failure to determine the involvement of telomeric factors in disease progression. 
Elucidating the mechanisms of telomere maintenance in the heart holds promise to better 
prevent, diagnose, and treat cardiac dysfunction as well as potentiate regeneration after 
injury.  
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Aim and hypothesis  
As discussed in my literature review, a significant body of research has demonstrated that TL 
is inversely associated with heart failure but the cause/s of short telomeres in failing hearts is 
unknown. Importantly, uncovering the involvement of telomere shortening in the 
pathophysiology of heart failure could provide novel targets for therapeutic and preventative 
interventions. As cardiac hypertrophy is the key antecedent to heart failure, the overall aim of 
this thesis was to determine the role of telomeres in the development of cardiac hypertrophy. 
It was hypothesised that decreases in telomere length and/or maintenance would increase 
cardiomyocyte size. This was formally tested with four experimental studies (Chapters 2-5). 
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Experimental design  
Many of the animal models in which cardiac TL has been determined suffer from specific 
gene deletions or confounding comorbidities that could obscure the identification of factors 
involved in the development of cardiac hypertrophy. Similarly, many human studies have 
relied on measurement of TL from circulating leukocytes and it has not been shown if TL in 
circulating leukocytes is representative of the hypertrophic heart. To address these 
deficiencies in the literature, I first studied cardiac telomeres during the development of 
cardiac hypertrophy and progression to heart failure in the hypertrophic heart rat (HHR), a 
polygenetic model that suffers from primary cardiac hypertrophy independently of 
confounding diseases. I also measured TL in circulating leukocytes in the presence of 
established cardiac hypertrophy (Chapter 2). I then sought to determine if there were 
telomeric changes in adult intrauterine growth restricted (IUGR) rats, an environmental 
model of low birthweight and/or delayed postnatal growth leading to cardiac hypertrophy in 
adulthood. A subset of IUGR rats also underwent exercise training to investigate the 
influence of exercise on cardiac telomeric variables in the context of cardiac hypertrophy 
after growth restriction (Chapter 3). 
 Despite the utility of the HHR and IUGR as in vivo models of cardiac hypertrophy, 
important differences exist between rodents and humans in terms of TL, life span, and 
cardiomyocyte morphology. To determine the role of telomeres in human cardiac 
hypertrophy and if animal models are representative of this disease, human primary 
cardiomyocytes (HPCs) and rat immortalised cardiomyoblast (H9c2) cells were grown in 
vitro. I treated HPCs and H9c2 cells with five different hypertrophic agonists to increase cell 
size and then determined if this was accompanied by changes in telomere maintenance and/or 
length (Chapter 4). Conversely, I then disrupted telomere maintenance in HPCs using small 
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interfering RNAs (siRNAs) for TERT and TRF2 as well as pharmacological inhibition of 
telomerase with the small molecule BIBR1532. Cell size was subsequently measured to 
determine if inhibiting telomere maintenance was sufficient to induce human cardiomyocyte 
hypertrophy (Chapter 5). The specific research questions addressed by each of these Chapters 
are listed below.  
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Research questions  
Chapter 2 
• Are there changes in cardiac and cardiomyocyte TL and/or telomeric gene expression 
and, if so, do they reflect the development of polygenic cardiac hypertrophy?  
• Is leukocyte TL representative of cardiac and cardiomyocyte TL in polygenic cardiac 
hypertrophy? 
Chapter 3 
• Does cardiac hypertrophy induced by growth restriction affect cardiac TL?  
• Can exercise training protect cardiac telomeres after growth restriction? 
Chapter 4 
• Can inducing cardiomyocyte hypertrophy cause telomere attrition and/or changes in 
telomeric gene expression in rat and/or human cells?  
• Are there any changes inflammation, oxidative stress, and/or proliferation, that could 
also lead to telomere shortening in HPCs?  
Chapter 5 
• Can inhibiting telomere maintenance induce human cardiomyocyte hypertrophy? 
• Does impaired telomere maintenance affect hypertrophic gene expression, 
proliferation, apoptosis, or oxidative stress in HPCs? 
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Abstract 
Background and aims: Cardiac hypertrophy and short cardiomyocyte telomere length is 
associated with heart failure but there is no clear link. The aim of this study was to investigate 
telomere length, telomeric genes, and microRNAs in the heart before, during, and after the 
development of cardiac hypertrophy.  
Methods and Results: The ontogeny of cardiac hypertrophy and subsequent heart failure was 
studied in the hypertrophic heart rat (HHR), a polygenic model of cardiac hypertrophy, and 
its control strain the normal heart rat (NHR). Ages used corresponded with the 
pathophysiological sequence beginning with fewer cardiomyocytes (2-days), the 
development and onset of cardiac hypertrophy (4- and 13-weeks) and progression to heart 
failure (38- and 52-weeks). Telomere length, telomerase activity, and expression of the 
telomeric microRNA miR-34a were determined using qPCR. Telomere length was longer in 
the HHR at 2-days and 38-weeks, shorter at 4- and 13-weeks, and not different at 52-weeks. 
Similarly, telomerase activity in the HHR was higher at 2-days, lower at 4- and 13-weeks, 
and not different at 38-weeks. miR-34a expression was a significant predictor of telomere 
length at all ages in both strains.  
Discussion and conclusions: Longer telomeres in the HHR at 2-days may reflect fewer fetal 
and early postnatal cardiomyocyte divisions and explain the reduced number of cells in this 
model that predisposes to cardiac hypertrophy and heart failure. The sharp reduction in 
telomere length and telomerase activity in the HHR in early life may contribute to the 
development of cardiac hypertrophy but short cardiac telomeres were not present at the 
progression to heart failure. 
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Introduction 
Telomeres, the specialized DNA-protein complexes located at the ends of eukaryotic 
chromosomes, are essential for genomic and cell viability. Telomere length and its age-
dependent shortening is regarded as a marker of age-associated diseases in general and 
cardiovascular disease in particular (38). This is strongly supported by investigations showing 
that patients with atherosclerosis, coronary artery disease, chronic heart failure and stroke 
have shorter leukocyte telomere length (4, 13, 16, 43, 46). There are, however, some 
paradoxical findings in regards to telomere length and cardiac hypertrophy – one of the key 
indicators of target-organ damage in cardiovascular disease (24). For example, population-
based studies have shown that cardiac mass and wall thickness are associated with longer, 
rather than shorter, telomeres (19, 44). This is difficult to explain since cardiac mass 
represents the time-averaged exposure to several cardiovascular risk factors which also 
decrease telomere length, such as age, inflammation, oxidative stress, hypertension, and 
obesity (6, 7, 23).  
Less well studied is the importance of cardiac telomere dynamics to the developmental 
changes in cardiac mass leading to heart failure. Indeed, shorter telomeres at an early age can 
lead to impaired cell division, enhanced cardiomyocyte death and hypertrophy, all of which 
are concomitant with cardiac dysfunction and disease (22). Animal models have been be used 
to assess changes in telomeres (22), but in the case of cardiac hypertrophy this may be 
hindered by the confounding effects of hypertension (12, 30), and, hence, mask the genetic 
origin of this disease. This highlights the need to elucidate specific pathways that affect 
telomere length throughout the lifespan in the absence of increased blood pressure. Crucial to 
our understanding of the molecular mechanisms that underlie the development of cardiac 
hypertrophy and heart failure, and to the design of preventive and therapeutic regimens, are 
animal models that are bred to genetically develop cardiac hypertrophy leading to heart 
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failure. One such model is the hypertrophic heart rat (HHR), which develops cardiac 
hypertrophy independently of hypertension (15).  
Given the established link between telomere dysfunction and cardiomyocyte 
proliferative defects (22), we postulated that cardiac telomere homeostasis would be 
perturbed in the HHR. To test this hypothesis, we first measured telomere length in the heart 
of the HHR at key ages corresponding to the pathophysiological sequence of fewer 
cardiomyocytes (2-days), cardiac hypertrophy (4- and 13-weeks) and subsequent progression 
to heart failure (38- and 52-weeks). In the search for the molecular basis of telomere 
regulation in the hypertrophic heart, we then measured changes in the telomere lengthening 
enzyme telomerase and quantified mRNA levels of its two subunits – telomerase reverse 
transcriptase (Tert) and telomerase RNA component (Terc). MicroRNAs (miRNAs), small 
non-coding RNA molecules which negatively regulate gene transcription by binding to the 3’ 
untranslated region of their target mRNAs, have also emerged as key regulators of cardiac 
growth (40) and telomere length (3). As such, we also investigated whether changes in 
telomere length are due to alterations in the newly discovered telomeric regulator miR-34a (3, 
35). Finally, to determine if leukocyte telomere length is representative of the hypertrophic 
heart, we measured telomeres in blood and corresponding cardiac tissue in 13-week old HHR 
and NHR.  
75 
 
Methods 
Ethical clearance 
The study was approved by the Animal Ethics Committees at the University of Melbourne 
and Deakin University, and ratified at Federation University Australia.  
Animal models 
The HHR is a polygenic model of cardiac hypertrophy that was developed by cross-breeding 
the spontaneously hypertensive rat, a model of hypertension and cardiac hypertrophy, and the 
Fischer 334 rat, which has normal blood pressure and a small heart. These strains were 
selectively interbred over 13 generations to create the HHR, which presents with pathological 
cardiac hypertrophy in the absence of a pressure load at maturity. The sister strain used as the 
control, the normal heart rat (NHR), has normal heart size and blood pressure (15). Compared 
to the NHR the HHR is born with a smaller heart containing fewer cardiomyocytes (33) but 
by 12 weeks of age presents with established cardiac hypertrophy which leads to premature 
death due to heart failure as early as 48 weeks of age (15, 33). 
Samples and tissue collection 
2-day old HHR (n=7, 5 females and 2 males) and NHR (n=9, 7 females and 2 males) were 
euthanized by decapitation. 4-week (n=10 HHR, 6 females and 4 males; and n=10 NHR, 4 
females and 4 males), 13-week (n=9 HHR, 5 females and 4 males; and n=11 NHR, 6 females 
and 5 males), 38-week (n=9 HHR, 6 females and 3 males; and n=7 NHR, 4 females and 3 
males), and 52-week old (n=12 HHR, 6 females and 6 males; and n=10 NHR, 5 females and 
5 males) were euthanized with an overdose of pentobarbitone (Lethobarb). No more than one 
female and one male were used per litter. Hearts were immediately removed, and the left 
ventricle dissected from the atria. Cardiac weight index (CWI) was calculated from the total 
heart weight (mg) relative to total body weight (g) of each animal. Left ventricle tissue 
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samples were also collected from 52-week old HHR and NHR using the same method but 
heart weight and body weight data were not recorded. Finally, whole blood was collected in 
heparin tubes after cardiac puncture from 13-week old rats only as it was not available from 
other age groups. All tissues were first preserved in liquid nitrogen then later transferred to a 
–80oC freezer.  
Cardiomyocyte isolation 
Cardiomyocytes were isolated from snap frozen tissue using a protocol adapted from a 
publication (28) and personal communication to Prof. Cris dos Remedios (University of 
Sydney). Briefly, cardiac tissue was sectioned into 300μm sections and stored at -20°C for 4 
hours. We then added 1 mL of digestion buffer (PBS, 1mg/mL collagenase B, 1mg/ml 
collagenase D, and 30mM BDM, filtered using a 0.22μm filter) for every 300μm cardiac 
section and digested immediately for 20 minutes on an incubated rocking plate (37 °C, 99 
RPM). The tubes containing the tissue where placed on ice and manually digested by 
pipetting the solution up and down repeatedly (~20 times with a 10ml sterile pipette). The 20-
minute incubations and manual digestion steps were repeated 3 times. The solution was then 
passed through a 100μm mesh filter and increasing volumes (0.1, 0.2, 0.3 and 0.5) of RCGM 
media (Lonza) were added with 10 minutes rest intervals on ice. The cell pellet was collected 
by centrifugation at 200 RPM for 4 minutes at 4°C and this was used for the extractions 
described below.  
DNA and RNA extraction 
DNA from cardiac tissue, cardiomyocytes, and circulating leukocytes was extracted using the 
PureLink® Genomic Extraction kit (Life Technologies). RNA was extracted from cardiac 
tissue using the miRNeasy kit (Qiagen). All extractions adhered to the manufacturer’s 
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instructions. Both RNA and DNA were quantified by spectrophotometry using a NanoDrop® 
ND-100 spectrophotometer (Thermo Scientific).  
Telomere length 
The telomere-repeat copy number (T) to single-copy gene number (S) ratio (T/S ratio) was 
determined by real-time quantitative PCR (qPCR). Tel1 and 36B4 were used to reflect T and 
S, respectively, as previously described as previously described (5). Briefly, a 10ng template 
of extracted DNA was loaded in triplicate into a 384-well plate with SensiMix SYBR No-
Rox (Bioline) and run in a Viia7 instrument (Life Technologies). Primer sequences and 
concentrations were: Tel1 forward, GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGT 
GAGGGT [300nM]; Tel1 reverse, TCCCGACTATCCCTATCCCTATCCCTATCCCT 
ATCCCTA [300nM]; 36B4 forward, CAGCAACTGGGAAGGTGTAATCC [300nM]; and 
36B4 reverse, CCCATTCTATCATCAACGGGTACAA [500nM]. Cycling conditions 
involved one hold step at 95oC for ten minutes followed by 36 cycles of 95oC for 15 seconds, 
54oC for 20 seconds, and 72oC for 2 minutes. The square root of the average cycle threshold 
(CT) for 36B4 was then divided by the square root of the average CT for Tel1 to yield the T/S 
ratio, a measure of telomere length.  
Telomerase activity 
Telomerase activity was measured using the TRAPeze® Kit RT Telomerase Detection Kit 
(Merck Millipore) and Platinum® Taq DNA Polymerase (Life Technologies) according to 
the manufacturer’s instruction. Briefly, protein was extracted using CHAPS Lysis Buffer 
(Merck Millipore), and one µg of protein was added to each reaction. Samples were 
measured in duplicate, and telomerase activity was quantified relative to a standard curve by 
qPCR in a Viia7 instrument (Life Technologies). The activity of telomerase was presented as 
78 
 
the number of copies based on the standard curve supplied by the manufacturer. Telomerase 
activity was not determined in 52-week old rats. 
miRNA and gene expression 
The levels of Tert and Terc, both components of telomerase, the enzyme responsible for the 
elongation of telomeres, and protein phosphatase 1 regulatory subunit 10 (Ppp1r10, also 
known as and hereafter referred to as Pnuts) mRNA, and miR-34a were measured using 
qPCR. For mRNA levels, the first-strand complementary synthesis reaction was performed 
using the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Primers were 
designed to flank exon-exon junctions using Primer3 (37) and NCBI tool Primer Blast. 
Amplification reactions used the SensiFastTM SYBR Low-ROX Kit qPCR reagent (Bioline). 
The specificity of qPCRs was ensured by melting curve analysis and DNA gel 
electrophoresis (data not shown). For miR-34a expression, RNA was transformed to cDNA 
using the TaqMan® MicroRNA Reverse Transcription Kit for miRNA cDNA (Life 
Technologies). Amplification reactions used TaqMan assays and the TaqMan® Fast 
Advanced Master Mix (Life Technologies). For both mRNA and miRNA expression, all 
samples were run in duplicates in a Viia7 qPCR instrument (Life Technologies). The cycling 
conditions for gene expression involved a hold step of 95°C for ten minutes then 40 cycles of 
95°C for 5 seconds, 58°C for 10 seconds, and 72°C for 10 seconds. For miRNA expression 
quantitation, samples were heated to 50°C for 2 minutes then 95°C for 20 seconds followed 
by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) was used as reference transcript for mRNA levels and the miRNAs 
RNU6, 4.5S and Sno87 for miRNA expression. Primers, probe assays, and conditions are 
listed in Table 1. Significance was assessed using 2-ΔΔCT for both mRNA and miRNA 
expression calculations and presented as the relative expression to allow inter- and intra-
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group comparisons (39). miRNA and gene expression was not determined in 52-week old 
rats. 
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Table 1. Primers, probe assays and conditions used for gene and miRNA expression. 
Gene name Primer Sequence (5’3’) Annealing temperature Concentration Product length 
Gapdh F: GGGGCTCTCTGCTCCTCCCTG 
R: ACGGCCAAATCCGTTCACACC 
58oC 200 nM 
200 nM 
108 bp 
Punts F: CTCAAGCAGAACAACACAGCG 
R: CTACTCTGGGAGCGGATGAC 
58oC 200 nM 
200 nM 
125 bp 
Tert F: AACTACGAGCGGACCAAACA 
R: CCCTGTCACATCTGCCTTAAC 
58oC 200 nM 
200 nM 
150 bp 
Terc 
 
F: TGTTATAGCTGTGGGTTCTGTTCTT 
R: CCGCTGCAGGTCTGAACTTT 
58oC 200 nM 
200 nM 
91 bp 
Official microRNA symbol TaqMan assay ID Annealing temperature   
rno-miR-34a 000426 60 oC   
4.5S 001716 60 oC   
Sno87 AF272707 60 oC   
RNU6B 001973 60 oC   
bp, base pairs; F: forward; R: reverse. 
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Statistical analyses 
GraphPad PRISM (version 6) and SPSS (version 21) were used for graphing and statistical 
analyses, respectively. Data sets were tested for normal distribution using the D'Agostino & 
Pearson normality test and equal variances were analysed using the F test. An independent 
sample t-test, Welch’s test, or Mann-Whitney test were used to compare data between the 
groups. Pearson’s or Spearman’s correlations were used to correlate telomere length, miR-
34a and telomeric gene expression, and CWI data. Analyses of variance (ANOVA) using 
Tukey's multiple comparisons test was used to compare between ages within the same strain. 
Step-wise regression analyses were used to identify potential predictors of cardiac size and 
telomere length, with age and sex as independent variables (F-entry probability: 0.05, 
removal: 0.1). Significance was set at P<0.05. 
82 
 
Results 
Cardiac size 
Table 2 provides the characteristics of the samples used in this study. 2-day old HHR had 
significantly smaller hearts (P<0.001) but by 4 weeks of age, the HHR had significantly 
larger hearts than age-matched NHR (P=0.023). This early increase in CWI in the HHR was 
even more pronounced at 13-weeks (P<0.001) and continued until 38-weeks (P=0.012), the 
oldest age that was measured, validating the presence of cardiac hypertrophy in these animals 
(Table 2). 
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Table 2. Characteristics of HHR and NHR samples used in this study. 
Age NHR HHR 
 n Body weight (g) Heart weight (mg) CWI (mg/g) n Body weight (g) Heart weight (mg) CWI (mg/g) 
2-day 9 5.9±0.2 44.1±2.0 7.4±0.1 7 5.3±0.3 34.3±2.4** 6.4±0.2*** 
4-week 10 43.2±1.6 247.2± 8.1 5.7±0.1 10 46.5±3.0 293.0±13.5** 6.4±0.3* 
13-week 11 205.2±15.9 697.0±44.8 3.4± 0.1 9 186.2±13.0 890.8±46.8** 4.9±0.3*** 
38-week 9 355.0±35.7 1188.6±83.0 3.4±0.1 7 253.1±20.5* 1038.5±108.8 4.5±0.5* 
CWI, cardiac weight index. Values are represented as mean ± standard error of mean. * indicates P<0.05, **P<0.01, ***P<0.001. 
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Cardiac and cardiomyocyte telomere length 
There was a positive correlation between telomere length in isolated cardiomyocytes and 
cardiac tissue in both strains at all ages (r=0.295, P=0.017). Cardiac telomere length was 
significantly longer in 2-day old HHR (P=0.023) but shorter in 4-week (P=0.012) and 13-
week old HHR (P=0.024) compared to age-matched NHR (Figure 1A). In 38-week old HHR, 
cardiac telomere length was significantly longer than the NHR (P=0.009) but there were no 
differences in telomere length between the strains at 52 weeks of age (P=0.261) (Figure 1A). 
When we compared cardiac telomere length within strains, 2-day old HHR had significantly 
longer telomeres than all other ages (P<0.05) and 52-week old HHR had significantly shorter 
telomeres than all other ages (P<0.001) (Figure 1B). In the NHR, telomeres were 
significantly shorter at 38-weeks (all P<0.05) and 52-weeks (all P<0.001) when each was 
compared to all younger ages (Figure 1C).  
Circulating leukocyte telomere length 
To investigate whether telomere length in circulating leukocytes is representative of the heart, 
we measured telomere length in circulating leukocytes and matching cardiac tissue from 13-
week old NHR and HHR. As with cardiac telomere length, leukocyte telomere length was 
significantly shorter in 13-week old HHR compared to age-matched NHR (P=0.048) (Figure 
1D). Moreover, there was a positive correlation between cardiac and leukocyte telomere 
length (r=0.448, P=0.031) (Figure 1E) but this correlation was driven by the HHR (r=0.81, 
P=0.026) as we did not detect a significant correlation in the NHR (r=0.18, P=0.605). 
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Figure 1. Telomere length. (A) At 2-days the HHR has significantly longer cardiac telomere 
compared to the NHR. In 4- and 13-week old animals, the HHR has shorter telomeres than 
age-matched NHRs. At 38-weeks of age, telomeres are again longer in the HHR compared to 
the NHR. (B) The shortening of telomeres in the HHR happened early in life compared to (C) 
the NHR where telomere shortening occurred in late adulthood. (D) Circulating leukocyte 
telomere length was shorter in 13-week old HHR compared to age-matched NHR. (E) 
Circulating leukocyte telomere length is correlated to cardiac telomere length in 13-week old 
animals. The appropriate independent-sample t-tests were used for (A) and (D), ANOVAs for 
(B) and (C), and Pearson’s correlation for (E). Graphs represent mean, error bars represent 
standard error of the mean. * indicates P<0.05, **P<0.01, ***P<0.001.  
86 
 
Telomerase activity 
In accordance with cardiac telomere length, telomerase activity was higher in 2-day old 
(P<0.001) and lower in 4-week old HHR (P=0.005) (Figure 2A). At 13- and 38-weeks of age, 
however, we did not discover significant difference in telomerase activity between strains 
(both P>0.05) (Figure 2A). Within strains, both 2-day old HHR (Figure 2B) and NHR 
(Figure 2C) had significantly higher telomerase activity than all other ages (all P<0.01). 
Moreover, telomerase activity was correlated to telomere length at all ages (r=0.27, 
P=0.035), especially in the NHR (r=0.51, P=0.005). Telomerase activity was not measured at 
52 weeks of age as there was no change in cardiac telomere length in this group. 
87 
 
 
Figure 2. Telomerase activity. (A) Telomerase activity is higher at 2-days and lower at 4- in 
the HHR while there is no difference between strains at 13- or 38-weeks. (B) In the HHR, 
telomerase activity is higher at 2-days compared to all other ages. (C) In the NHR, telomerase 
activity is also higher at 2-days compared to all other ages along with a second significant 
decrease between 4- and 38-wees of age. The appropriate independent-sample t-tests were 
used for (A), ANOVAs for (B) and (C). Graphs represent mean, error bars represent standard 
error of the mean. * indicates P<0.05, **P<0.01, ***P<0.001.  
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Tert and Terc expression 
Tert expression was up-regulated at 2-days (P=0.021) and 38-weeks (P<0.001) but down-
regulated at 4-weeks (P<0.001) in the HHR compared to age-matched NHR. There was also a 
tendency for Tert mRNA levels to be higher at 13-weeks of age, but this did not reach 
significance (P=0.066) (Figure 3A). In accordance with telomere length, Tert mRNA levels 
in the HHR were significantly lower at 4- and 13-weeks compared to 2–days and 38-weeks of 
age (all P<0.001) (Figure 3B). In the NHR, Tert expression was significantly lower later in 
life, at 13- and 38-weeks, when compared to younger 2-day and 4-week old rats (all P<0.001) 
(Figure 3C).  
Terc mRNA levels did not significantly differ between the HHR and NHR at 2-days or 
13-weeks of age (both P>0.05). At 4-weeks, however, the HHR had significantly lower Terc 
expression (P=0.046) while at 38-weeks the HHR had significantly higher Terc mRNA levels 
(P=0.018) (Figure 3D). Within the HHR strain, Terc expression was significantly higher at 
38-weeks of age compared to all other ages (P<0.01) (Figure 3E). In the NHR, Terc mRNA 
levels were significantly higher at 4-weeks compared to 2-days and 13-weeks (both P<0.001) 
and 38-weeks compared to 2-days and 13-weeks (both P<0.01) (Figure 3F). 
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Figure 3. Tert and Terc expression. (A) Tert mRNA levels were significantly higher at 2-
days and 38-weeks but lower at 4-weeks in the HHR compared to the NHR. (B) In the HHR, 
Tert expression is lower and 4- and 13-weeks when compared to 2-day and 38-week old 
animals. (C) In the NHR, Tert expression is higher in 2-days and 4-weeks when compared to 
13- and 38-weeks. (D) Terc mRNA levels are significantly higher in the NHR at 4-weeks and 
the HHR at 38-weeks with no differences at 2-days or 13-weeks. (E) In the HHR, Terc 
expression was higher at 38-weeks than all other ages. (F) In the NHR, Terc expression was 
higher at 4-weeks when compared to 2-days and 13-weeks and at 38-weeks when compared 
to 13-weeks and 2-days. The appropriate independent-sample t-tests were used for (A) and 
(D), ANOVAs for (B), (C), (E), and (F). Graphs represent mean, error bars represent standard 
error of the mean. * indicates P<0.05, **P<0.01, ***P<0.001. Tert, telomerase reverse 
transcriptase; Terc, telomerase RNA component.  
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miR-34a and Pnuts expression 
The miRNA miR-34a was significantly over-expressed in HHR compared to the NHR at 2-
days (P=0.004), 4-weeks (P=0.024) and 13-weeks (P<0.001), but down-regulated at 38-
weeks (P=0.019) of age (Figure 4A). In the HHR, miR-34a had the highest expression at 38-
weeks of age compared to other ages (P<0.001), and was also higher at 13-weeks compared 
to 4- weeks and 2-days (both P<0.05) (Figure 4B). In the NHR, miR-34a was also 
upregulated at 38-weeks compared to all other ages (P<0.001), and at 13-weeks compared to 
2-days (P<0.001) (Figure 4C).  
 Pnuts was previously described as a target of miR-34a in the mouse heart and plays 
an anti-apoptotic role in cardiomyocytes (3). Since miR-34a was over-expressed in the HHR, 
we measured Pnuts mRNA levels and found it was significantly down-regulated in the HHR 
at 4-weeks (P<0.001) but over-expressed at 38-weeks (P<0.001) (Figure 4D). Within the 
HHR, Pnuts mRNA levels were significantly lower at 4- (P<0.05) and 13-weeks (P<0.05) 
when compared to all other ages (Figure 4E). In the NHR, Pnuts expression was significantly 
higher at 2-days (P<0.05) and 4-weeks (P<0.05) when compared to all other ages (Figure 
4F). Pnuts mRNA levels were borderline negatively correlated with miR-34a levels in all 
ages besides 38-weeks (2-days r=–0.38, P=0.067; 4-weeks r=–0.32, P=0.113; and 13-weeks 
r=–0.35, P=0.067).  
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Figure 4. miR-34a and Pnuts expression. (A) miR-34a was upregulated in the HHR at all 
ages besides 38-weeks when it was lower than in the NHR. In both the HHR (B) and NHR 
(C) miR-34a expression at 4-weeks was significantly higher than all other ages and 13-weeks 
was higher compared to 2-days. (D) Pnuts mRNA levels were lower at 2-days and 4-weeks 
and higher at 38-weeks in the HHR compared to the NHR. In the HHR (E), Pnuts expression 
was significantly lower at 4- and 13-weeks compared to 2-days and 38-weeks while in the 
NHR (F) Pnuts was higher at 2-days and 4-weeks compared to 13- and 38-weeks. The 
appropriate independent-sample t-tests were used for (A) and (D), ANOVAs for (B), (C), (E), 
and (F). Graphs represent mean, error bars represent standard error of the mean. * indicates 
P<0.05, **P<0.01, ***P<0.001. miR-34a, microRNA-34a; Pnuts, protein phosphatase 1 
regulatory subunit 10. 
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Predictors of cardiac weight index and cardiac telomere length  
In a step-wise regression analysis, cardiac telomere length was a significant negative 
predictor of CWI in both strains at all ages (Table 3). According to the standardised β 
coefficients, however, age had the largest effect on CWI, while the contribution of telomere 
length was similar to strain and sex (Table 3).  In another step-wise regression analysis, Tert 
mRNA and miR-34a levels were the only molecular determinants of cardiac telomere length 
in all samples (Table 4).  
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Table 3. Significant predictors of cardiac weight index. 
Variable β±S.E. Standardised β 95% C.I. P-value 
Age in weeks –0.20±0.02 –0.80 –0.24 to –0.16 <0.0001 
Female compared to male –0.54±0.22 –0.18 –0.97 to –0.11 0.016 
HHR compared to NHR 0.44±0.20 0.15 0.03 to 0.84 0.038 
Cardiac telomere length –1.03±0.50 –0.15 –2.03 to –0.03 0.043 
C.I., confidence interval; S.E., standard error. Results are from a step-wise regression 
analyses used to determine predictors of cardiac weight index. Covariates included cardiac 
telomere length, age, sex (female compared to male), and strain (HHR compared to NHR). 
n=44 female and n=27 male rats. F-entry probability: 0.05, removal: 0.1. 
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Table 4. Significant predictors of cardiac telomere length.  
Variable β±S.E. Standardised β 95% C.I. P-value 
miR-34a –0.02±0.003 –0.62 0.03 to 0.84 0.038 
Tert mRNA 0.015±0.50 0.22 –2.03 to –0.03 0.043 
C.I., confidence interval; S.E., standard error. Results are from a step-wise regression 
analyses used to determine predictors of cardiac telomere length. Covariates included miR-
34a, Pnuts, Terc, Tert, telomerase activity and strain. F-entry probability: 0.05, removal: 0.1.  
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Discussion 
Dissecting the effect of telomere length on cardiac hypertrophy and heart failure has been 
hindered by the difficulty of obtaining human cardiac tissue and by the lack of animal models 
that are not affected by pressure overload. Here we set out to investigate the changes in 
telomere length in a normotensive model, the HHR, during the development of polygenic 
cardiac hypertrophy and progression to heart failure. We found that the HHR was born with 
longer telomeres, higher telomerase activity, and smaller hearts compared to the NHR. This 
was followed by accelerated telomere shortening that paralleled the development of cardiac 
hypertrophy. Alterations in telomere length were linked to dysregulation of the telomeric 
regulators Tert and miR-34a at all ages. Other molecular changes associated with telomere 
length at some ages included fluctuations in telomerase activity as well as Pnuts and Terc 
mRNA levels. This highlights the importance of these variables to cardiac telomere length 
and, hence, the dynamic regulation of cardiomyocyte growth and function (summarised in 
Figure 5).  
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Figure 5. A simplified diagram of molecular mechanisms involved in regulating cardiac 
telomere length and heart size. Tert synergises with Terc to form telomerase, while miR-
34a acts through regulating levels of Pnuts to maintain telomere length and heart size (blue 
arrows). Both Tert and miR-34a may also have hypertrophic effects on the heart through 
other pathways (grey arrows) such as increased proliferation (31) and apoptosis (3). Tert, 
telomerase reverse transcriptase; Terc, telomerase RNA component; miR-34a, microRNA-
34a; Pnuts, protein phosphatase 1 regulatory subunit 10. 
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The concept of being born smaller and having longer telomeres, as observed in the 
HHR, is consistent with results found in young men born small due to intra-uterine growth 
restriction (20). The longer telomeres in 2-day old HHR could, at least in part, be due to 
fewer cell divisions in the heart during embryogenesis. This would also explain the reduced 
complement of cardiomyocytes previously reported in the HHR (33). Furthermore, recent 
studies in mice have shown that cardiomyocytes proliferate until post-natal day 7 (34), which 
is followed by another proliferative burst in the third week of life (29). In this regard, it is 
possible that cardiomyocytes in the HHR may be forced to divide more in postnatal life to 
compensate for their reduced number, which would contribute to the accelerated telomere 
attrition between 2-days and 4-weeks of age. Moreover, cardiomyocytes produced from cells 
with short telomeres inherit this defect and quickly acquire the senescent phenotype (17), 
limiting these cells to hypertrophic growth and predisposing to heart failure (17, 36). When 
combined with the sharp reduction in telomere length observed in the HHR in early life, this 
suggests telomere shortening could play a causal role in the development of cardiac 
hypertrophy.  
In the current study, we also found significantly higher telomerase activity in neonatal 
HHR which may also contribute to the longer telomeres found in these animals. Indeed, 
telomerase activity decreased by around 60 times between 2-days and 38-weeks of age in the 
HHR, while in the NHR this was less pronounced with only around 17 times less telomerase 
activity at 38-weeks. Interestingly, telomerase also promotes cell viability independently of 
telomere length (14, 41, 45), suggesting it may contribute to cardiac hypertrophy through 
non-telomeric pathways. Indeed, the rapid decrease in telomerase activity and expression of 
its catalytic component Tert at critical stages of cardiac growth in the HHR, implicates these 
variables in the development of cardiac hypertrophy as drivers of telomere length and 
potentially through other mechanisms.  
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Another key finding of this study was the over-expression of miR-34a in the HHR at 
several ages. During normal development, over-expression of miR-34a was only previously 
reported in the aged heart, a phenomenon which leads to cell death (3). This suggests that the 
up-regulation of this miRNA early in life could also be involved in the reduced complement 
of cardiomyocytes in the HHR (33), thereby stimulating compensatory hypertrophy in the 
remaining cells (17, 36). Indeed, therapies targeting miR-34a or the miR-34 family by 
Bernardo and colleagues (1, 2) were shown to have beneficial effects in the diseased heart. 
Furthermore, we found that Pnuts mRNA, a target of miR-34a, was down-regulated in the 
HHR at the onset of hypertrophy and this gene is known to have an important role in 
telomere maintenance by directly interacting with non-redundant telomeric protein telomere 
repeat-binding factor 2 (Trf2) (18, 32). Indeed in primary rat cardiomyocytes, decreased 
expression of Trf2 causes accelerated telomere attrition and increased apoptosis (32). 
Furthermore, Trf2 protects against apoptosis even in non-dividing cells (21), highlighting the 
importance of this pathway in the heart.  
 Consistent with the documented positive correlation between cardiac mass and longer 
leukocyte telomere length in humans (19, 44), 38-week old HHR had significantly longer 
telomeres than the age-matched controls. Importantly, however, our data indicate that 
telomere length in the HHR does not show significant increases with age. Instead, telomeres 
were longer at birth, and then become shorter early in development, with no significant 
changes observed thereafter. Indeed, cardiomyocyte division in adulthood has been shown to 
occur at a slower pace, accounting for only a fraction of the telomere attrition observed 
throughout the lifespan (34). This phenomenon was also observed in the NHR, where 
telomere shortening happened only later in life. These findings suggest that the various 
mechanisms involved in telomere maintenance and their relative importance may differ 
between normal and hypertrophic hearts. In this regard, we showed a significant correlation 
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between leukocyte and cardiac telomere length in the HHR but not in the NHR. Although 
some research has shown synchronous telomere shortening between tissues (8), our findings 
combined with others (11, 26) suggest that telomere length in circulating leukocytes does not 
reliably reflect telomere measurements in the heart. 
The longer telomere length in the presence of cardiac hypertrophy may seem 
paradoxical, but the adaptive response of the heart to stress is a ubiquitous theme in the 
literature. For instance, telomerase activity in dogs was increased at the onset and further 
again at the progression of ventricular dysfunction (25). Similar results have been found in 
human hearts (42). While compensatory increases in telomerase activity at the development 
of cardiac hypertrophy could explain the longer telomeres in the HHR at 38-weeks and in 
humans with cardiac hypertrophy (19, 44), this was not detected at the ages measured in the 
present study. This points to the involvement of other protective mechanisms, such as Terc 
and Pnuts mRNA levels, which were upregulated in older HHRs.  
The increase Terc and Pnuts expression could also explain, at least in part, the 
surprising finding that short telomeres were not present in the HHR at 52-weeks of age. It is 
possible, however, as heart and body weight data were not available, that this cohort did not 
have cardiac hypertrophy compared to the NHR. Indeed, cardiac telomere length was 
significantly shorter than all other ages at 52-weeks in the NHR as well as the HHR. In this 
regard, the negative regulator of telomere length and proapoptotic miR34-a (3) was 
upregulated at 38-weeks in the NHR which could contribute to the reduction in telomere 
length at 52-weeks of age. Furthermore, all animals in this study were euthanised and, as 
such, the HHRs had outlived some members of previous cohorts which have died from heart 
failure as early as 48 weeks of age (33). In this regard, we would expect significantly shorter 
telomeres in post-mortem examinations of diseased hearts, as previously reported (32). 
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Although the use of qPCR to measure relative telomere length is widely used in the 
literature (6, 7, 10), the lack of cell-specific or critically-short telomere measurements needs 
to be acknowledged as a limitation. Previous studies, however, have shown that this method 
is reliable and the results are highly comparable to other techniques, such as mean terminal 
restriction fragment (TRF) length (5) and single telomere length analysis (STELA) (27). 
Moreover, we have previously shown that telomere length varies according to the method of 
DNA extraction (9). In the present study, all samples were collected, processed, and extracted 
using the same method, and samples were run in the same qPCR plate to minimise variation. 
Therefore, we believe the results presented here are highly robust. Irrespectively, however, it 
would be still useful to validate these findings in other animal and human models of cardiac 
hypertrophy.  
Findings from this study suggest that telomeres in cardiomyocytes and cardiac tissue 
play an important role in the development of cardiac hypertrophy, independently of 
hypertension. We found accelerated telomere shortening, decreased telomerase activity, and 
lower Tert mRNA levels in the HHR early in life which paralleled increases in cardiac mass. 
Although the NHR also suffers from age-associated changes in telomeric variables and 
cardiac mass, these changes are more pronounced and present early in life in the HHR. As 
such, these telomeric regulators could be targeted for diagnostic and therapeutic use to 
identify and treat early-stage cardiac hypertrophy, thereby preventing the development of 
degenerative heart failure. 
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Abstract 
Background and aims: Fetal and postnatal growth restriction predisposes to cardiac 
hypertrophy and subsequent cardiovascular disease in adulthood. Telomeres are repetitive 
DNA-protein structures that protect chromosome ends, and the loss of these repeats (a 
reduction in telomere length) is associated with cardiac hypertrophy. As exercise preserves 
telomere length and heart function, the aim of this study was to determine the effects of 
growth restriction and exercise training on cardiac telomere length and telomeric genes.   
Methods and results: Pregnant Wistar Kyoto rats underwent bilateral uterine vessel ligation 
to induce uteroplacental insufficiency and fetal growth restriction (‘Restricted’). Sham 
operated rats had either intact litters (‘Control’) or their litters reduced to five pups with 
slowed postnatal growth (‘Reduced’). Control, Restricted, and Reduced male rats were then 
randomly assigned to Sedentary, Early exercise (5-9 weeks of age) or Late exercise (20-24 
weeks of age) groups. Hearts were excised at 24 weeks of age for telomere length and gene 
expression measurements by qPCR. Growth restriction shortened cardiac telomere length 
(P<0.001) but this was rescued by early exercise (P<0.001). Early and Late exercise 
increased cardiac weight index (P<0.001) but neither this nor telomere length was associated 
with expression of the telomeric genes Tert, Terc, Trf2, Pnuts, or Sirt1.  
Discussion and conclusions: Growth restriction shortens cardiac telomere length, reflecting 
the cardiac pathologies associated with low birth weight. Exercise in early life may offer 
long-term protective effects on cardiac telomere length which could help prevent adverse 
cardiac events in later life.  
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Introduction 
Cardiac hypertrophy (also known as left ventricular hypertrophy) is an abnormal increase in 
cardiac mass (23) and the most potent risk factor for cardiovascular disease after old age (32). 
Although reversible in its early stages, cardiac hypertrophy is asymptomatic and typically 
becomes degenerative before diagnosis (22), leading progressively to heart failure (57). This 
highlights the need to identify at-risk individuals and implement preventative treatments as 
well as reverse cardiac decline in established cardiovascular disease. 
With the exception of rare congenital heart defects and genetic cardiomyopathies, the 
earliest risk factors for developing heart disease are low birth weight (6, 24, 54) and reduced 
growth in the postnatal period (7, 9). In rats, uteroplacental insufficiency results in low birth 
weight (‘Restricted’) and a reduction in litter size slows postnatal growth (‘Reduced’) (49). 
Despite a normal heart to body weight ratio at birth (49), both Restricted and Reduced rats 
have fewer cardiomyocytes (10, 45) and develop established cardiac hypertrophy by 22 
weeks of age (66), making them an ideal model to study the epigenetic causes of cardiac 
hypertrophy.  
One key preventative factor for cardiovascular disease is exercise (4, 19) which 
induces an adaptive increase in cardiac mass known as physiological cardiac hypertrophy 
(25, 43). We recently reported that a 4-week endurance exercise treatment at 5- or 20-weeks 
of age increases heart mass at 24-weeks of age in both Restricted and Reduced male rats (60). 
These findings suggest that exercise may help remodel the cardiac hypertrophy commonly 
detected in growth-restricted individuals (6, 7, 9, 24, 54) to better reflect the physiological 
type. This, however, remains to be characterised and the molecular mechanisms involved in 
physiological changes in the heart are poorly understood. 
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Telomeres are non-coding TTAGGG repeats that complex with proteins to protect 
chromosome ends from degradation (12, 18). A loss of telomeric repeats (a reduction in 
telomere length) and protective proteins, such as telomere repeat-binding factor 2 (Trf2), 
causes cellular senescence and apoptosis which can lead to cell loss and organ failure (3, 11), 
as reported in heart disease (16, 51). Failing hearts also have decreased expression of the 
telomere-lengthening enzyme telomerase and associated telomeric genes (41, 50), 
particularly Trf2 (51).  In contrast, endurance exercise can preserve these pathways and 
telomere length (33, 65), suggesting that telomeric gene expression and telomere length may 
be integral to the development of physiological cardiac hypertrophy (14). 
Despite mounting evidence that telomere length (16, 39, 51) and exercise (20, 27, 28, 
42, 65) are positively associated with cardiac function, these relationships are not well 
defined. The aims of this study were to determine whether telomere length and telomeric 
gene expression are altered in Reduced and Restricted rats and if this can be influenced by 
Early (5-9 weeks of age) and Late (20-24 weeks of age) endurance exercise training. It was 
hypothesised that Restricted and Reduced rats would have shorter cardiac telomeres and 
reduced telomeric gene expression and that this would be attenuated with exercise.  
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Methods 
Ethical approval 
This study was approved by the University of Melbourne Animal Experimentation Ethics 
Sub-committee, ratified at Federation University Australia, and conducted in accordance with 
accepted standards of humane animal care. 
Animal models 
The animals in this study have been described previously (34, 35, 60). Briefly, Wistar Kyoto 
rats aged 9-13 weeks were obtained for breeding purposes from the Australian Resource 
Centre (Murdoch, WA, Australia). Rats were then housed in a 12-hour light-dark cycle with 
ad libitum standard chow and water.  
To induce uteroplacental insufficiency, the primary cause of low birthweight in the 
developed world (8), pregnant rats underwent bilateral uterine vessel ligation surgery to 
create the ‘Restricted’ group or a sham operation to create the ‘Control’ group. Both surgeries 
were performed on day 18 of gestation (term 22 days) and used intraperitoneal injections of 
ilium xylazil-20 (10 mg. kg-1) and ketamine (50 mg. kg-1) as anaesthesia. 
Reduced postnatal growth is primarily caused by poor postnatal nutrition (7, 9). In 
rats, decreases in litter size also decrease the quality and quantity of milk during lactation 
and, consequently, slows postnatal growth (49, 56) which leads to catch-up growth and 
increased risk of heart disease (10). Restricted rats have decreased litter sizes (~5 pups) 
compared to sham-operated Controls (10-14 pups) (49, 62). Therefore, to create a litter-size 
control for the Restricted group, and provide a model of delayed postnatal growth (relative to 
the Control group), half of the sham-operated Control rats had their litters size reduced at 
birth to 5 pups to create a ‘Reduced’ group. Each growth cohort consisted of 22-24 male rats.  
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Exercise training and bodyweight 
At 5 weeks of age, rats from each growth cohort (Restricted, Reduced, and Control) were 
randomly divided into 3 exercise groups. The first of the 3 exercise groups remained 
sedentary for the entirety of the study (24 weeks) to create the ‘Sedentary’ group. The second 
underwent 4 weeks of exercise training from 5-9 weeks of age to create the ‘Early exercise’ 
group. The remaining third were exercised from 20-24 weeks of age to create the ‘Late 
exercise’ group. Therefore, this further division of the 3 growth cohorts into 3 exercise 
groups created 9 growth/exercise subgroups. Each of the 3 exercise groups consisted of 22-24 
male rats, with 7-8 in each of the 9 subgroups. A maximum of three pups were used per dam 
and each pup was assigned to a different exercise protocol.  
Both Early and Late exercise training involved treadmill running 5 days a week. 
Exercise duration progressively increased from 20 minutes per day at a speed of 15 metres 
per minute up to 60 minutes for the first week. The following three weeks were all conducted 
at 20 metres per minute for 60 minutes per day (34, 35, 60). Individual body weight of each 
animal was determined at day 6 (when the animals were sexed), as well as weeks 2, 5, 9, 16, 
20, and 24.  
Heart collection and analyses 
At 24 weeks of age all animals were euthanized with an intraperitoneal injection of ilium 
xylazil-20 (30 mg/kg) and ketamine (225 mg/kg). This occurred 72 hours after the final 
exercise training session in the Late exercise cohort. The entire heart was excised, weighed, 
and snap-frozen before being crushed into a powder as previously described (60) and stored 
at -80°C until the extractions. To measure heart weight relative to body weight, the cardiac 
weight index (CWI) was calculated (body weight (g) / heart weight (mg)). This body weight 
and heart weight data are subsets of those we have previously published (35, 60). 
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Genomic DNA was extracted from whole heart tissue using the Purelink Genomic 
DNA Mini Kit (Life Technologies). Telomere length was measured by quantitative 
polymerase chain reaction (qPCR) using the telomere (T) to single-copy gene (S) T/S ratio 
method (15). Briefly, the square of the cycle threshold (Ct) for the single-copy gene ('S') 
36B4, which is present only once in the genome, is divided by the squared Ct for Tel1 ('T'), 
which reflects telomere length. This yields the T/S ratio, a measure of average telomere 
length.  
RNA was isolated with TRI reagent (Life Technologies) and then reverse transcribed 
into cDNA using the High Transcriptase cDNA kit (Life Technologies). mRNA levels of 
telomerase reverse transcriptase (Tert), the rate-limiting step of the telomere-lengthening 
enzyme telomerase (37), and telomerase RNA component (Terc) (48), were assessed. 
Telomerase activity was not directly measured as other studies have shown that Tert mRNA 
expression strongly correlates with telomerase activity in the rat heart (39, 50).  
A key telomeric gene shown to be essential in maintaining telomere length and cell 
viability in the heart (51) is telomere repeat-binding factor 2 (Trf2). Protein phosphatase 1 
regulatory subunit 10 (Ppp1r10, also known, and hereafter referred to, as Pnuts) can facilitate 
the binding of Trf2 and is protective of cardiac telomere length and apoptosis (13) but its 
involvement in exercise-induced hypertrophy is not known. Moreover, the histone 
deacetylase Sirtuin 1 (Sirt1) is also associated with heart disease and aberrations in telomeric 
proteins (2, 40). As such, the mRNA levels of Trf2, Pnuts, and Sirt1 were also assessed. 
For all telomere length and gene expression analyses, the SensiFast SYBR Low-ROX 
Kit (Bioline) was used in a Viia7 qPCR machine (Life Technologies). For gene expression 
studies, glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was the housekeeping gene as 
used in Chapter 2 (44). The primers used were also the same as Chapter 2 (44) except for 
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Trf2 (forward: CTCCACGACAGCCTCGGAA [200nM] and reverse: GGGATGCTAGG 
TTAGGAAGTACCA [200nM]) and Sirt1 (forward: TGTTTCCTGTGGGATACCTGA 
[200nM] and reverse: TGAAGAATGGTCTTGGGTCTTT [200nM]) which were designed to 
flank exon-exon junctions and melt at 60°C using the Primer Blast tool from NCBI.  
qPCR conditions for telomere measurement involved one step of 95°C for 10 minutes 
followed by 36 cycles of 95°C for 15 seconds, 54°C for 20 seconds and 72°C for 2 minutes. 
For gene expression analyses, samples were heated to 95°C for ten minutes and then 
underwent 40 cycles of 95°C for 5 seconds, 58°C for 10 seconds, and 72°C for 10 seconds. 
Following each run protocol, specificity of product amplification was determined by melting 
curve analysis and DNA gel electrophoresis (data not shown). 
Statistical analyses 
Two-way analysis of variance (ANOVA) was used to determine the effects of growth and 
exercise as well as a possible growth/exercise interaction for all variables. Significant 
differences within growth cohorts and exercise groups were investigated using Bonferroni’s 
correction. Significant interactions were inspected using one-way ANOVAs. Normality and 
homogeneity of variances were assessed using the Shapiro-Wilk and Lavene tests, 
respectively. Pearson’s (normally distributed) or Spearman’s (nonparametric) tests were used 
to detect significant correlations. Stepwise multiple regression was performed to identify 
significant predictors of CWI and cardiac telomere length (F-entry probability, 0.05; removal, 
0.1). Data were analysed using SPSS version 24 with P<0.05 regarded as significant.  
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Results 
Body weight 
Restricted rats were significantly lighter than Control and Reduced rats at postnatal day 6 and 
the beginning of Early exercise training at 5 weeks of age (all P<0.05) (Table 1). Reduced 
rats, however, were not lighter than Controls at any age measured (all P>0.05) but had 
accelerated growth such that they were heavier than Controls from 16 weeks of age onward 
(all P<0.05) (35). At 24 weeks of age, body weight was significantly affected by growth 
restriction (P=0.004) and exercise treatment (P=0.042) but there was no interaction effect 
(Figure 1A). Reduced rats were significantly heavier than Control (P=0.010) and Restricted 
(P=0.013) rats (Figure 1A). Early exercise rats were significantly heavier than Late exercise 
rats (P=0.037) with Control rats being intermediate.  
Heart weight and cardiac weight index 
There was a significant main effect for growth restriction (P=0.017) and exercise treatment 
(P=0.002) on heart weight at 24 weeks of age (Figure 1B). There was a trend for Reduced 
rats to have heavier hearts than Control (P=0.062) and Restricted (P=0.050) rats. Early 
(P=0.001) and Late (P=0.046) exercise significantly increased heart weight relative to the 
Sedentary group (Figure 1B). Only exercise had a significant overall effect on CWI 
(P<0.001) with no significant interaction or influence of growth restriction detected (Figure 
1C). Both Early (P=0.002) and Late (P=0.005) exercise significantly increased CWI relative 
to the Sedentary group.  
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Table 1. Body weight by growth cohort before Early exercise treatment. 
Growth cohort BW 6 days of age BW 2 weeks of age BW 5 weeks of age 
Control 8.78 ± 0.18 21.70 ± 0.35 80.48 ± 1.13 
Restricted 7.68 ± 0.29*# 20.03 ± 0.76# 74.38 ± 2.08*# 
Reduced 8.86 ± 0.15 23.27 ± 0.39 80.34 ± 1.27 
Data are presented as M ± SEM, n=22-24 per growth cohort. BW, body weight. *P=<0.05 
compared to Control, #P<0.05 compared to Reduced, both Bonferroni comparisons of main 
effects. 
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Figure 1. Heart weight, body weight, and cardiac weight index. (A) Reduced growth and 
Early exercise increased body weight; (B) Early exercise increased heart weight; and (C) 
Early and Late exercise increased CWI. All at 24 weeks of age. Clear bars indicate Sedentary, 
lightly shaded bars indicate early exercise (Early Ex), and dark bars indicate late exercise 
(Late Ex) groups. Data are presented as mean ± SEM (n = 7-8/group). Significant differences 
for Growth Restriction effects are denoted by capital letters where ‘B’ is significantly higher 
than ‘A’. Lower case letters refer to Exercise effects where ‘b’ is significantly higher than ‘a’ 
with ‘ab’ intermediate and not significantly different from ‘a’ or ‘b’. All Bonferroni 
comparisons of main effects; P<0.05. NS, not significant. This data is a subset of what has 
been previously published (60). 
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Telomere length and telomerase genes 
Both growth restriction (P<0.001) and exercise treatment (P<0.001) significantly influenced 
cardiac telomere length (T/S ratio) (P<0.001, main effect of exercise) (Figure 2A). Restricted 
rats had significantly shorter cardiac telomeres than Control and Reduced rats (Figure 2A). 
Rats treated with Early exercise had significantly longer cardiac telomeres than Sedentary 
(P<0.001) and Late (P=0.001) exercise groups (Figure 2A). Cardiac telomere length was 
significantly correlated with bodyweight (r=0.371, P=0.001) and heart weight (r=0.289, 
P=0.012) but not CWI (r=0.010, P=0.931).  
Growth restriction (P=0.022), but not exercise or the interaction between the two, had 
a significant effect on Tert mRNA levels (Figure 2B). Tert expression was significantly 
higher in Reduced rats compared to Controls (P<0.001) with Restricted rats being 
intermediate (Figure 2B). Interestingly, Tert expression was not correlated with telomere 
length (ρ=-0.011, P=0.931).  
There was no significant effect of growth restriction, exercise treatment, or interaction 
between the two on Terc mRNA levels (Figure 2C). Cardiac Tert and Terc mRNA levels 
were positively correlated (ρ=0.414, P<0.001) however Terc expression was not correlated 
with telomere length (ρ=-0.102, P=0.410). 
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Figure 2. Telomere length and telomerase genes. (A) Telomere length (T/S ratio) was 
shorter in Restricted rats but longer following Early exercise; (B) Tert expression was higher 
in Reduced rats; and (C) Terc mRNA levels did not change because of Growth restriction or 
Exercise treatment. All whole-heart tissue at 24 weeks of age. Clear bars indicate Sedentary, 
lightly shaded bars indicate early exercise (Early Ex), and dark bars indicate late exercise 
(Late Ex) groups. Data are presented as mean ± SEM (n = 7-8/group). Significant differences 
for Growth Restriction effects are denoted by capital letters where ‘B’ is significantly higher 
than ‘A’ with ‘AB’ intermediate and not significantly different from ‘A’ or ‘B’. Lower case 
letters refer to Exercise effects where ‘b’ is significantly higher than ‘a’. All Bonferroni 
comparisons of main effects; P<0.05. NS, not significant.   
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Telomere-related genes 
Trf2 expression was not affected by growth restriction or exercise treatment but the 
interaction between the two was significant (P=0.032) (Figure 3A). There was a significant 
effect of growth restriction within the Sedentary group (P=0.011) with Restricted and 
Reduced rats having higher Trf2 expression than Controls (P<0.05) (Figure 3A). Exercise 
also had a significant effect of on cardiac Trf2 expression within the Control cohort 
(P=0.044) but post hoc analysis did not reveal significant differences between the exercise 
groups.  
There was a significant effect of growth restriction (P=0.042) but not exercise 
treatment, on Pnuts mRNA levels (Figure 3B). Control rats had significantly lower cardiac 
Pnuts mRNA levels than Restricted rats with Reduced rats intermediate. Pnuts and Trf2 
expression were strongly correlated (r=0.589, P<0.001). 
There was a significant effect of growth restriction (P=0.021) and growth 
restriction/exercise treatment interaction (P=0.001) but not exercise treatment on Sirt1 
mRNA levels (Figure 3C). In Sedentary rats, there was a significant effect of exercise 
(P<0.001) with Restricted and Reduced having higher Sirt1 expressions than Controls 
(P<0.05) (Figure 3C). There were significant effects of exercise for Control rats (P=0.0001) 
with Late exercise having higher Sirt1 mRNA than Sedentary and Early exercise intermediate 
(P<0.05); and Reduced rats (P=0.008), with Early and Late exercise having lower Sirt1 
mRNA than Sedentary (P<0.05) (Figure 3C). Sirt1 expression was also positively correlated 
with Trf2 (r=0.642, P<0.001) and Pnuts (r=0.709, P<0.001) expression. 
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Figure 3. Telomere-related genes. (A) Trf2 expression was higher in Restricted and 
Reduced Sedentary rats relative to Control Sedentary rats; (B) Pnuts expression was higher in 
Restricted rats; and (C) Sirt1 mRNA levels were higher in Restricted and Reduced rats 
compared to the Controls. All whole-heart tissue at 24 weeks of age. Clear bars indicate 
Sedentary, lightly shaded bars indicate early exercise (Early Ex), and dark bars indicate late 
exercise (Late Ex) groups. Data are presented as mean ± SEM (n = 7-8/group). Significant 
differences for Growth Restriction effects are denoted by capital letters where ‘B’ is 
significantly higher than ‘A’ with ‘AB’ intermediate and not significantly different from ‘A’ 
or ‘B’. Lower case letters refer to Exercise effects where ‘b’ is significantly higher than ‘a’ 
with ‘ab’ intermediate and not significantly different from ‘a’ or ‘b’. All Bonferroni 
comparisons of main effects; P<0.05. NS, not significant.  
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Predictors of cardiac weight index and cardiac telomere length  
Stepwise multiple regression analysis revealed that Early and Late exercise were the only 
significant predictors of CWI. Both exercise regimes had a positive effect on relative heart 
weight, accounting for 18.5% of the variation in CWI (adjusted R2=0.185) (P=0.001) (Table 
2). For cardiac telomere length, Early exercise (positive effect) and Restricted growth 
(negative effect) were the only significant predictors and together explained 36.9% of the 
variation in T/S ratio (adjusted R2=0.369) (P<0.001) (Table 3).   
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Table 2. Significant predictors of cardiac weight index.  
CWI β ± S.E. Standardised β 95% C.I. for β P value 
Late exercise  0.305 ± 0.075 0.526 0.156 to 0.455 <0.001 
Early exercise  0.181 ± 0.072 0.323 0.037 to 0.326 0.015 
C.I., confidence interval, S.E, standard error of the mean. Covariates included cardiac Tert, 
Terc, Pnuts, Trf2, and Sirt1 mRNA levels, cardiac telomere length, Restricted (compared to 
Control), Reduced (compared to Control), Early exercise (compared to Sedentary), and Late 
exercise (compared to Sedentary). F-entry probability: 0.05, removal: 0.1. 
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Table 3. Significant predictors of cardiac telomere length.  
T/S ratio β ± S.E. Standardised β 95% C.I. for β P value 
Early exercise  0.171 ± 0.035 0.486 0.102 to 0.240 <0.001 
Restricted  -0.136 ± 0.035 -0.382 -0.206 to -0.066 <0.001 
C.I., confidence interval; S.E., standard error of the mean. Covariates included cardiac Tert, 
Terc, Pnuts, Trf2, and Sirt1 mRNA levels, CWI, Restricted (compared to Control), Reduced 
(compared to Control), Early exercise (compared to Sedentary), and Late exercise (compared 
to Sedentary). F-entry probability: 0.05, removal: 0.1. 
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Discussion  
The present study sought to identify the effects of growth restriction and exercise treatment 
on cardiac mass and telomeres in male rats. Growth restriction shortened cardiac telomere 
length and Early exercise increased heart weight and prevented cardiac telomere attrition 
relative to Sedentary and Late exercise groups. Importantly, increased cardiac telomere 
length detected 15 weeks after early exercise occurred in all three growth cohorts, suggesting 
that early intervention with exercise treatment can increase cardiac telomere length in both 
normal and growth-restricted individuals. This finding also provides further evidence that this 
early exercise regime induces a physiological and not pathological increase in heart mass in 
adulthood. Indeed, a recent study using the same early exercise protocols on male rats found 
that early exercise increases cardiomyocyte proliferation and cardiac mass without affecting 
cardiac function, chamber size, or cardiac fibrosis levels (5). These findings highlight the 
utility of early exercise to improve cardiac health in later life.  
An increase in cardiac telomere length has important consequences in terms of 
cardiovascular health as only cardiomyocyte precursor cells with long telomeres can produce 
functional and long-living daughter cells (30). Indeed, one explanation for the increase in 
telomere length following early exercise is an increase in the number of young 
cardiomyocytes, as we have recently reported in 24-week-old WKY rats treated with Early 
exercise (5). The increased complement of cardiomyocytes in the adult heart following this 
training regime supports the concept that these early-life exercise interventions increased the 
number of proliferating cardiomyocytes with long telomeres within the myocardium (38, 63). 
This could also explain why the Late exercise groups did not have longer telomeres. In 
accordance with this finding, there was no difference in the number of cardiomyocytes as a 
result of Late exercise (5), suggesting that the increase in cardiac mass and relative heart 
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weight in the Late exercise groups in the present study is due to cardiomyocyte hypertrophy 
and not hyperplasia. Similarly, cardiomyocyte number is critical in the regards to cardiac 
health, with a cardiomyocyte apoptotic rate of only 0.023% considered pathologically 
significant (64). This suggests that even a small decrease in average cardiac telomere length 
may significantly affect cardiomyocyte viability and thus cardiac function. Future studies that 
directly measure cardiomyocyte size and proliferation are required to confirm the effects of 
exercise on the heart at different ages.  
Another key finding of this study was that Restricted rats had shorter cardiac 
telomeres than Reduced and Control rats in all exercise groups. Interestingly, in the 
hypertrophic heart rat studied in Chapter 2, body weight was also lighter throughout life and 
cardiac telomere length shorter at 13 weeks of age (44). This suggests that both prenatal and 
postnatal growth restriction are needed to shorten cardiac telomere length and that low birth 
weight compounds the risk of cardiovascular disease. Importantly, these findings are not 
confounded by typical risk factors for cardiovascular disease and short telomeres, such as 
obesity (46) and old age (32). In contrast to the findings of Chapter 2 (44), however, CWI 
was not correlated with the T/S ratio in the present study so a relationship between cardiac 
telomere length and relative heart weight could not be determined. Indeed, only exercise 
treatment and Restricted (but not Reduced) growth were identified as significant predictors of 
CWI and telomere length in the present study. 
The similar telomere lengths detected in the Sedentary and Late exercise groups is 
consistent with previous research showing that changes in telomere length take time to occur. 
For instance, there were no differences in cardiac telomere length between heart/muscle-
specific manganese superoxide dismutase-deficient mice (H/M-SOD2−/−), a model of 
premature heart failure, and the control strain after 4 weeks of antioxidant treatment (41). In 
contrast, 8 weeks of antioxidant treatment rescued the decreased telomere length observed in 
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untreated H/M-SOD2−/− mice (52). Similarly, telomere length in the heart was unchanged in 
mice immediately following 3 weeks of exercise (65) whereas 44 weeks of exercise resulted 
in significantly longer cardiac telomeres in rats (39). The current study demonstrates that a 
short-term exercise treatment in early life can significantly increase cardiac telomere length. 
Indeed, this early exercise training protocol is analogous to early adolescence in humans 
which suggests that exercise interventions in school curricula could help prevent heart disease 
even if exercise is not continued into adulthood (5). Benefits may also be possible in later 
life, but we could not determine this, as the present study concluded only three days after 
Late exercise treatment ended. Longer studies could confirm if exercise interventions in 
adulthood produce lasting effects into later life. 
In contrast to telomere length, changes in Tert and Trf2 can occur after only short 
treatments. Indeed, telomerase activity and Trf2 protein levels are downregulated in H/M-
SOD2−/− mice but this can be inhibited with only 4 weeks of antioxidant treatment (before 
changes in telomere length are observed) (41). In the present study, Tert expression was 
higher in Reduced compared to Control rats and Trf2 expression increased in Restricted and 
Reduced Sedentary rats relative to Control Sedentary rats. Similarly, Pnuts expression was 
higher in Restricted and Sirt1 higher in Restricted and Reduced rats compared to the 
Controls. These changes can all be viewed as compensatory responses to the stresses of 
Restricted and Reduced growth or the benefits of exercise. In support of this suggestion, there 
is much evidence that Tert expression increases at the onset of cardiac dysfunction but returns 
to basal levels or lower after chronic stress (reviewed in (14)). Similarly, Tert protein levels 
increase after three weeks of voluntary running in mice (65) but no differences were found in 
rats after 44 weeks of exercise (39). In contrast, Terc is often relatively unchanged in animal 
models of heart disease (17, 41, 44), as it was in the present study. Despite these trends, there 
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is still little evidence to suggest that these telomeric genes have the sensitivity and/or stable 
expression to identify cardiac hypertrophy while it is still reversible. 
Due to the low mitotic index in the heart, oxidative stress has been suggested to 
account for the majority of cardiac telomere attrition throughout life (29, 36). Indeed, this is a 
leading hypothesis regarding the utility of antioxidants to preserve both telomere length (58) 
and heart function (1). Interestingly, improved anti-oxidant capacity is also an adaptive 
response to exercise (65) and thus decreased telomere oxidation could explain the longer 
telomere length found after chronic exercise training. In this regard, our previous research has 
shown that Reduced and Restricted rats have dysregulated antioxidant as well as metabolic 
genes in the heart during postnatal life, although these normalise by five weeks of age (with 
the exception of the antioxidant enzyme manganese superoxide dismutase in males) (61). As 
telomere length is negatively associated with metabolic dysregulation (59) and oxidative 
stress (58), this could pre-dispose individuals with perinatal growth restriction to accelerated 
telomere attrition, leading to premature cell loss and organ failure. In this regard, the 
opposing effects of exercise (39, 65) could rescue cells from oxidative and metabolic injury, 
thereby preventing cardiac decline in this model (Figure 4). 
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Figure 4. A simplified pathway of the proposed development of heart disease in 
Restricted male rats and the possible protective effects of early exercise.  PGC-1α, 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha; mtTFA, 
mitochondrial transcription factor A; mnSOD, manganese superoxide dismutase. This Figure 
is based on data from the present study and Wadley, et al. (61).  
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As there are many risk factors for short telomere length and heart disease (26), there 
are likely several pathways that collectively contribute to cardiac dysfunction, with some 
being specific to certain types of heart disease or present only at specific stages or in some 
species. Unlike the dynamic expression of telomeric genes, variables such as increased heart 
weight (32) and decreased telomere length (31), seem to be universal markers of poor cardiac 
function despite taking longer to present. In this regard, there is a need for future research to 
ascertain the survivability of Restricted and Reduced rats compared to Controls and 
determine if exercise treatment does increase lifespan and delay the onset of cardiovascular 
disease. Furthermore, detailed analyses of cardiac phenotype and function, such as 
measurements of cardiac output and histological assessments, of exercised and sedentary rats 
are required to confirm the relationship between telomere length and the type of cardiac 
hypertrophy being studied. It would also be interesting to determine telomere length and the 
levels of telomeric genes at different stages of development and in other tissues. Indeed, 
accelerated telomere attrition in other tissues may be involved in pathologies, such as 
diabetes (34) and kidney disease (66), which are also associated with fetal growth restriction.  
In regards to cardiac telomere length, much research has focused specifically on 
cardiomyocytes (16, 36, 51, 55, 58), the functional cells the produce the contractions. The 
present study, however, along with others (29, 39, 67), used whole-heart tissue which 
contains endothelial cells, fibroblasts, and leukocytes (47, 53). Telomere length in separated 
cardiomyocytes, however, was shown to strongly correlate with telomere length in whole 
heart tissue in Chapter 2 (44). Nevertheless, there is a strong intra-individual variation in 
telomere length (21) to the extent that there are significant differences in telomere length 
between cardiomyocytes from the same individual (55). Therefore, the use of whole heart 
tissue has some limitations but provides telomere measurements at the site of interest, instead 
of simply using circulating leukocytes (the most common approach (3)) because they can be 
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easily acquired. Importantly, the present study reveals that Early exercise increases cardiac 
telomere length in Control, Restricted, and Reduced rats, likely protecting the heart and 
attenuating the adverse cardiac effects induced by prenatal and postnatal growth restriction. 
Given the reliability of this finding, we would predict that the effect of Early exercise would 
be more pronounced if telomere length was only measured in cardiomyocytes.  
In conclusion, the present study demonstrates that low birth weight after fetal growth 
restriction reduces cardiac telomere length. Importantly this can be attenuated by exercise 
early in life, however, the molecular mechanisms regulating cardiac telomere length remain 
mostly elusive as there were no reliable correlations with telomeric genes at 24 weeks of age. 
Nonetheless, such findings suggest there are key pathways that elicit changes in heart weight 
and cardiac telomere length in response to exercise which could be targeted for therapeutic 
benefit. Although future studies are required to determine the effects of exercise on the heart 
at different ages and into later adulthood, our findings, combined with the well-established 
degenerative nature of heart disease, highlight the importance of early interventions for 
susceptible individuals. Indeed, exercise may only be a viable treatment option before 
telomeres reach a critical length and irreversible cell loss ensues. 
  
 135 
 
References 
1. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, Peters H, Birch-Machin 
MA, von Zglinicki T, and Saretzki G. Telomerase does not counteract telomere shortening 
but protects mitochondrial function under oxidative stress. J Cell Sci 121: 1046-1053, 2008. 
2. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, 
Vatner SF, and Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the 
heart. Circ Res 100: 1512-1521, 2007. 
3. Armanios M, and Blackburn EH. The telomere syndromes. Nat Rev Genet 13: 693-
704, 2012. 
4. Ascensao A, Ferreira R, and Magalhaes J. Exercise-induced cardioprotection--
biochemical, morphological and functional evidence in whole tissue and isolated 
mitochondria. Int J Cardiol 117: 16-30, 2007. 
5. Asif Y, Wlodek ME, Black MJ, Russell AP, Soeding PF, and Wadley GD. 
Sustained cardiac programming by short-term juvenile exercise training in male rats. J 
Physiol 2017. 
6. Barker DJ. Fetal nutrition and cardiovascular disease in later life. Br Med Bull 53: 
96-108, 1997. 
7. Barker DJ, Osmond C, Forsen TJ, Kajantie E, and Eriksson JG. Trajectories of 
growth among children who have coronary events as adults. N Engl J Med 353: 1802-1809, 
2005. 
8. Barker DJ, Osmond C, Golding J, Kuh D, and Wadsworth ME. Growth in utero, 
blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 
298: 564-567, 1989. 
9. Barker DJ, Winter PD, Osmond C, Margetts B, and Simmonds SJ. Weight in 
infancy and death from ischaemic heart disease. Lancet 2: 577-580, 1989. 
 136 
 
10. Black MJ, Siebel AL, Gezmish O, Moritz KM, and Wlodek ME. Normal 
lactational environment restores cardiomyocyte number after uteroplacental insufficiency: 
implications for the preterm neonate. Am J Physiol Regul Integr Comp Physiol 302: R1101-
1110, 2012. 
11. Blackburn EH. Switching and signaling at the telomere. Cell 106: 661-673, 2001. 
12. Blackburn EH. Telomeres. Trends Biochem Sci 16: 378-381, 1991. 
13. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, 
Treguer K, Carmona G, Bonauer A, Horrevoets AJ, Didier N, Girmatsion Z, Biliczki P, 
Ehrlich JR, Katus HA, Muller OJ, Potente M, Zeiher AM, Hermeking H, and 
Dimmeler S. MicroRNA-34a regulates cardiac ageing and function. Nature 495: 107-110, 
2013. 
14. Booth SA, and Charchar FJ. Cardiac Telomere Length in Heart Development, 
Function, and Disease. Physiol Genomics physiolgenomics 00024 02017, 2017. 
15. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 30: 
e47, 2002. 
16. Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, Di Meglio 
F, Nadal-Ginard B, Frustaci A, Leri A, Maseri A, and Anversa P. Senescence and death 
of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res 
93: 604-613, 2003. 
17. Chiu CL, Hearn NL, Paine D, Steiner N, and Lind JM. Does Telomere Shortening 
Precede the Onset of Hypertension in Spontaneously Hypertensive Mice? Twin Res Hum 
Genet 19: 422-429, 2016. 
18. de Lange T. How shelterin solves the telomere end-protection problem. Cold Spring 
Harb Symp Quant Biol 75: 167-177, 2010. 
 137 
 
19. Denham J, Nelson CP, O'Brien BJ, Nankervis SA, Denniff M, Harvey JT, 
Marques FZ, Codd V, Zukowska-Szczechowska E, Samani NJ, Tomaszewski M, and 
Charchar FJ. Longer leukocyte telomeres are associated with ultra-endurance exercise 
independent of cardiovascular risk factors. PLoS One 8: e69377, 2013. 
20. Denham J, O'Brien BJ, and Charchar FJ. Telomere Length Maintenance and 
Cardio-Metabolic Disease Prevention Through Exercise Training. Sports Med 46: 1213-1237, 
2016. 
21. Dlouha D, Maluskova J, Kralova Lesna I, Lanska V, and Hubacek JA. 
Comparison of the relative telomere length measured in leukocytes and eleven different 
human tissues. Physiol Res 63 Suppl 3: S343-350, 2014. 
22. Dorn GW, 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in 
ventricular remodelling. Cardiovasc Res 81: 465-473, 2009. 
23. Dorn GW, 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 
49: 962-970, 2007. 
24. Eriksson JG, Forsen T, Tuomilehto J, Winter PD, Osmond C, and Barker DJ. 
Catch-up growth in childhood and death from coronary heart disease: longitudinal study. 
BMJ 318: 427-431, 1999. 
25. Frey N, and Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu 
Rev Physiol 65: 45-79, 2003. 
26. Fyhrquist F, Saijonmaa O, and Strandberg T. The roles of senescence and 
telomere shortening in cardiovascular disease. Nat Rev Cardiol 10: 274-283, 2013. 
27. Hakim AA, Curb JD, Petrovitch H, Rodriguez BL, Yano K, Ross GW, White 
LR, and Abbott RD. Effects of walking on coronary heart disease in elderly men: the 
Honolulu Heart Program. Circulation 100: 9-13, 1999. 
 138 
 
28. Hakim AA, Petrovitch H, Burchfiel CM, Ross GW, Rodriguez BL, White LR, 
Yano K, Curb JD, and Abbott RD. Effects of walking on mortality among nonsmoking 
retired men. N Engl J Med 338: 94-99, 1998. 
29. Hemmeryckx B, Hohensinner P, Swinnen M, Heggermont W, Wojta J, and 
Lijnen HR. Antioxidant Treatment Improves Cardiac Dysfunction in a Murine Model of 
Premature Aging. J Cardiovasc Pharmacol 68: 374-382, 2016. 
30. Kajstura J, Gurusamy N, Ogorek B, Goichberg P, Clavo-Rondon C, Hosoda T, 
D'Amario D, Bardelli S, Beltrami AP, Cesselli D, Bussani R, del Monte F, Quaini F, 
Rota M, Beltrami CA, Buchholz BA, Leri A, and Anversa P. Myocyte turnover in the 
aging human heart. Circ Res 107: 1374-1386, 2010. 
31. Kajstura J, Rota M, Urbanek K, Hosoda T, Bearzi C, Anversa P, Bolli R, and 
Leri A. The telomere-telomerase axis and the heart. Antioxid Redox Signal 8: 2125-2141, 
2006. 
32. Katholi RE, and Couri DM. Left ventricular hypertrophy: major risk factor in 
patients with hypertension: update and practical clinical applications. Int J Hypertens 2011: 
495349, 2011. 
33. Kim JH, Ko JH, Lee DC, Lim I, and Bang H. Habitual physical exercise has 
beneficial effects on telomere length in postmenopausal women. Menopause 19: 1109-1115, 
2012. 
34. Laker RC, Gallo LA, Wlodek ME, Siebel AL, Wadley GD, and McConell GK. 
Short-term exercise training early in life restores deficits in pancreatic beta-cell mass 
associated with growth restriction in adult male rats. Am J Physiol Endocrinol Metab 301: 
E931-940, 2011. 
 139 
 
35. Laker RC, Wlodek ME, Wadley GD, Gallo LA, Meikle PJ, and McConell GK. 
Exercise early in life in rats born small does not normalize reductions in skeletal muscle 
PGC-1alpha in adulthood. Am J Physiol Endocrinol Metab 302: E1221-1230, 2012. 
36. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, Nadal-Ginard 
B, Kajstura J, Anversa P, and Blasco MA. Ablation of telomerase and telomere loss leads 
to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J 22: 131-139, 
2003. 
37. Liu K, Hodes RJ, and Weng N. Cutting edge: telomerase activation in human T 
lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein 
but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 166: 
4826-4830, 2001. 
38. Liu X, Xiao J, Zhu H, Wei X, Platt C, Damilano F, Xiao C, Bezzerides V, 
Bostrom P, Che L, Zhang C, Spiegelman BM, and Rosenzweig A. miR-222 is necessary 
for exercise-induced cardiac growth and protects against pathological cardiac remodeling. 
Cell Metab 21: 584-595, 2015. 
39. Ludlow AT, Witkowski S, Marshall MR, Wang J, Lima LC, Guth LM, 
Spangenburg EE, and Roth SM. Chronic exercise modifies age-related telomere dynamics 
in a tissue-specific fashion. J Gerontol A Biol Sci Med Sci 67: 911-926, 2012. 
40. Makino N, Maeda T, Oyama J, Higuchi Y, and Mimori K. Improving insulin 
sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of 
OLETF rats. Am J Physiol Heart Circ Physiol 297: H2188-2195, 2009. 
41. Makino N, Maeda T, Oyama J, Sasaki M, Higuchi Y, Mimori K, and Shimizu T. 
Antioxidant therapy attenuates myocardial telomerase activity reduction in superoxide 
dismutase-deficient mice. J Mol Cell Cardiol 50: 670-677, 2011. 
 140 
 
42. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, 
Perri MG, Sheps DS, Pettinger MB, and Siscovick DS. Walking compared with vigorous 
exercise for the prevention of cardiovascular events in women. N Engl J Med 347: 716-725, 
2002. 
43. Maron BJ, and Pelliccia A. The heart of trained athletes: cardiac remodeling and the 
risks of sports, including sudden death. Circulation 114: 1633-1644, 2006. 
44. Marques FZ, Booth SA, Prestes PR, Curl CL, Delbridge LM, Lewandowski P, 
Harrap SB, and Charchar FJ. Telomere dynamics during aging in polygenic left 
ventricular hypertrophy. Physiol Genomics 48: 42-49, 2016. 
45. Master JS, Zimanyi MA, Yin KV, Moritz KM, Gallo LA, Tran M, Wlodek ME, 
and Black MJ. Transgenerational left ventricular hypertrophy and hypertension in offspring 
after uteroplacental insufficiency in male rats. Clin Exp Pharmacol Physiol 41: 884-890, 
2014. 
46. Mendis S, Davis S, and Norrving B. Organizational update: the world health 
organization global status report on noncommunicable diseases 2014; one more landmark 
step in the combat against stroke and vascular disease. Stroke 46: e121-122, 2015. 
47. Nag AC. Study of non-muscle cells of the adult mammalian heart: a fine structural 
analysis and distribution. Cytobios 28: 41-61, 1980. 
48. Nandakumar J, and Cech TR. Finding the end: recruitment of telomerase to 
telomeres. Nat Rev Mol Cell Biol 14: 69-82, 2013. 
49. O'Dowd R, Kent JC, Moseley JM, and Wlodek ME. Effects of uteroplacental 
insufficiency and reducing litter size on maternal mammary function and postnatal offspring 
growth. Am J Physiol Regul Integr Comp Physiol 294: R539-548, 2008. 
 141 
 
50. Oh H, Taffet GE, Youker KA, Entman ML, Overbeek PA, Michael LH, and 
Schneider MD. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, 
hypertrophy, and survival. Proc Natl Acad Sci U S A 98: 10308-10313, 2001. 
51. Oh H, Wang SC, Prahash A, Sano M, Moravec CS, Taffet GE, Michael LH, 
Youker KA, Entman ML, and Schneider MD. Telomere attrition and Chk2 activation in 
human heart failure. Proc Natl Acad Sci U S A 100: 5378-5383, 2003. 
52. Oyama JI, Shiraki A, Nishikido T, Maeda T, Komoda H, Shimizu T, Makino N, 
and Node K. EGCG, a green tea catechin, attenuates the progression of heart failure induced 
by the heart/muscle-specific deletion of MnSOD in mice. J Cardiol 69: 417-427, 2017. 
53. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, 
Chandran A, Wang L, Arora K, Rosenthal NA, and Tallquist MD. Revisiting Cardiac 
Cellular Composition. Circ Res 118: 400-409, 2016. 
54. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz 
GA, Willett WC, and Hennekens CH. Birth weight and risk of cardiovascular disease in a 
cohort of women followed up since 1976. BMJ 315: 396-400, 1997. 
55. Rota M, Hosoda T, De Angelis A, Arcarese ML, Esposito G, Rizzi R, Tillmanns 
J, Tugal D, Musso E, Rimoldi O, Bearzi C, Urbanek K, Anversa P, Leri A, and 
Kajstura J. The young mouse heart is composed of myocytes heterogeneous in age and 
function. Circ Res 101: 387-399, 2007. 
56. Russell JA. Milk yield, suckling behaviour and milk ejection in the lactating rat 
nursing litters of different sizes. J Physiol 303: 403-415, 1980. 
57. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, and 
Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the 
transition to heart failure. J Clin Invest 115: 2108-2118, 2005. 
 142 
 
58. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh 
K, Rosenzweig A, Sussman MA, Urbanek K, Nadal-Ginard B, Kajstura J, Anversa P, 
and Leri A. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth 
factor-1 overexpression. Circ Res 94: 514-524, 2004. 
59. van der Harst P, Wong LS, de Boer RA, Brouilette SW, van der Steege G, Voors 
AA, Hall AS, Samani NJ, Wikstrand J, van Gilst WH, van Veldhuisen DJ, and Group 
M-HS. Possible association between telomere length and renal dysfunction in patients with 
chronic heart failure. Am J Cardiol 102: 207-210, 2008. 
60. Wadley GD, Laker RC, McConell GK, and Wlodek ME. Endurance training in 
early life results in long-term programming of heart mass in rats. Physiol Rep 4: 2016. 
61. Wadley GD, McConell GK, Goodman CA, Siebel AL, Westcott KT, and Wlodek 
ME. Growth restriction in the rat alters expression of metabolic genes during postnatal 
cardiac development in a sex-specific manner. Physiol Genomics 45: 99-105, 2013. 
62. Wadley GD, Siebel AL, Cooney GJ, McConell GK, Wlodek ME, and Owens JA. 
Uteroplacental insufficiency and reducing litter size alters skeletal muscle mitochondrial 
biogenesis in a sex-specific manner in the adult rat. Am J Physiol Endocrinol Metab 294: 
E861-869, 2008. 
63. Waring CD, Vicinanza C, Papalamprou A, Smith AJ, Purushothaman S, 
Goldspink DF, Nadal-Ginard B, Torella D, and Ellison GM. The adult heart responds to 
increased workload with physiologic hypertrophy, cardiac stem cell activation, and new 
myocyte formation. Eur Heart J 35: 2722-2731, 2014. 
64. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani 
J, Armstrong RC, and Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart 
failure. J Clin Invest 111: 1497-1504, 2003. 
 143 
 
65. Werner C, Hanhoun M, Widmann T, Kazakov A, Semenov A, Poss J, 
Bauersachs J, Thum T, Pfreundschuh M, Muller P, Haendeler J, Bohm M, and Laufs 
U. Effects of physical exercise on myocardial telomere-regulating proteins, survival 
pathways, and apoptosis. J Am Coll Cardiol 52: 470-482, 2008. 
66. Wlodek ME, Westcott K, Siebel AL, Owens JA, and Moritz KM. Growth 
restriction before or after birth reduces nephron number and increases blood pressure in male 
rats. Kidney Int 74: 187-195, 2008. 
67. Wong LS, Windt WA, Roks AJ, van Dokkum RP, Schoemaker RG, de Zeeuw D, 
and Henning RH. Renal failure induces telomere shortening in the rat heart. Neth Heart J 
17: 190-194, 2009. 
 
 
 
 
 
 
 
 
 
 144 
 
 
 
 
Chapter 4 
 
Human Cardiomyocyte Telomeres after 
Inducing Hypertrophy   
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Abstract 
Background and aims: Cardiomyocyte hypertrophy is a hallmark cellular defect of heart 
disease. Association studies have shown that cardiomyocyte size correlates with decreases in 
telomere length and maintenance, but possible causal relationships remain unknown. The aim 
of the present study was to determine whether changes in cardiomyocyte size effect telomeres 
and the mechanism/s through which this might occur.  
Methods and results: Hypertrophy was induced in human primary cardiomyocytes (HPCs) 
using the hypertrophic agonists adrenaline, angiotensin II, endothelin-1, isoproterenol, and 
phenylephrine. Cell size, proliferation, and oxidative stress were determined using 
immunocytochemistry and/or confocal microscopy. Telomere length and the expression of 
telomeric, hypertrophic, and inflammatory genes were assessed with qPCR. All treatments 
significantly increased HPC size (P<0.05) but only Endothelin-1 had a significant effect on 
telomeres, which were shorter after 48 hours, 10 days, and 16 days of treatment (P<0.05). 
ET-1 also induced oxidative stress (P=0.004) while all agonists caused increased 
inflammation, proliferation, and dysregulated metabolic gene expression (P<0.05).  
Discussion and conclusions: The present study demonstrates that cardiomyocyte hypertrophy 
can occur independently of changes in telomere length and maintenance. The increase in 
inflammation and proliferation provide an explanation for the telomere attrition observed in 
late-stage cardiac hypertrophy and heart failure. Endothelin-1, however, may play a more 
direct role in cardiomyocyte aging and viability which could be targeted for therapeutic use. 
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Introduction 
All organs of the body rely on the constant circulation of blood which has made 
cardiomyocytes, the contractile cells of the heart, extremely responsive to stimuli that 
communicate the needs of other tissues (76). Although most physiological demands can be 
met by a temporary rise in heart rate, extreme or sustained stimulation to boost cardiac output 
causes an increase in cardiomyocyte size (21). As such, a certain degree of cardiomyocyte 
growth is involved in normal development (maturational hypertrophy) as well as strenuous 
exercise and pregnancy (physiological cardiac hypertrophy) (44). In contrast, pathological 
stress on the cardiovascular system, such as hypertension (13), atherosclerosis (52), and 
obesity (90), leads to overt cardiomyocyte growth which causes an abnormal increase in heart 
mass known as cardiac (or left ventricular) hypertrophy. Therefore, cardiomyocyte 
hypertrophy is a hallmark cellular defect of heart (or cardiovascular) disease, the worldwide 
leading cause of death (50).  
Excessive stress on the cardiovascular system is associated with an increase in the 
release of hypertrophic agonists, such as angiotensin-II (Ang-II) (88) and endothelin-1 (ET-1) 
(3). This activates adrenergic receptors (ARs) on cardiomyocytes (25), leading to alterations 
in gene expression reminiscent of the fetal and neonatal period (64). Indeed, the most 
important markers of cardiac hypertrophy and subsequent heart failure are members of the 
so-called fetal gene program, such as the peptide hormones atrial and brain natriuretic peptide 
(ANP and BNP) (20). In contrast, physiological hypertrophy boosts cardiac output and is 
considered harmless (48), typically presenting with the upregulation of mitogen-activated 
protein kinase 1 (MAPK1) (the gene for ERK2) (9), mechanistic target of rapamycin 
(MTOR) (68), and protein kinase AMP-activated catalytic subunit alpha 2 (PRKKA2) (91). 
Despite these important distinctions, all types of cardiac hypertrophy result from stimuli 
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inducing transcriptional changes that increase intra-cellular protein levels (particularly the 
key contractile unit α-sarcomeric actin) and thus cardiomyocyte size.  
Cardiomyocyte hypertrophy is also accompanied by cell behaviours associated with 
senescence and apoptosis, such as morphological changes in cytoskeletal (60) and nuclear 
(57) structure. In this regard, both senescence and apoptosis are controlled by telomere length 
(2, 5), the number of TTAGGG repeats that protect chromosome ends (6, 19). Indeed, several 
studies have found that short telomeres (i.e. fewer protective repeats) are associated with 
cardiomyocyte hypertrophy (12, 45, 74). In addition, the upregulation of the telomere-
lengthening enzyme telomerase accompanies the onset of heart disease (75) whereas a 
reduction is found in its later stages (36, 70). Moreover, reduced expression of proteins that 
bind to the telomeric sequence, such as telomere repeat-binding factor 2 (TRF2), is observed 
in diseased hearts (59). In contrast, exercise preserves cardiac telomere length (42), 
cardiomyocyte viability (58), as well as telomerase and TRF2 expression levels (81). Taken 
together, these findings suggest that telomeric factors may play an important role in the 
development of pathological but not physiological cardiac hypertrophy.  
Despite several studies, it is still not known whether telomere attrition is a cause, 
consequence, or epiphenomenon of cardiomyocyte hypertrophy and there are several reasons 
for this. Firstly, systemic treatments that induce cardiac hypertrophy in vivo also induce 
confounding diseases such as hypertension (61) and renal failure (82). Secondly, findings 
from animal studies must be interpreted with caution as there are significant interspecies 
differences in telomere length (66, 75), nuclear morphology, and cardiac histology (37). 
Thirdly, oxidative stress (75), inflammation (46), and metabolic aberrations (55), are known 
to decrease telomere length and heart function, however these confounding factors are often 
not measured or controlled for (23, 65). Finally, it is not always directly established if the 
hypertrophy being studied reflects the pathological type and is likely to progress to heart 
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failure. The aim of the present study is to induce hypertrophy in human primary 
cardiomyocytes (HPCs) in vitro and measure the effect on telomere length and maintenance. 
Importantly, measurements of key confounding factors and markers of different types of 
cardiac hypertrophy will also be determined. It is hypothesised that the hypertrophic response 
will cause alterations in telomeric regulators, oxidative stress, metabolic gene expression, and 
inflammation before significant changes in telomere length are detected. 
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Methods 
Ethical approval 
As this study used a cell line, no ethical clearance was required.  
Cell culture  
The present study used human primary cardiomyocytes (HPCs) from a healthy 56-year-old 
Caucasian male grown in ready-to-use myocyte growth medium (both from Promo Cell, 
Heidelberg, Germany). As cardiomyocyte mitosis is very minimal in adult humans (69), this 
cell line is derived from adult cardiac progenitor cells and, for research purposes, can be 
expanded for more than 15 population doublings in culture. Importantly, HPCs are not 
immortal, as the immortalisation of cell culture lines prevents telomere attrition (7) and thus 
limits the utility of such models in studies of cellular aging. In this study, passage 4 cells 
(unless otherwise indicated) were seeded at 25% confluence, and allowed to adhere for 24 
hours before treatment. 6-well dishes were used for nucleic acid and protein extraction and 
single glass-bottom dishes of the same size for imaging (Mattek Corporation, Ashland, USA). 
All cultures were grown, passaged, and stored using the manufacturer’s recommended 
reagents and protocols. 
The common immortalised rat embryonic cardiomyoblast (H9c2) cell line was also used to 
determine if it could be used to model HPC hypertrophy and telomere dynamics. Passage 7 
H9c2 cells were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% 
(v/v) Fetal Bovine Serum and 1% (v/v) Penicillin/Streptomycin, L-Glutamate (Life 
Technologies). H9c2 cells were seeded at 15% confluence because of their more rapid 
population doubling time but were otherwise treated identically to the HPCs.  
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Induction of hypertrophy  
The hypertrophic agonists adrenaline (Adren) (100nM), Ang-II (20µM), ET-1 (10nM), 
isoproterenol (ISO) (10µM), and phenylephrine (PE) (100µM) (all from Sigma Aldrich) were 
used to increase cell size. All these agonists have been shown to significantly induce 
hypertrophy in cardiomyocytes in 48 hours or less (26, 28, 62, 72, 89). Optimisations were 
performed in HPCs for each agonist using five different concentrations one order of 
magnitude apart (data not shown). This was carried out due to the vastly different 
concentrations used in previous studies (63, 88). The concentrations used in this study were 
those which induced the greatest increase in HPC size. A synergistic treatment was also 
performed with each agonist at 10% of its solo concentration because additive effects have 
been reported (87). The lower concentration for this treatment was used to minimise the risk 
of off-target effects, such as the induction of apoptosis, and to preserve reagents.  
Cells were treated at zero and 24 hours, then collected at 48 hours for various 
downstream applications as described below. If significant differences in telomere length 
were found, 24-hour treatments continued and telomeres were measured again after 10 and 16 
days. For telomere length and gene expression analyses, each treatment was performed in 
triplicate to provide enough data for statistical analyses. 
Cell size and proliferation 
Immunocytochemistry 
Following the treatments, HPCs were washed twice in phosphate buffered saline (PBS), fixed 
in 4% paraformaldehyde for 30 minutes, washed four times in PBS, then blocked and 
permeablised in 0.75% 2mg/mL BSA (Thermo Fischer), 2% horse serum, and 0.4% Tx100 in 
PBS for 30 minutes all at room temperature. Cells received another two washes in PBS then 
the anti-α-sarcomeric actin monoclonal antibody (Sigma Aldrich) 1:100 (for hypertrophy) or 
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anti-Ki67 antibody with conjugated fluorescent tag (Abcam) 1:100 (for proliferation) was 
applied overnight in blocking and permeablisation buffer (see above) at 4ºC (and away from 
light until imaging was completed). The next morning, cells containing the α-sarcomeric 
actin antibody were washed four times in PBS then probed with AP130C Goat Anti-Mouse 
IgG & IgM Antibody, Cy3 conjugate (Merck Millipore) 1:100 for two hours in blocking and 
permeabilisation buffer (see above) at room temperature. All cells were washed twice in PBS 
and then Hoerscht (Life Technologies) (1:500 in PBS) was applied for five minutes (and 
remained at room temperature until after imaging). Finally, all cells were washed four times 
in PBS and then imaged in PBS.  
Confocal microscopy  
A Nikon Eclipse Ti-E confocal microscope was to create tomographic images by capturing a 
section every 1μm over a 15μm z-range. For cell size measurements, five z-stacks were taken 
and a minimum of 25 cells were included in each group. To determine proliferation, seven z-
stacks were captured, each with a minimum of 10 cells. Images were saved as TIFF (for 
analysis) and JPG (for presentation) files. For cell size measurements, surface area (defined 
as α-sarcomeric actin fluorescence) was quantified using image J software. This entailed 
compression into a single image for integrated density quantification. To assess levels of 
proliferation, cells expressing the Ki67 antigen were divided by the total number of cells per 
image. 
Live cell imaging for reactive oxygen species  
Oxidative stress was measured using the Image-iT LIVE Green Reactive Oxygen Species 
Detection Kit (Life Technologies) and HPC reagents (Promo Cell) according to the 
manufacture’s protocol. Single images were taken (to avoid photobleaching) on a Nikon 
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Eclipse Ti-E confocal microscope system with a 37°C chamber. Total fluorescence was 
determined using image J and a minimum of 25 cells were analysed per group (as above).  
Telomere Length 
DNA extraction 
Cells were washed in PBS then scraped into 200uL of PBS using a rubber policeman and 
stored at -20ºC. Genomic DNA was later extracted from three independent preparations using 
the Purelink Genomic DNA Mini Kit (Life Technologies) as per the manufacturer’s 
instructions and diluted to 2.5ng/µL based on quantitation with a Nanodrop 2000. A 10ng 
template of cDNA was then added to a 384-well quantitative polymerase chain reaction 
(qPCR) plate (Life Technologies) and stored at -20ºC until telomere measurement.  
Telomere to Single-copy gene (T/S ratio)  
Telomere length was determined using the telomere (T) to single-copy gene (S) T/S ratio 
method with qPCR as described previously (10). Briefly, the squared cycle threshold (Ct) for 
36B4, a single-copy gene ('S') present only once in the genome, is divided by the square of 
the Ct for Tel1 ('T'), which reflects telomere length. This provides a measure of average 
telomere length, known as the T/S ratio.  
The human primers used are shown in Table 1 and qPCR conditions were one step of 
95°C for 10 minutes followed by 36 cycles of 95°C for 15 seconds and 58°C for one minute. 
Rat primers are shown in Table 2 and measurement involved one step of 95°C for 10 minutes 
followed by 36 cycles of 95°C for 15 seconds, 54°C for 20 seconds, and 72°C for two 
minutes. The SensiFast SYBR Low-ROX Kit (Bioline) was used in a Viia7 qPCR machine 
(Life Technologies) and specificity of amplification was determined by melting curve 
analysis.  
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Gene expression 
RNA extraction and cDNA synthesis 
Cells were washed in PBS, de-attached and mixed with TRI reagent (Life Technologies) by 
vigorous pipetting, then stored at -80ºC. RNA was later extracted from three independent 
preparations, quantified with a Nanodrop 2000, then reverse transcribed into cDNA using the 
High Transcriptase cDNA kit (Life Technologies), and diluted to 5ng/µL. Both protocols 
were followed as per the manufacturer’s instructions. A 20ng template (4µL) was then added 
to a 384-well qPCR plate (Life Technologies) and stored at -20ºC until the gene expression 
analyses with qPCR.  
Primer design and running conditions 
Primers were designed using the NCBI tool Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi) to span exon-exon junctions, 
produce an amplicon of 75-150 base pairs in length, and have a melting temperature as close 
to 60°C as possible. The SensiFast SYBR Low-ROX Kit (Bioline) was used in a Viia7 qPCR 
machine (Life Technologies) with β-actin as the housekeeping gene as used previously (73). 
Amplification specificity was determined by melting curve analysis and DNA gel 
electrophoresis (data not shown). qPCR conditions involved heating the samples to 95°C for 
ten minutes followed by 40 cycles of 95°C for 5 seconds, 58°C or 56°C (see Tables 1 and 2) 
for ten seconds, and 72°C for ten seconds. Selected genes that were reliably dysregulated in 
HPCs were then evaluated in H9c2 cells to determine the similarities between these two 
models, with glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as the housekeeping gene, 
as used previously (45). Housekeeping genes were also selected because β-actin was more 
stably expressed than Gapdh in HPCs and Western blot revealed two isoforms of β-actin in 
H9c2 extracts (data not shown).  
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Table 1. Human primer information.  
Gene name Rationale for inclusion Primer sequence 5’  3’ Concentration Annealing 
temperature 
Tel 1 forward Reflects telomere length (10) GGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTT
GGGTT 
300nM 58°C 
Tel 1 reverse GGCTTGCCTTACCCTTACCCTTACCCTTACCCTT
ACCCT 
300nM 58°C 
36B4 forward Single-copy reference gene for 
Tel 1 (10) 
CAGCAAGTGGGAAGGTGTAATCC 300nM 58°C 
36B4 reverse CCCATTCTATCATCAACGGGTACAA 500nM 58°C 
TERT forward Catalytic component of 
telomerase (40) 
CAAGCTGTTTGCGGGGATTC 200nM 56°C 
TERT reverse GGGCATAGCTGAGGAAGGTTT 200nM 56°C 
TERC forward RNA-template component of 
telomerase (56) 
ACCCTAACTGAGAAGGGCGT 200nM 58°C 
TERC reverse GGCCAGCAGCTGACATTTTT 200nM 58°C 
TRF1 forward Binds to and protects telomeric 
DNA (16) 
TGCTCGATTTCCTCTGCCTC 200nM 58°C 
TRF1 reverse TGAATAATAGCCTCTGCGCTGT 200nM 58°C 
TRF2 forward Binds to and protects telomeric 
DNA (79) 
AGAACTTGGCCCATCCTGTT 200nM 58°C 
TRF2 reverse GCCTTTTTGGCCATCGTGAG 200nM 58°C 
TINF2 forward Interacts with TRF1 (56) CCAGGGGGAAGGAAAGGAATC 200nM 58°C 
TINF2 reverse GGTGGCTTCCACAAGCATCT 200nM 58°C 
TERF2IP forward Bridges TRF2 (56) AGCGGGGAACCACAGAATAAG 200nM 58°C 
TERF2IP reverse GGTGGCTTCCACAAGCATCT 200nM 58°C 
TPP1 forward Binds to single-stranded ACACGGTGCAAAAATGGCTC 200nM 58°C 
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TPP1 reverse telomeric DNA (19) TCTGCTTGTCGGATGCTCAG 200nM 58°C 
POT1 forward Binds to single-stranded 
telomeric DNA (19) 
AGCAGAGATGGTAAACCTTGC 200nM 58°C 
POT1 reverse TGTTGCTGGAACCAAAGACAT 200nM 58°C 
PNUTS forward Facilitates the binding of TRF2 
to telomeres (34) 
CGTCCGGGTATAAAAGACTCCA 200nM 58°C 
PNUTS reverse AAATTCAAACCTCTAAACGAACCCC 200nM 58°C 
SIRT1 forward  Promotes telomere elongation 
and genomic stability (18) 
CGGTTCCTACTGCGCGA 200nM 58°C 
SIRT1 reverse CCGAACAGAAGGTTATCTGGCT 200nM 56°C 
NPPA forward Key member of the fetal gene 
program (14) 
TAAAAAGCAAGCTGAGGGCG 200nM 56°C 
NPPA reverse ATCTTCAGTACCGGAAGCTGTTA 200nM 58°C 
NPPB forward Key member of the fetal gene 
program (14) 
CTTTCCTGGGAGGTCGTTCC 200nM 58°C 
NPPB reverse GTTGCGCTGCTCCTGTAAC 200nM 58°C 
PKCα forward Causes pathological 
hypertrophy in rodents (8, 33) 
AGAGGGACGTGAGAGAGCAT 200nM 58°C 
PKCα reverse CCTTTGCCACACACTTTGGG 200nM 58°C 
NFKB1 forward Knockout causes pathological 
hypertrophy in mice (24) 
GCTTAGGAGGGAGAGCCCA 200nM 58°C 
NFKB1 reverse TGAAACATTTGTTCAGGCCTTCC 200nM 58°C 
MCP-1 forward Activated by Ang-II in 
pathological hypertrophy (47)  
GAAAGTCTCTGCCGCCCTT 200nM 58°C 
MCP-1 reverse GCATTGATTGCATCTGGCTGAG 200nM 58°C 
MTOR forward Associated with physiological 
hypertrophy (68) 
GAAGCCGCGCGAACCT 200nM 58°C 
MTOR reverse TGGTTTCCTCATTCCGGCTC 200nM 58°C 
MAPK1 forward Upregulated in physiological 
hypertrophy (9) 
TTTGTCAGGACAAGGGCTCAG 200nM 58°C 
MAPK1 reverse CAGGACCAGGGGTCAAGAAC 200nM 58°C 
PRKAA2 forward Promotes physiological ACCAGGTGATCAGCACTCCA 200nM 58°C 
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PRKAA2 reverse hypertrophy (91) TCTCTTCAACCCGTCCATGC 200nM 58°C 
IL-1β forward Marker of inflammation in 
cardiomyocytes (84) 
GAGACAAAACAAAGAAGGCTGGA 200nM 58°C 
IL-1β reverse AGATAGGTTCTCTGGTGACAATGTA 200nM 58°C 
IL-6 forward Marker of inflammation (84) CTCAATATTAGAGTCTCAACCCCCA 200nM 58°C 
IL-6 reverse AAGGCGCTTGTGGAGAAGG 200nM 58°C 
COX2 forward Marker of inflammation in 
cardiomyocytes (71) 
AATCCTTGCTGTTCCCACCC 200nM 58°C 
COX2 reverse TCAAAAATTCCGGTGTTGAGCA 200nM 58°C 
Mi67 forward Marker of proliferation in 
cardiomyocytes (31) 
TGCAGCGAACGCGAC 200nM 58°C 
Mi67 reverse CTGGCTCCTGTTCACGTATT 200nM 58°C 
Β-actin forward Housekeeping gene (73) CCTTCTACAATGAGCTGCGTG 200nM 58°C 
Β-actin reverse TCAGAGAAGAGAGTCCTGGGTC 200nM 58°C 
Tel1, telomere primers 1; 36B4, acidic ribosomal phosphoprotein PO; TERT, telomerase reverse transcriptase; TERC, telomerase RNA 
component; TRF1, telomere repeat-binding factor 1; TRF2, telomere repeat-binding factor 2; TINF2, TRF1 interacting nuclear factor 2; 
TERF2IP, TRF2-interacting protein ; TPP1, tripeptidyl peptidase 1; POT1, protection of telomeres 1; PNUTS, protein phosphatase 1 regulatory 
subunit 10; SIRT1, sirtuin 1; NPPA, gene for atrial natriuretic peptide; NPPB, gene for brain natriuretic peptide; PKCα, phosphokinase C alpha; 
NFKB1, nuclear factor NF-kappa-B p105 subunit; MTOR, mechanistic target of rapamycin; MCP-1, monocyte chemotactic protein 1; MAPK1, 
mitogen-activated protein kinase 1; PRKAA2, protein kinase AMP-activated catalytic subunit alpha 2; IL-1β, interleukin-1β; IL-6, Interleukin 6; 
COX2, cyclooxygenase-2; Mi67, gene for Ki67.  
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Table 2. Rat primer information.  
Gene name Primer sequence 5’  3’ Concentration Annealing temperature 
Tel 1 forward  GGTTTTTGAGGGTGAGGGTGA GGGTGAGGGTGAGGGT 300nM 56°C 
Tel 1 reverse  TCCCGACTATCCCTATCCCTA TCCCTATCCCTATCCCTA 300nM 56°C 
36B4 forward  CAGCAACTGGGAAGGTGTAATCC 300nM 56°C 
36B4 reverse  CCCATTCTATCATCAACGGGTACAA 500nM 56°C 
Tert forward AACTACGAGCGGACCAAACA 200nM 58°C 
Tert reverse CCCTGTCACATCTGCCTTAAC 200nM 58°C 
Terc forward TGTTATAGCTGTGGGTTCTGTTCTT 200nM 58°C 
Terc reverse CCGCTGCAGGTCTGAACTTT 200nM 58°C 
Mapk1 forward AAATTGGTCAGGACAAGGGCTC  200nM 58°C 
Mapk1 reverse CTCGGAACGGCTCAAAGGAG 200nM 58°C 
Il-1β forward CAGCTTTCGACAGTGAGGAGA  200nM 58°C 
Il-1β reverse TGTCGAGATGCTGCTGTGAG 200nM 58°C 
Cox2 forward TGCTGTTCCAACCCATGTCA  200nM 58°C 
Cox2 reverse TCTTGTCAGAAACTCAGGCGT 200nM 58°C 
Mi67 forward GACACCAGACCATGCCAATG  200nM 58°C 
Mi67 reverse GGGTTCTAACTGGTCTTCCTGG 200nM 58°C 
Gapdh forward GGGGCTCTCTGCTCCTCCCTG 200nM 58°C 
Gapdh reverse ACGGCCAAATCCGTTCACACC 200nM 58°C 
Tel1, telomere primers 1; 36B4, acidic ribosomal phosphoprotein PO; TERT, telomerase reverse transcriptase; TERC, telomerase RNA 
component; TRF2, telomere repeat-binding factor 2; PNUTS, protein phosphatase 1 regulatory subunit 10; SIRT1, sirtuin 1; MAPK1, mitogen-
activated protein kinase 1; IL-1β, interleukin-1β; COX2, cyclooxygenase-2; Mi67, gene for Ki67; Gapdh, glyceraldehyde 3-phosphate 
dehydrogenase. 
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Protein levels 
Protein extraction  
Cells were washed in PBS then scraped into 300uL of RIPA buffer (Sigma Aldrich) 
containing 1% Halt Protease & Phosphatase Inhibitor Cocktail (Thermo Scientific) and stored 
at -80ºC until protein extraction. Once extracted, total soluble protein was then diluted 1:3 
and measured with the bicinchoninic acid (BCA) assay kit (Bio-Rad) against a standard curve 
of bovine serum albumin (BSA) (Thermo Scientific) with eleven points ranging from 0.0 – 
2.0 mg/mL. The absorbance at 570nm was determined using a Multiskan Microplate 
Photometer (Thermo Scientific). All procedures strictly adhered to the manufacturer’s 
instructions. 
Western blot 
25µg of cell protein was mixed with 5% β-Mercaptoethanol (Sigma Aldrich) in Laemelli 
Sample Buffer (Bio-Rad) then denatured at 100°C for 5 minutes. Samples were resolved on a 
4–15% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad) at 80 volts for around 90 minutes 
at room temperature then electroblotted on to a Nitrocellulose Membrane (Thermo Scientific) 
at 100 volts for one hour at 4°C. The membrane was blocked for one hour at room 
temperature using 5% skim milk in TBS-Tween 20 before the primary antibody was applied 
at 4ºC overnight. Four 15-minute washes in TBS-Tween 20 were performed followed by the 
application of the appropriate secondary antibody in a 0.5% skim milk in TBS-Tween 20 
solution for 1 hour at room temperature. The wash steps were then repeated before detection 
using enhanced chemiluminescence SuperSignal West Pico Substrate (Thermo Scientific). 
Images were captured with a UVITEC Alliance digital imaging system (Thermo Scientific). 
To determine levels of apoptosis, the presence of caspase-3 (Cell Signalling #9665) (1:2500) 
was assessed then the membrane was stripped for 15 minutes at room temperature using 
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RestoreTM Western Blot Stripping Buffer (Thermo Scientific) and re-blocked and probed for 
cleaved caspase-3 (Cell Signalling #9664) (1:2500).  
Data analyses 
Microsoft Excel, SPSS for windows, and PRISM were used to organise and transform data, 
perform statistical tests, and create the graphs, respectively. For confocal microscopy and 
gene expression experiments, statistical analyses were performed on the least transformed 
relative data (the integrated density and delta Ct values, respectively) which was later 
transformed to a fold change for graphical representation. In this regard, all treatment groups 
are displayed together for simplicity, with one graph per dependent variable. Each treatment 
group, however, is compared only to the control using the appropriate t-test. All data are 
presented as means (M) ± the standard deviation (SD) with P<0.05 regarded as significant.  
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Results 
Validation of hypertrophy 
In HPCs, all agonists significantly increased cell size (P<0.05) compared to the control 
(Figure 1). Interestingly, a synergistic treatment (each agonist at 10% of its solo 
concentration) caused a significant decrease in HPC size (P=0.005) relative to the control 
(Figure 1). Similarly, in H9c2 cells, all agonists significantly increased cell size (P<0.05) 
compared to the control (Figure 2).  
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Figure 1. HPC size. (A) Anti-α-sarcomeric actin immunocytochemistry on HPCs; (B) 
Agonist stimulation increased HPC size. Data are presented as mean ± SD (n=25) with Cont. 
normalised to 1. * indicates P<0.05 and ** P<0.01 compared to Cont. Cont, control; Adren, 
adrenaline; Ang-II, angiotensin-II; ET-1, endothelin-1; ISO, isoproterenol; PE, 
phenylephrine; All, all agonists.   
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Figure 2. H9c2 cell size. (A) Anti-α-sarcomeric actin immunocytochemistry on H9c2 cells; 
(B) Agonist stimulation increased H9c2 cell size. Agonist stimulation increased H9c2 cell 
size Data are presented as mean ± SD (n=25) with Cont. normalised to 1. * indicates P<0.05, 
** P<0.01, and ** P<0.001 compared to Cont. Cont, control; Adren, adrenaline; Ang-II, 
angiotensin-II; ET-1, endothelin-1; ISO, isoproterenol; PE, phenylephrine.   
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Telomere length  
In HPCs, ET-1 caused a significant reduction in HPC telomere length after 48 hours 
(P=0.010). Telomere length continued to shorten in response to ET-1 treatment for 10 
(P=0.034) and 16 (P=0.044) days (Figure 3A). In contrast, there were no significant 
differences in telomere length between adrenaline, angiotensin-II, isoproterenol, 
phenylephrine, and the control cells after 48-hours of treatment (Figure 3B). Similarly, the 
synergistic treatment did not alter telomere length and as this also failed to increase cell size, 
no further experiments were carried out on this group. In H9c2 cells, there were no 
significant differences in telomere length between the control cells and any of the groups 
after 48 hours of treatment (Figure 4A). 
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Figure 3. Telomere length. (A) Treatment with adrenaline, angiotensin-II, isoproterenol, 
phenylephrine, or all agonists for 48 hours did not affect telomere length; (B) Treatment with 
endothelin-1 shortened telomere length in a time-dependent manner. Data are presented as 
mean ± SD (n=3). * indicates P<0.05 compared to Cont. of same treatment duration. Cont, 
control; Adren, adrenaline; Ang-II, angiotensin-II; ET-1, endothelin-1; ISO, isoproterenol; 
PE, phenylephrine; All, all agonists. T/S ratio, telomere to single-copy gene ratio.  
  
 166 
 
 
Figure 4. H9c2 telomere length and telomere-associated genes. (A) Inducing hypertrophy 
did not affect telomere length; (B) Isoproterenol treatment decreased H9c2 cell Tert mRNA 
levels; (C) Inducing hypertrophy did not affect Terc, (D) Trf2, or (E) Pnuts mRNA levels. All 
H9c2 cells. Data are presented as mean ± SD (n=3) with Cont normalised to 1. * indicates 
P<0.05 compared to Cont. Cont, control; Adren, adrenaline; Ang-II, angiotensin-II; ET-1, 
endothelin-1; ISO, isoproterenol; PE, phenylephrine. T/S ratio, telomere to single-copy gene 
ratio; Tert, telomerase reverse transcriptase; Terc, telomerase RNA component; Trf2, 
telomere repeat-binding factor 2; Pnuts, phosphatase nuclear-targeting subunit 1. 
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Telomerase gene expression 
In HPCs, all agonists except Adren increased telomerase RNA component (TERC) mRNA 
levels (P>0.05) (Figure 5A). In contrast, however, there were no significant changes in 
telomerase reverse transcriptase (TERT) expression in any of the groups (Figure 5B). In H9c2 
cells, Tert mRNA levels were significantly decreased following ISO treatment (P=0.025) 
(Figure 4B). Unlike the HPCs, there were no significant changes in Terc expression in any of 
the H9c2 cell groups (Figure 4C).  
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Figure 5. Telomerase gene expression. (A) Inducing hypertrophy increased TERC but not 
(B) TERT expression in HPCs. Data are presented as mean ± SD (n=3) with Cont. normalised 
to 1. * indicates P<0.05, ** P<0.01, and ** P<0.001 compared to Cont. Cont, control; Adren, 
adrenaline; Ang-II, angiotensin-II; ET-1, endothelin-1; ISO, isoproterenol; PE, 
phenylephrine. TERT, telomerase reverse transcriptase; TERC, telomerase RNA component.   
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Telomeric gene expression  
In HPCs, telomere repeat-binding factor 1 (TRF1) expression was upregulated as a result of 
ISO treatment (P=0.003) (Figure 6A). Similarly, TRF1 interacting nuclear factor 2 (TINF2) 
mRNA levels were higher in ISO (P=0.010) as well as Ang-II (P=0.030) and ET-1 (P=0.010) 
groups (Figure 6B). In contrast, however, there were no significant changes in telomere 
repeat-binding factor 2 (TRF2) expression in any of the groups (Figure 6C). ISO significantly 
increased TRF2-interacting protein (TERF2IP) mRNA levels (P=0.011) (Figure 6D). 
Furthermore, both ISO and PE significantly upregulated tripeptidyl peptidase 1 (TPP1) 
(Figure 6E) and protection of telomeres 1 (POT1) expression (all P>0.05) (Figure 6F). 
Finally, sirtuin 1 (SIRT1) was significantly upregulated following ISO treatment (P=0.015) 
(Figure 6G) but there were no changes in protein phosphatase 1 regulatory subunit 10 (also 
known, and hereafter referred to, as PNUTS) expression in any of the groups (to Figure 6H). 
There were also no changes in Trf2 (Figure 4D) or Pnuts (Figure 4E) mRNA levels in H9c2 
cells.  
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Figure 6. Telomeric gene expression. (A) Endothelin-1, isoproterenol, and phenylephrine 
increased TRF-1 mRNA levels; (B) Angiotensin-II, endothelin-1, and isoproterenol 
upregulated TINF-2 expression; (C) Inducing hypertrophy did not affect TRF2 mRNA levels; 
(D) Isoproterenol increased TERF2IP expression; (E) Isoproterenol and phenylephrine 
increased TPP1 and (F) POT1 mRNA levels; (G) isoproterenol upregulated SIRT1 
expression; (H) Agonist stimulation did not affect PNUTS mRNA levels. All HPCs. Data are 
presented as mean ± SD (n=3) with Cont. normalised to 1. * indicates P<0.05 and ** 
P<0.01compared to Cont. Cont, control; Adren, adrenaline; Ang-II, angiotensin-II; ET-1, 
endothelin-1; ISO, isoproterenol; PE, phenylephrine. TRF1, telomere repeat-binding factor 1; 
TRF2, telomere repeat-binding factor 2; TINF2, TRF1 interacting nuclear factor 2; TERF2IP, 
TRF2-interacting protein; TPP1, adrenocortical dysplasia homolog; POT1, protection of 
telomeres 1; PNUTS, phosphatase nuclear-targeting subunit 1; SIRT1, sirtuin 1.   
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Markers of pathological and physiological cardiac hypertrophy  
In HPCs, the gene for atrial natriuretic peptide (NPPA) was not significantly dysregulated in 
any treatment groups (Figure 7A). Expression levels of the brain natriuretic peptide (NPPB) 
were significantly downregulated in Adren (P=0.048) and PE (P=0.035) groups relative to 
the control (Figure 7B). Gene expression of the pro-hypertrophic and pro-inflammatory 
nuclear factor NF-kappa-B p105 subunit (NFKB1) was significantly upregulated in all 
treatment groups besides ET-1 (P<0.05) (Figure 7C). The gene for monocyte chemotactic 
protein 1 (MCP-1) was down regulated in AngII (P<0.001) and ET-1 (P=0.004) groups 
(Figure 7D). Mechanistic target of rapamycin (MTOR) was significantly upregulated after 
ET-1 (P=0.027), ISO (P=0.024), and PE (P=0.021) stimulation (Figure 7E). Phosphokinase C 
alpha (PKCα) was also upregulated after ISO (P=0.010) and PE (P=0.049) treatment (Figure 
7F). 
Markers of physiological cardiac hypertrophy were also significantly upregulated in 
HPCs. For instance, mitogen-activated protein kinase 1 (MAPK1) expression was 
significantly higher in all treatment groups (P<0.05) (Figure 7G). Furthermore, there was a 
trend towards increased expression of Protein Kinase AMP-Activated Catalytic Subunit 
Alpha 2 (PRKAA2) in all treatment groups but only PE (P=0.047) reached significance 
(Figure 7H). In contrast, there were no significant changes in Mapk1 expression after agonist 
stimulation in H9c2 cells (Figure 8A).  
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Figure 7. Markers of pathological and physiological cardiac hypertrophy. Agonist 
stimulation increased markers of pathological (A-F) and physiological (G-H) cardiac 
hypertrophy. All HPCs. Data are presented as mean ± SD (n=3) with Cont. normalised to 1. * 
indicates P<0.05, ** P<0.01, and ** P<0.001 compared to Cont. Cont, control; Adren, 
adrenaline; Ang-II, angiotensin-II; ET-1, endothelin-1; ISO, isoproterenol; PE, 
phenylephrine. NPPA gene for atrial natriuretic peptide; NPPB, gene for Brain natriuretic 
peptide; NFKB1, Nuclear factor NF-kappa-B p105 subunit; MCP-1, Monocyte chemotactic 
protein 1; PKCα, phosphokinase C alpha. MTOR, Mechanistic target of rapamycin; MAPK1, 
Mitogen-activated protein kinase 1; PRKAA2, Protein Kinase AMP-Activated Catalytic 
Subunit Alpha 2. 
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Figure 8. Expression of selected genes in H9c2 cells. These genes were selected for 
comparison because were dysregulated in HPCs. (A) Inducing hypertrophy did not affect 
Mapk1 mRNA levels; (B) Adrenaline, endothelin-1, isoproterenol, and phenylephrine 
increased Il-1β expression; (C) Inducing hypertrophy did not affect Cox2 mRNA levels; (D) 
Endothelin-1 and isoproterenol decreased Mi67 expression. All H9c2 cells. Data are 
presented as mean ± SD (n=3) with Cont. normalised to 1. * indicates P<0.05 and ** 
P<0.01compared to Cont. Cont, control; Adren, adrenaline; Ang-II, angiotensin-II; ET-1, 
endothelin-1; ISO, isoproterenol; PE, phenylephrine. Mapk1, Mitogen-activated protein 
kinase 1; Il-1β, Interleukin-1β; Cox2, cyclooxygenase-2; Mi67, gene for Ki67. 
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Inflammation and oxidative stress  
Interleukin 6 (IL6) expression was significantly downregulated (P<0.05) (Figure 9A) while 
interleukin-1β (IL-1β) mRNA levels were significantly upregulated (P<0.05) in all treatment 
groups (Figure 9B). Similarly, all agonists increased cyclooxygenase-2 (COX2) expression 
(P<0.05) (Figure 9C). In H9c2 cells, Il-1β was also significantly upregulated in all groups 
besides Ang-II (P<0.05) (Figure 8B) but there were no changes in Cox2 mRNA levels 
(Figure 8C). Live cell imaging of HPCs revealed that reactive oxygen species (ROS) were 
significantly higher in Ang-II and ET-1 treated groups (Figure 9D and E).  
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Figure 9. Inflammation and oxidative stress. (A) Inducing hypertrophy decreased IL6 
mRNA levels; (B) Inducing hypertrophy increased IL-1β expression; (C) Inducing 
hypertrophy increased COX2 mRNA levels; (D) Angiotensin-II and endothelin-1 increased 
ROS levels; (E) 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate immunofluorescence 
for ROS. All HPCs. Data are presented as mean ± SD (n=3 for gene expression and n=25 for 
ROS) with Cont. normalised to 1. * indicates P<0.05, ** P<0.01, and ** P<0.001 compared 
to Cont. Cont, control; Adren, adrenaline; Ang-II, angiotensin-II; ET-1, endothelin-1; ISO, 
isoproterenol; PE, phenylephrine. IL6, Interleukin 6; IL-1β, Interleukin-1β; COX2, 
cyclooxygenase-2; ROS, reactive oxygen species.  
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Proliferation and apoptosis 
The nuclear antigen and marker of cardiomyocyte proliferation, Ki67 and its gene Mi67, were 
used to determine levels of proliferation. In HPCs, all agonists significantly increased Mi67 
expression relative to the control (P<0.05) (Figure 10A). Ki67 antigen expression was also 
higher in all groups but only Adren (P=0.047), Ang-II (P=0.040), and ET-1 (P=0.007) 
reached significance (Figure 10B and C). In contrast, there was a significant decrease in Mi67 
expression following ET-1 (P=0.013) and ISO (P=0.029) treatment in H9c2 cells (Figure 8F). 
Immunoblotting of cleaved and native caspase 3 isoforms did not detect apoptosis in any of 
the HPC groups (Figure 10D). 
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Figure 10. Proliferation and apoptosis. (A) Inducing hypertrophy increased Mi67 mRNA 
levels; (B) Adrenaline, angiotensin-II, and endothelin-1 increased Ki67 antigen expression; 
(C) Anti-Ki67 immunocytochemistry; (D) Western blot of cleaved caspase 3. All HPCs. Data 
are presented as mean ± SD (n=3 for gene expression and n=7 for Ki67 
immunocytochemistry) with Cont. normalised to 1. * indicates P<0.05, ** P<0.01, and ** 
P<0.001 compared to Cont. Cont, control; Adren, adrenaline; Ang-II, angiotensin-II; ET-1, 
endothelin-1; ISO, isoproterenol; PE, phenylephrine. Mi67, gene for Ki67. 
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Discussion  
The present study is the first to directly assess the effects of cardiomyocyte hypertrophy on 
telomeres. Results demonstrated that all five agonists significantly increased HPC size after 
48 hours of treatment but only ET-1 caused a reduction in telomere length. In addition, ET-1 
treatment for 10 and 16 days continued to shorten telomeres. These findings point to an 
important and novel pathophysiological mechanism for ET-1 in human cardiac hypertrophy 
and aging. Importantly, this is independent of the vasoconstrictive and hypertensive 
properties typically attributed to ET-1. Agonist stimulation also increased H9c2 cell size but 
there were no significant changes in telomere length or the expression of selected genes that 
were dysregulated in the HPCs. This suggests that H9c2 cells do not accurately model human 
cardiomyocyte telomere dynamics in vitro. 
Previous research has alluded to the possibility of ET-1 playing a role in 
cardiomyocyte aging. For instance, increased plasma concentrations of ET-1 have been 
observed in heart failure (49) and myocardial infarction (54), as have short cardiac telomeres 
(59, 74, 78, 82). Similarly, aging is associated with increases in ET-1 levels (53) and 
decreases in telomere length (7). Moreover, aerobic exercise interventions decrease ET-1 
levels (43) and telomere attrition (42). On cardiomyocytes, there are two targets for ET-1 – 
ETA (1) and ETB receptors (67) – and ET-1 induces hypertrophy through the ETA receptor 
(87). In contrast, Adren, ISO and PE activate α and/or β-ARs and Ang-II activates 
angiotensin type 1 and 2 receptors (92). Of these agonists, only Ang-II has been directly 
implicated in telomere shortening in cardiomyocytes (15) and other cell types (22). 
Interestingly, Ang-II can illicit ET-1 production (27, 39) and aging in the carotid arteries is 
dependent on ET-1 and not Ang-II (51). This suggests that ET-1 may play a role in the 
telomere attrition that has been attributed to Ang-II. Importantly, accelerated aging in human 
cardiomyocytes due to ET-1 and telomere shortening could have important consequences for 
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cardiac health as only young cells can produce functional progeny and replenish the heart 
(30). 
One study suggested that the telomere attrition observed in cardiac hypertrophy and 
heart failure is likely a consequence of βAR-activation (65). Indeed, Raymond and colleagues 
found that daily ISO injections (0.02 mg/kg/day) for six months caused LV dilation and 
systolic chamber dysfunction in rats without affecting cardiac mass or telomere length (65). 
In the present study, ISO had a reliable influence on telomeric genes, upregulating six out of 
eight genes known to be associated with telomere length and structure which could, in part, 
explain the preservation of telomere length. In contrast to ISO treatments, there were few or 
no changes in telomeric gene expression in the other agonist groups. This demonstrates that 
cardiomyocyte hypertrophy can occur independently of changes in telomeres. Dysregulated 
telomeric gene expression, however, can be transient (11) so basal mRNA levels could be 
expected given there was 24 hours between the second agonist treatment and the extractions. 
TERC expression, however, was higher in all agonist groups besides Adren. Interestingly, an 
increase in TERC expression is cardio- and telomere-protective (81), suggesting this finding 
is likely to be a short-term compensatory mechanism, similar to the increase in telomerase 
activity observed in early-stage heart disease (36, 70, 75). 
In contrast to telomeric genes, hypertrophic genes have been shown to peak 24-48 
hours after agonist stimulation (71). In the present study, however, there were no increases in 
expression of the fetal genes and markers of heart failure NPPA and NPPB in any of the 
hypertrophic groups. Indeed, with the exception of ISO and PE increasing PKCα and mTOR 
mRNA levels, most gene expression findings reflected physiological rather than pathological 
cardiac hypertrophy. For instance, the cardioprotective genes MAP1K and NFKB1 (85, 86) 
were significantly upregulated in all treatment groups (except for ET-1 in the latter). 
Although this suggests that acute agonist stimulation in HPCs may model physiological 
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rather than pathological cardiac hypertrophy, a transient increase in the concentration of 
hypertrophic agonists is often associated with cardio-protective activities. For instance, both 
plasma ET-1 (17) and Ang-II (83) levels have been shown to increase after exercise in 
healthy young males. Therefore, it may be unreasonable to expect short-term agonist 
treatments to reflect all the changes observed in degenerative and irreversible (i.e. 
pathological) cardiac hypertrophy.  
Consistent with previous research (4, 35, 47), ROS was significantly upregulated 
following Ang-II and ET-1 treatment which could explain the telomere attrition observed in 
the ET-1 group. Furthermore, Ang-II is thought to contribute to the development of 
pathological hypertrophy in rodents by inducing oxidative stress (35, 89) and findings of the 
present study suggest this mechanism may also be involved in HPC hypertrophy. 
Interestingly, mice with short telomeres have increased endothelin-converting enzyme-1 
(ECE-1) and thus synthesise more ET-1. Importantly, treatment with antioxidants reduces 
ECE-1 promoter activity and ET-1 levels (61). Telomerase-deficient cells also have increased 
ROS synthesis (61), further suggesting a link between ET-1 and ROS. Taken together, these 
findings demonstrate that ET-1 can induce ROS which may cause telomere shortening, 
accelerated cardiomyocyte aging, and cardiac hypertrophy. Given Terc-/- mice have increased 
ROS (61), it is possible that insufficient telomerase could catalyse and/or exacerbate this 
pathway.  
Results of the present study also suggest an important role for inflammation in 
cardiomyocyte hypertrophy, with all agonists increasing IL6 and COX2 mRNA levels, as 
previously reported (38, 46). Inflammation is thought to be an important mediator of telomere 
length and may be the epiphenomenon linking heart failure and short telomere length (65). In 
support of this suggestion, ET-1 is pro-inflammatory in vascular smooth muscle cells (29). 
Furthermore, Ang-II-induced telomere attrition in human glomerular mesangial cells could be 
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partially reversed by losartan (a β-AR antagonist) treatment (22) which has been shown to 
reduce inflammation (and oxidative stress) (32). Increased inflammation was also the only 
finding observed in both the HPCs and H9c2 cells (besides increases in cell size). As H9c2 
cells and primary neonatal rat cardiomyocytes show similar hypertrophic responses in vitro 
(80), this suggests that the inflammatory response may be highly conserved. However, given 
the lack of overall similarity in the expression of telomeric variables between HPCs and H9c2 
cells, embryonic rat cells may not be appropriate models of human heart disease. 
Like increased inflammation, another consistent finding of the present study was an 
increase in HPC proliferation following agonist stimulation (although this was observed only 
in HPCs and not H9c2 cells). Although Ki67 has been used as a marker of cardiomyocyte 
proliferation (31), it is also associated with cardiomyocyte ploidy (77) and thus may reflect 
changes in DNA content and other cell cycle activities rather than true cell division. 
Importantly, cardiomyocyte nuclear mitotic division is observed in late-stage heart failure, 
but this is accompanied by even higher rates of cardiomyocyte apoptosis (41). Therefore, 
measures of proliferation alone may not reflect an adaptive response as increased cell cycle 
activity in cardiomyocytes could also indicate a compensatory response to even higher levels 
of apoptosis. In this regard, however, no cleaved caspase 3 was detected in the present study, 
suggesting that the apoptotic rate did not increase in agonist-treated cells. Importantly, the 
increase in markers of proliferation and inflammation provide potential mechanisms through 
which agonist stimulation could lead to telomere attrition, as observed in late-stage cardiac 
hypertrophy and heart failure (59). In addition, data from the present study suggests that ET-1 
may play a more direct role in cardiomyocyte telomere regulation, ROS levels, and thus 
viability (Figure 11).   
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Figure 11. A simplified pathway of the proposed involvement of agonist-induced 
hypertrophy in cardiomyocyte telomere shortening, senescence, apoptosis, and heart 
failure. ROS, reactive oxygen species. 
  
 183 
 
This study also has some limitations. Firstly, the use of immature human 
cardiomyocytes and immortalised rat cardiomyoblasts from homogenous populations fails to 
indicate if the changes reported here are universal. Secondly, the 48-hour timepoint may have 
missed acute transient changes in gene expression in the short-term and possible effects on 
telomere length and apoptosis in the long-term. Thirdly, while the in vitro approach allowed 
ET-1 and other agonists to be studied independently of vasoconstrictive (and thus 
biomechanical stress-inducing) affects, this leaves unanswered questions regarding 
interactions in vivo. Future studies could utilise selective ETA/B agonists or antagonists to 
elucidate the mechanism of action of ET-1 on telomeres and perform rescue treatments with 
recovery times from acute treatments and anti-inflammatory or antioxidant agents to preserve 
cardiomyocyte telomeres and function. This would help elucidate the involvement of 
telomeres in the development of cardiomyocyte hypertrophy and the mechanisms governing 
the transition into degenerative heart failure. 
In conclusion, results of the present study highlight a novel pathophysiological 
mechanism of ET-1 in cardiomyocyte aging and viability. These findings also demonstrate 
that changes in telomere length or telomeric gene expression are not necessary for AR-
induced increases in cardiomyocyte size. In this regard, the lack of changes in gene 
expression suggest that inflammation, proliferation, and oxidative stress may play crucial 
roles in cardiomyocyte telomere attrition. The inconsistent expression of hypertrophic genes 
highlights the need for more time points to uncover novel and reliable factors that are directly 
involved in the pathophysiology of cardiac hypertrophy leading to heart failure and could be 
targeted for therapeutic use. Finally, changes to telomeric variables following hypertrophy in 
HPCs are not reflected in H9c2 cells, highlighting important differences between human and 
rat cardiomyocyte aging and viability.  
  
 184 
 
References 
1. Arai H, Hori S, Aramori I, Ohkubo H, and Nakanishi S. Cloning and expression 
of a cDNA encoding an endothelin receptor. Nature 348: 730-732, 1990. 
2. Armanios M, and Blackburn EH. The telomere syndromes. Nat Rev Genet 13: 693-
704, 2012. 
3. Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, and Liu P. Activation 
of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac 
hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem 317: 189-196, 
2008. 
4. Barton M, and Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can 
J Physiol Pharmacol 86: 485-498, 2008. 
5. Blackburn EH. Switching and signaling at the telomere. Cell 106: 661-673, 2001. 
6. Blackburn EH. Telomeres. Trends Biochem Sci 16: 378-381, 1991. 
7. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev 
Genet 6: 611-622, 2005. 
8. Braz JC, Bueno OF, De Windt LJ, and Molkentin JD. PKC alpha regulates the 
hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 
(ERK1/2). J Cell Biol 156: 905-919, 2002. 
9. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, 
Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, and Molkentin JD. The MEK1-
ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. 
EMBO J 19: 6341-6350, 2000. 
10. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 30: 
e47, 2002. 
 185 
 
11. Chilton WL, Marques FZ, West J, Kannourakis G, Berzins SP, O'Brien BJ, and 
Charchar FJ. Acute exercise leads to regulation of telomere-associated genes and 
microRNA expression in immune cells. PLoS One 9: e92088, 2014. 
12. Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, Di Meglio 
F, Nadal-Ginard B, Frustaci A, Leri A, Maseri A, and Anversa P. Senescence and death 
of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res 
93: 604-613, 2003. 
13. Chiu CL, Hearn NL, Paine D, Steiner N, and Lind JM. Does Telomere Shortening 
Precede the Onset of Hypertension in Spontaneously Hypertensive Mice? Twin Res Hum 
Genet 19: 422-429, 2016. 
14. Cox EP, O'Dwyer N, Cook R, Vetter M, Cheng HL, Rooney K, and O'Connor H. 
Relationship between physical activity and cognitive function in apparently healthy young to 
middle-aged adults: A systematic review. J Sci Med Sport 19: 616-628, 2016. 
15. D'Amario D, Cabral-Da-Silva MC, Zheng H, Fiorini C, Goichberg P, Steadman 
E, Ferreira-Martins J, Sanada F, Piccoli M, Cappetta D, D'Alessandro DA, Michler RE, 
Hosoda T, Anastasia L, Rota M, Leri A, Anversa P, and Kajstura J. Insulin-like growth 
factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic 
potential for myocardial regeneration. Circ Res 108: 1467-1481, 2011. 
16. Danial NN, and Korsmeyer SJ. Cell death: critical control points. Cell 116: 205-
219, 2004. 
17. Davis PG, Ferguson MA, Alderson NL, Pate RR, Bodary PF, and Durstine JL. 
Effect of exercise duration on plasma endothelin-1 concentration. J Sports Med Phys Fitness 
45: 419-423, 2005. 
 186 
 
18. De Bonis ML, Ortega S, and Blasco MA. SIRT1 is necessary for proficient telomere 
elongation and genomic stability of induced pluripotent stem cells. Stem Cell Reports 2: 690-
706, 2014. 
19. de Lange T. How shelterin solves the telomere end-protection problem. Cold Spring 
Harb Symp Quant Biol 75: 167-177, 2010. 
20. Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. 
Cardiovasc Res 68: 8-17, 2005. 
21. Dorn GW, 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 
49: 962-970, 2007. 
22. Feng X, Wang L, and Li Y. Change of telomere length in angiotensin II-induced 
human glomerular mesangial cell senescence and the protective role of losartan. Mol Med 
Rep 4: 255-260, 2011. 
23. Fyhrquist F, Saijonmaa O, and Strandberg T. The roles of senescence and 
telomere shortening in cardiovascular disease. Nat Rev Cardiol 10: 274-283, 2013. 
24. Gaspar-Pereira S, Fullard N, Townsend PA, Banks PS, Ellis EL, Fox C, Maxwell 
AG, Murphy LB, Kirk A, Bauer R, Caamano JH, Figg N, Foo RS, Mann J, Mann DA, 
and Oakley F. The NF-kappaB subunit c-Rel stimulates cardiac hypertrophy and fibrosis. 
Am J Pathol 180: 929-939, 2012. 
25. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal 
transduction to signal integration. Oncogene 17: 1331-1342, 1998. 
26. Hahn NE, Musters RJ, Fritz JM, Pagano PJ, Vonk AB, Paulus WJ, van Rossum 
AC, Meischl C, Niessen HW, and Krijnen PA. Early NADPH oxidase-2 activation is 
crucial in phenylephrine-induced hypertrophy of H9c2 cells. Cell Signal 26: 1818-1824, 
2014. 
 187 
 
27. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, and Cheng TH. 
Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase 
pathway in rat aortic smooth muscle cells. Cardiovasc Res 61: 159-168, 2004. 
28. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi 
K, and Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-
specific genes in cultured neonatal rat cardiomyocytes. Circ Res 69: 209-215, 1991. 
29. Ivey ME, Osman N, and Little PJ. Endothelin-1 signalling in vascular smooth 
muscle: pathways controlling cellular functions associated with atherosclerosis. 
Atherosclerosis 199: 237-247, 2008. 
30. Kajstura J, Gurusamy N, Ogorek B, Goichberg P, Clavo-Rondon C, Hosoda T, 
D'Amario D, Bardelli S, Beltrami AP, Cesselli D, Bussani R, del Monte F, Quaini F, 
Rota M, Beltrami CA, Buchholz BA, Leri A, and Anversa P. Myocyte turnover in the 
aging human heart. Circ Res 107: 1374-1386, 2010. 
31. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, and Anversa P. Myocyte 
proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A 95: 8801-
8805, 1998. 
32. Kayabasi H, Yilmaz Z, Sit D, Kadiroglu AK, and Yilmaz E. The effects of 
Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic 
hemodialysis. Eur Rev Med Pharmacol Sci 17: 235-242, 2013. 
33. Kerkela R, Ilves M, Pikkarainen S, Tokola H, Ronkainen J, Vuolteenaho O, 
Leppaluoto J, and Ruskoaho H. Identification of PKCalpha isoform-specific effects in 
cardiac myocytes using antisense phosphorothioate oligonucleotides. Mol Pharmacol 62: 
1482-1491, 2002. 
 188 
 
34. Kim H, Lee OH, Xin H, Chen LY, Qin J, Chae HK, Lin SY, Safari A, Liu D, and 
Songyang Z. TRF2 functions as a protein hub and regulates telomere maintenance by 
recognizing specific peptide motifs. Nat Struct Mol Biol 16: 372-379, 2009. 
35. Kurdi M, and Booz GW. New take on the role of angiotensin II in cardiac 
hypertrophy and fibrosis. Hypertension 57: 1034-1038, 2011. 
36. Leri A, Barlucchi L, Limana F, Deptala A, Darzynkiewicz Z, Hintze TH, 
Kajstura J, Nadal-Ginard B, and Anversa P. Telomerase expression and activity are 
coupled with myocyte proliferation and preservation of telomeric length in the failing heart. 
Proc Natl Acad Sci U S A 98: 8626-8631, 2001. 
37. Li F, Wang X, Capasso JM, and Gerdes AM. Rapid transition of cardiac myocytes 
from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 28: 1737-
1746, 1996. 
38. Liao PH, Hsieh DJ, Kuo CH, Day CH, Shen CY, Lai CH, Chen RJ, Padma VV, 
Kuo WW, and Huang CY. Moderate exercise training attenuates aging-induced cardiac 
inflammation, hypertrophy and fibrosis injuries of rat hearts. Oncotarget 6: 35383-35394, 
2015. 
39. Lin YJ, Kwok CF, Juan CC, Hsu YP, Shih KC, Chen CC, and Ho LT. 
Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating 
endothelin type A receptor. Biochem Biophys Res Commun 451: 263-269, 2014. 
40. Liu K, Hodes RJ, and Weng N. Cutting edge: telomerase activation in human T 
lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein 
but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 166: 
4826-4830, 2001. 
 189 
 
41. Liu Y, Cigola E, Cheng W, Kajstura J, Olivetti G, Hintze TH, and Anversa P. 
Myocyte nuclear mitotic division and programmed myocyte cell death characterize the 
cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 73: 771-787, 1995. 
42. Ludlow AT, Witkowski S, Marshall MR, Wang J, Lima LC, Guth LM, 
Spangenburg EE, and Roth SM. Chronic exercise modifies age-related telomere dynamics 
in a tissue-specific fashion. J Gerontol A Biol Sci Med Sci 67: 911-926, 2012. 
43. Maeda S, Tanabe T, Miyauchi T, Otsuki T, Sugawara J, Iemitsu M, Kuno S, 
Ajisaka R, Yamaguchi I, and Matsuda M. Aerobic exercise training reduces plasma 
endothelin-1 concentration in older women. J Appl Physiol (1985) 95: 336-341, 2003. 
44. Maillet M, van Berlo JH, and Molkentin JD. Molecular basis of physiological heart 
growth: fundamental concepts and new players. Nat Rev Mol Cell Biol 14: 38-48, 2013. 
45. Marques FZ, Booth SA, Prestes PR, Curl CL, Delbridge LM, Lewandowski P, 
Harrap SB, and Charchar FJ. Telomere dynamics during aging in polygenic left 
ventricular hypertrophy. Physiol Genomics 48: 42-49, 2016. 
46. Masi S, Nightingale CM, Day IN, Guthrie P, Rumley A, Lowe GD, von Zglinicki 
T, D'Aiuto F, Taddei S, Klein N, Salpea K, Cook DG, Humphries SE, Whincup PH, and 
Deanfield JE. Inflammation and not cardiovascular risk factors is associated with short 
leukocyte telomere length in 13- to 16-year-old adolescents. Arterioscler Thromb Vasc Biol 
32: 2029-2034, 2012. 
47. Matsuda S, Umemoto S, Yoshimura K, Itoh S, Murata T, Fukai T, and 
Matsuzaki M. Angiotensin Activates MCP-1 and Induces Cardiac Hypertrophy and 
Dysfunction via Toll-like Receptor 4. J Atheroscler Thromb 22: 833-844, 2015. 
48. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, and 
Izumo S. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of 
 190 
 
physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 100: 
12355-12360, 2003. 
49. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, and Morton JJ. Plasma 
endothelin in chronic heart failure. Circulation 85: 1374-1379, 1992. 
50. Mendis S, Davis S, and Norrving B. Organizational update: the world health 
organization global status report on noncommunicable diseases 2014; one more landmark 
step in the combat against stroke and vascular disease. Stroke 46: e121-122, 2015. 
51. Meyer MR, Fredette NC, Barton M, and Prossnitz ER. Endothelin-1 but not 
angiotensin II contributes to functional aging in murine carotid arteries. Life Sci 118: 213-
218, 2014. 
52. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, and Komuro I. 
Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial 
dysfunction. Circulation 105: 1541-1544, 2002. 
53. Miyauchi T, Yanagisawa M, Iida K, Ajisaka R, Suzuki N, Fujino M, Goto K, 
Masaki T, and Sugishita Y. Age- and sex-related variation of plasma endothelin-1 
concentration in normal and hypertensive subjects. Am Heart J 123: 1092-1093, 1992. 
54. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, 
Ajisaka R, Goto K, and Masaki T. Increased plasma concentrations of endothelin-1 and big 
endothelin-1 in acute myocardial infarction. Lancet 2: 53-54, 1989. 
55. Moslehi J, DePinho RA, and Sahin E. Telomeres and mitochondria in the aging 
heart. Circ Res 110: 1226-1237, 2012. 
56. Nandakumar J, and Cech TR. Finding the end: recruitment of telomerase to 
telomeres. Nat Rev Mol Cell Biol 14: 69-82, 2013. 
 191 
 
57. Nicol RL, Frey N, and Olson EN. From the sarcomere to the nucleus: role of 
genetics and signaling in structural heart disease. Annu Rev Genomics Hum Genet 1: 179-
223, 2000. 
58. Oh H, Taffet GE, Youker KA, Entman ML, Overbeek PA, Michael LH, and 
Schneider MD. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, 
hypertrophy, and survival. Proc Natl Acad Sci U S A 98: 10308-10313, 2001. 
59. Oh H, Wang SC, Prahash A, Sano M, Moravec CS, Taffet GE, Michael LH, 
Youker KA, Entman ML, and Schneider MD. Telomere attrition and Chk2 activation in 
human heart failure. Proc Natl Acad Sci U S A 100: 5378-5383, 2003. 
60. Oka T, and Komuro I. Molecular mechanisms underlying the transition of cardiac 
hypertrophy to heart failure. Circ J 72 Suppl A: A13-16, 2008. 
61. Perez-Rivero G, Ruiz-Torres MP, Rivas-Elena JV, Jerkic M, Diez-Marques ML, 
Lopez-Novoa JM, Blasco MA, and Rodriguez-Puyol D. Mice deficient in telomerase 
activity develop hypertension because of an excess of endothelin production. Circulation 
114: 309-317, 2006. 
62. Ponicke K, Heinroth-Hoffmann I, and Brodde OE. Role of beta 1- and beta 2-
adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult 
rat ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 367: 592-599, 2003. 
63. Putinski C, Abdul-Ghani M, Stiles R, Brunette S, Dick SA, Fernando P, and 
Megeney LA. Intrinsic-mediated caspase activation is essential for cardiomyocyte 
hypertrophy. Proc Natl Acad Sci U S A 110: E4079-4087, 2013. 
64. Rajabi M, Kassiotis C, Razeghi P, and Taegtmeyer H. Return to the fetal gene 
program protects the stressed heart: a strong hypothesis. Heart Fail Rev 12: 331-343, 2007. 
 192 
 
65. Raymond AR, Hodson B, Woodiwiss AJ, Norton GR, and Brooksbank RL. 
Telomere length and adrenergic-induced left ventricular dilatation and systolic chamber 
dysfunction in rats. Eur J Appl Physiol 113: 2803-2811, 2013. 
66. Rota M, Hosoda T, De Angelis A, Arcarese ML, Esposito G, Rizzi R, Tillmanns 
J, Tugal D, Musso E, Rimoldi O, Bearzi C, Urbanek K, Anversa P, Leri A, and 
Kajstura J. The young mouse heart is composed of myocytes heterogeneous in age and 
function. Circ Res 101: 387-399, 2007. 
67. Sakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, and Masaki 
T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. 
Biochem Biophys Res Commun 178: 656-663, 1991. 
68. Sciarretta S, Volpe M, and Sadoshima J. Mammalian target of rapamycin signaling 
in cardiac physiology and disease. Circ Res 114: 549-564, 2014. 
69. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, Wu TD, 
Guerquin-Kern JL, Lechene CP, and Lee RT. Mammalian heart renewal by pre-existing 
cardiomyocytes. Nature 493: 433-436, 2013. 
70. Sheng R, Gu ZL, and Xie ML. Epigallocatechin gallate, the major component of 
polyphenols in green tea, inhibits telomere attrition mediated cardiomyocyte apoptosis in 
cardiac hypertrophy. Int J Cardiol 162: 199-209, 2013. 
71. Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen 
PH, van der Vusse GJ, and van Bilsen M. Inflammatory pathways are activated during 
cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors 
PPARalpha and PPARdelta. J Biol Chem 283: 29109-29118, 2008. 
72. Somvanshi RK, Qiu X, and Kumar U. Isoproterenol induced hypertrophy and 
associated signaling pathways are modulated by somatostatin in H9c2 cells. Int J Cardiol 
167: 1012-1022, 2013. 
 193 
 
73. Tan SC, Carr CA, Yeoh KK, Schofield CJ, Davies KE, and Clarke K. 
Identification of valid housekeeping genes for quantitative RT-PCR analysis of cardiosphere-
derived cells preconditioned under hypoxia or with prolyl-4-hydroxylase inhibitors. Mol Biol 
Rep 39: 4857-4867, 2012. 
74. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh 
K, Rosenzweig A, Sussman MA, Urbanek K, Nadal-Ginard B, Kajstura J, Anversa P, 
and Leri A. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth 
factor-1 overexpression. Circ Res 94: 514-524, 2004. 
75. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri F, 
Beltrami CA, Bussani R, Beltrami AP, Quaini F, Bolli R, Leri A, Kajstura J, and 
Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in 
ischemic heart failure. Proc Natl Acad Sci U S A 102: 8692-8697, 2005. 
76. Valentini M, and Parati G. Variables influencing heart rate. Prog Cardiovasc Dis 
52: 11-19, 2009. 
77. van Amerongen MJ, and Engel FB. Features of cardiomyocyte proliferation and its 
potential for cardiac regeneration. J Cell Mol Med 12: 2233-2244, 2008. 
78. van der Harst P, Wong LS, de Boer RA, Brouilette SW, van der Steege G, Voors 
AA, Hall AS, Samani NJ, Wikstrand J, van Gilst WH, van Veldhuisen DJ, and Group 
M-HS. Possible association between telomere length and renal dysfunction in patients with 
chronic heart failure. Am J Cardiol 102: 207-210, 2008. 
79. van Steensel B, Smogorzewska A, and de Lange T. TRF2 protects human telomeres 
from end-to-end fusions. Cell 92: 401-413, 1998. 
80. Watkins SJ, Borthwick GM, and Arthur HM. The H9C2 cell line and primary 
neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev 
Biol Anim 47: 125-131, 2011. 
 194 
 
81. Werner C, Hanhoun M, Widmann T, Kazakov A, Semenov A, Poss J, 
Bauersachs J, Thum T, Pfreundschuh M, Muller P, Haendeler J, Bohm M, and Laufs 
U. Effects of physical exercise on myocardial telomere-regulating proteins, survival 
pathways, and apoptosis. J Am Coll Cardiol 52: 470-482, 2008. 
82. Wong LS, Windt WA, Roks AJ, van Dokkum RP, Schoemaker RG, de Zeeuw D, 
and Henning RH. Renal failure induces telomere shortening in the rat heart. Neth Heart J 
17: 190-194, 2009. 
83. Woods D, Sanders J, Jones A, Hawe E, Gohlke P, Humphries SE, Payne J, and 
Montgomery H. The serum angiotensin-converting enzyme and angiotensin II response to 
altered posture and acute exercise, and the influence of ACE genotype. Eur J Appl Physiol 
91: 342-348, 2004. 
84. Wu J, Stefaniak J, Hafner C, Schramel JP, Kaun C, Wojta J, Ullrich R, Tretter 
VE, Markstaller K, and Klein KU. Intermittent Hypoxia Causes Inflammation and Injury to 
Human Adult Cardiac Myocytes. Anesth Analg 122: 373-380, 2016. 
85. Wu QQ, Zong J, Gao L, Dai J, Yang Z, Xu M, Fang Y, Ma ZG, and Tang QZ. 
Sulforaphane protects H9c2 cardiomyocytes from angiotensin II-induced hypertrophy. Herz 
39: 390-396, 2014. 
86. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, 
Singapuri A, Davis BB, Low R, Hammock BD, and Chiamvimonvat N. Prevention and 
reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci 
U S A 103: 18733-18738, 2006. 
87. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, 
Maemura K, Kurihara H, Aikawa R, Takano H, and Yazaki Y. Endothelin-1 is involved 
in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271: 3221-3228, 
1996. 
 195 
 
88. Yan L, Zhang JD, Wang B, Lv YJ, Jiang H, Liu GL, Qiao Y, Ren M, and Guo 
XF. Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and 
inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-gamma 
expression and suppressing AP-1 activity. PLoS One 8: e72548, 2013. 
89. Yao FR, Sun CW, and Chang SK. Morton lentil extract attenuated angiotensin II-
induced cardiomyocyte hypertrophy via inhibition of intracellular reactive oxygen species 
levels in vitro. J Agric Food Chem 58: 10382-10388, 2010. 
90. Zannolli R, Mohn A, Buoni S, Pietrobelli A, Messina M, Chiarelli F, and 
Miracco C. Telomere length and obesity. Acta Paediatr 97: 952-954, 2008. 
91. Zarrinpashneh E, Beauloye C, Ginion A, Pouleur AC, Havaux X, Hue L, Viollet 
B, Vanoverschelde JL, and Bertrand L. AMPKalpha2 counteracts the development of 
cardiac hypertrophy induced by isoproterenol. Biochem Biophys Res Commun 376: 677-681, 
2008. 
92. Zimmer HG, Kolbeck-Ruhmkorff C, and Zierhut W. Cardiac hypertrophy induced 
by alpha- and beta-adrenergic receptor stimulation. Cardioscience 6: 47-57, 1995. 
 
 
 
 
 
 196 
 
 
 
 
 
Chapter 5 
 
The Effects of Inhibiting Telomere 
Maintenance on Human Cardiomyocyte Size   
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Abstract 
Background and aims: Telomeres are nucleoprotein repeats that protect chromosome ends 
and prevent the cellular senescence and apoptosis. The number of these repeats (telomere 
length) is negatively associated with cardiomyocyte hypertrophy, a key feature of heart 
disease, but this relationship is poorly defined. The present study aims to characterise key 
aspects of the molecular and cellular phenotype of human primary cardiomyocytes (HPCs) 
after inhibiting telomere maintenance. 
Methods and results: HPCs were treated with small interfering RNA (siRNA) knockdowns of 
TERT, the catalytic component of the telomere-lengthening enzyme telomerase, and TRF2, 
an integral telomeric protein, and the small molecule telomerase inhibitor BIBR1532. Cell 
size, proliferation, apoptosis, and oxidative stress were measured by confocal microscopy. 
Telomere length and gene expression were determined using qPCR. HPC size significantly 
increased following siRNA knockdown of TERT, TRF2, both TERT and TRF2, and inhibition 
of telomerase activity for 48 hours (all P<0.001). Telomere length, however, only decreased 
in cells treated with BIBR1532 for ten days (P=0.016). Oxidative stress (P=0.010), apoptosis 
(P=0.001), and expression of the hypertrophic genes NPPA and NPPB (both P<0.001) 
increased following TRF2 knockdown while all treatments reduced proliferation (P<0.05) 
and expression of the cardioprotective gene MAPK1 (P<0.05).  
Discussion and conclusions: These findings demonstrate that disruptions in telomere 
maintenance are sufficient to induce cardiomyocyte hypertrophy independently of changes 
telomere length. The involvement of TRF2 in maintaining telomere loops suggests an 
important role for the telomeric structure in regulating hypertrophic gene expression and 
maintaining cardiomyocyte viability. 
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Introduction 
Telomeres are hexanucleotide TTAGGG repeats which combine with specialised proteins at 
the ends of eukaryotic chromosomes (11). The primary role of telomeres is to protect 
genomic content and prevent cellular senescence and apoptosis (10). To achieve this, 
sufficient telomere length must be maintained and telomeric proteins available to form the 
protective loops that encapsulate the genome (30). As such, several studies have measured 
telomere length and maintenance in search for mechanisms that regulate cell loss in aging and 
degenerative diseases (38, 39, 110). In this regard, there is a well-documented association 
between telomere attrition and heart disease, the worldwide leading cause of death (18). 
There is also significant evidence, however, linking short telomeres to old-age (13), obesity 
(108), diabetes (110), and other causes of heart disease (3). This overlap of primary risk 
factors has prevented researchers from identifying if the relationship between telomeres and 
heart disease is causal, consequential, or confounding.  
The cell-specific length of telomeres (33) and the multi-organ pathophysiology of 
many diseases, such as hypertension (26) and atherosclerosis (63), can also pose problems to 
uncovering causal relationships. Cardiac hypertrophy, however, is caused by the growth of 
individual cardiomyocytes, the contractile cells of the heart, in response to biomechanical 
stress or other hypertrophic stimuli (44, 107). Although this is harmless in its early stages, 
continued hypertrophy of the myocardium progressively decreases the size of the left 
ventricle and, consequently, cardiac output (35). As such, unchecked cardiac hypertrophy 
leads to heart failure (85), a disease which is characterised by cardiomyocyte-specific 
telomere shortening (81). Furthermore, cardiomyocyte telomere length is negatively 
associated with cell size in mouse hearts at various ages (78). Therefore, the involvement of 
telomeres in the pathophysiological sequence of cardiac hypertrophy leading to heart failure 
is contained to the cardiomyocytes. As such, changes to cardiomyocyte telomeres in relation 
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to cell size could uncover a causal relationship between telomeres, cardiac hypertrophy, and 
heart failure.  
The length of telomeres is determined by heritable differences (91), cellular 
replicative history (8), endogenous stresses (58), environmental toxins (3), and other factors 
(39). Consequently, telomeres shorten progressively throughout the lifespan but can be 
elongated by telomerase, an enzyme comprised of a reverse transcriptase (Tert) and an RNA 
component (Terc) (66). In mice deficient of either Tert or Terc, cardiomyocytes lose 3-5 kilo 
bases (kb) of telomeric repeats per generation and early-onset cardiac hypertrophy and heart 
failure occur by the second and fifth generations, respectively (15). Although this suggests a 
causal involvement for telomeres in cardiac hypertrophy and heart failure (90), systemic 
telomerase knockdowns cause hypertension and increased levels of the pro-hypertrophic 
peptide endothelin-1 (73) both of which can lead to cardiac hypertrophy (44). This confounds 
the direct relationship between telomeres and the development of cardiac hypertrophy, 
limiting the utility of these models.  
Another shortcoming of animal studies are the differences in the length and 
maintenance of telomeres. For instance, critical telomere length associated with senescence in 
rodents is around 15 kb (78) whereas in humans it is only 1.5 kb (97). Furthermore, Tert 
overexpression prevents the terminal differentiation of cardiomyocytes in neonatal mice (67) 
but has no influence on the senescence of human fetal cardiomyocytes (5). In this regard, 
fetal or neonatal cardiomyocytes are often used in the study of cardiac hypertrophy but have 
many key differences when compared to adult cells (18). For instance, the so-called fetal 
genes NPPA and NPPB are essential for cardiac development but their re-expression in 
adulthood is associated with cardiac hypertrophy and heart failure (102). Furthermore, a 
decrease in cardiac telomere length and telomerase activity is normal around birth (19, 96) 
but predisposes to heart disease in adulthood (25, 68). Similarly, immortalised cell cultures 
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are also used in cardiac research (18) but the circumvention of telomere-induced senescence 
and apoptosis seriously questions their relevance in the study of degenerative diseases. The 
final factor to consider is that cardiac hypertrophy can also be a physiological response to 
strenuous exercise (36). Although this is potentially confounding, physiological cardiac 
growth is associated with increased telomere length and maintenance (54, 101) as well as the 
expression of specific genes, such as mitogen activated protein kinase 1 (MAPK1) and  
protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2) (61). These findings 
suggest that telomere length and maintenance are important epigenetic factors in determining 
whether cardiac growth is normal, adaptive, or degenerative.  
The specialised proteins that bind to the telomeric sequence and form the so-called 
shelterin complex prevent telomeres from being recognised as DNA breaks (31). Of these, 
telomere repeat-binding factor 2 (TRF2) has been shown to be crucial for cardiomyocyte 
viability. For instance, interference with Trf2 in rat cardiomyocytes causes telomere 
shortening, decreased proliferation, and apoptosis whereas high levels of Trf2 are protective 
(68). Moreover, unlike telomerase-deficient mice, which are healthy in the F1 and F2 
generations (90), Trf2 knockouts are embryonically lethal (57). Interestingly, Trf2 deletion in 
the mouse liver did not impair liver regeneration or mouse survival (49), highlighting cell-
specific functions for Trf2. In humans, TRF2 insufficiency predisposes cardiomyocytes to 
apoptosis (17) and is associated with cardiomyocyte telomere attrition and heart failure (68). 
Taken together, these findings suggest an important role for TRF2 in the development of 
heart failure. However, the effects of TRF2 knockdown on cardiomyocyte size have not been 
determined. 
Given the involvement of telomere length and maintenance in the development of 
cardiac hypertrophy and subsequent heart failure, the present study used small-interfering 
RNAs (siRNAs) to knockdown the expression of TERT and TRF2 in adult human primary 
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cardiomyocytes (HPCs) and then measure cell size. Telomerase activity was also inhibited 
pharmacologically in HPCs with the small molecule BIBR1532, as no studies have 
determined the effects of telomerase inhibition on cardiomyocytes without the use of genetic 
manipulation. The aim of this study was to identify molecular factors that characterise cardiac 
hypertrophy and heart failure after inhibiting telomere maintenance to determine the 
possibility of a causal relationship. It was hypothesised that inhibiting telomere maintenance 
would lead to an increase in cardiomyocyte size.  
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Methods 
Ethical clearance 
As this study used a cell line, no ethical approval was necessary.  
Cell culture 
HPCs from a healthy 56-year-old Caucasian male were acquired commercially and cultured 
in ready-to-use myocyte growth medium (both from Promo Cell, Heidelberg, Germany). 
Although HPCs are derived from adult cardiac progenitor cells and replicated for at least 15 
population doublings in vitro, they also undergo senescence and normal cellular aging (95, 
105) and thus more accurately reflect human disease than immortalised cell lines and animal 
models. Passage 4 HPCs were seeded at 25% confluence, and allowed to adhere for 24 hours 
before treatment. 6-well dishes were used for nucleic acid and protein extraction and single 
glass-bottom dishes of the same size (Mattek Corporation, Ashland, USA) for imaging. All 
HPCs were passaged using HEPES wash buffer, myocyte trypsin, and myocyte trypsin 
inhibitor, and stored in myocyte cryo-media (all from Promo Cell). 
Cell treatments 
siRNA transfection 
HPCs were transfected with small interfering RNAs (siRNAs) for 48 hours to reduce TERT 
(Bioneer #1149877) and TRF2 (Bioneer #1149866) mRNA levels. A scramble siRNA 
(Bioneer #SN-1002) with no known binding regions in the human genome was used as a 
control. Each siRNA was diluted in Opti-MEM Reduced Serum Media (Life Technologies) 
to a concentration of 10nM and delivered using RNAimax Lipofectamine (Life 
Technologies). This concentration has been used previously in muscle cells (65) and early 
optimisations showed it produce at least a 50% knockdown of target gene expression in HPCs 
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(data not shown). A double transfection of TERT and TRF2 was also performed as research 
has suggested an interplay between these genes in the heart (47, 67). 
Pharmacological inhibition of telomerase activity 
Genetic methods of interfering with telomeric gene expression may decrease the presence of 
crucial components at telomeres and lead to telomere uncapping (76). Telomerase inhibition 
with small molecules, however, such as 2-((E)-3-naphthalen-2-yl-but-2-enoylamino)-benzoic 
acid, known as BIBR1532, may simply decrease telomerase activity without disturbing the 
structure of telomeres (23). Therefore, to inhibit telomerase activity without genetic 
interference, HPCs were treated with 930nM of the human telomerase inhibitor BIBR1532 
(Merck Millipore) for 48 hours. This concentration was selected as it lies between the lower 
(28) and higher (6) estimates of the half-maximal inhibitory concentration (IC50) values 
previously reported for HeLa cells.  
Despite telomerase activity being the only mechanism of elongating, and thus 
maintaining, telomere length in normal cells (66), changes in telomere length take time to 
occur, even in the absence of telomerase activity (12, 15, 51). To confirm the efficacy of 
BIBR1532 to reduce HPC telomere length, and not simply induce changes in telomere 
structure, 930nM treatment was continued on a subset of HPCs every 48 hours for ten days. 
Cells were passaged on days two and six and only telomere length was determined in this 
group. 
Telomere length 
HPCs were scraped from two wells with a rubber policeman into 200uL of PBS and Genomic 
DNA was extracted using the Purelink Genomic DNA Mini Kit (Life Technologies) 
according to the manufacturer’s protocol and diluted to 2.5ng/µL based on quantitation with a 
Nanodrop 2000. This was performed using three independent to provide enough data for 
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statistical analyses. A 10ng template (4µL) was then added to a 384-well quantitative 
polymerase chain reaction (qPCR) plate (Life Technologies) and telomere length was 
determined using the telomere (T) to single-copy gene (S) method as described previously 
(22). Briefly, the squared cycle threshold (Ct) for 36B4, a single-copy gene ('S') present only 
once in the genome, was divided by the square of the Ct for Tel1 ('T'), which reflects 
telomere length. This provides a measure of average telomere length, known as the T/S ratio. 
Primers, reagents, qPCR equipment, and cycling conditions were the same as used in Chapter 
5 and previously published (24).   
Gene expression 
RNA was isolated using 1mL of TRI reagent (Life Technologies) per 3 wells. Cell lysates 
were frozen at -80°C then extracted at a later date in accordance with the manufacturer’s 
guidelines. Immediately following extraction, the concentration of RNA was determined 
using a Nanodrop 2000 and 2µg of RNA was reverse transcribed into cDNA using the High 
Transcriptase cDNA kit (Life Technologies) as instructed by the manufacturers. This was 
performed on three independent replicates to provide enough data for statistical analyses. 
cDNA samples were diluted to 5ng/uL and the same reagents, qPCR equipment, and cycling 
conditions as per Chapter 5 and previous research (24) were used. Primers design was 
achieved with NCBI tool Primer Blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi) to ensure all primers spanned at least on exon-exon junction, produced an 
amplicon of 75-150 base pairs in length, and had a melting temperature as close to 60°C as 
possible. Key genes involved in telomere maintenance (7, 29, 31, 55), pathological (20, 27, 
40, 45, 59) and physiological (21, 80, 109) cardiac hypertrophy, inflammation (87, 103), and 
proliferation (43) were measured relative to the housekeeping gene β-actin (93). Primer 
sequences were the same as those used and listed in Chapter 5 (see pages 155-157).  
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Cell size 
HPCs size was demonstrated by immunocytochemistry (ICC) and z-stack confocal imaging. 
Briefly, cells were washed (in PBS) twice, fixed in 4% paraformaldehyde for 30 minutes, 
washed four more times, blocked and permeabilised in 0.75% 2mg/mL bovine serum 
albumin, 2% horse serum, and 0.4% Tx100 in PBS for 30 minutes, then probed with an anti-
α-sarcomeric actin monoclonal antibody (Sigma Aldrich) 1:100 overnight at 4°C. Following 
two washes, the AP130C Goat Anti-Mouse IgG & IgM Antibody Cy3 conjugate (Merck 
Millipore) 1:100 was applied for two hours in the dark at room temperature. Cells were then 
washed twice, 2μM of Hoechst 33342 in PBS was added for 5 minutes, and four final washes 
were performed before imaging in PBS. 1μm slices were captured over a 15μm z-range using 
a Nikon Eclipse Ti-E confocal microscope. A minimum of 25 cells within five z-stacks were 
analysed per group using integrated density measurements generated in ImageJ. 
Proliferation  
To measure levels of proliferation, siRNA-treated cells were prepared for ICC and confocal 
microscopy as described above then probed with a conjugated antibody for Ki67 (Abcam), a 
nuclear antigen and marker of cardiomyocyte proliferation (9), 1:100 overnight at 4°C. Cells 
were washed twice and 2μM of Hoechst 33342 in PBS was added for 5 minutes before four 
final washes and imaging in PBS. Eight sections containing 6-10 cells were captured on a 
Nikon Eclipse Ti-E confocal microscope. Proliferation was determined by dividing the 
number of cells expressing the Ki67 antigen by the total number of cells per image. 
Apoptosis  
Immunocytochemistry and confocal microscopy  
Cells were prepared as above then probed for cleaved caspase 3 (Cell Signalling #9664) 
1:100 overnight at 4°C to determine levels of apoptosis. Prior to this, a subset of HPCs were 
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treated with 500nM staurosporine (Sigma Aldrich) for 3 hours to induce apoptosis and act a 
positive control. Following two washes, the AP130C Goat Anti-Mouse IgG & IgM Antibody 
Cy3 conjugate (Merck Millipore) 1:100 was applied for two hours in the dark at room 
temperature. Cells were then washed twice, 2μM of Hoechst 33342 in PBS was added for 5 
minutes, and four final washes were performed before imaging in PBS. Five z-stacks 
consisting of one image every μm over a 15μm z-range were captured using a Nikon Eclipse 
Ti-E confocal microscope. Levels of apoptosis was defined as the integrated density of total 
cleaved caspase 3 fluorescence per cell generated in ImageJ.  
Protein extraction  
Protein samples were collected from 3 wells using 300uL of RIPA buffer (Sigma Aldrich) 
with 1% Halt Protease & Phosphatase Inhibitor Cocktail (Thermo Scientific) and then stored 
at -80ºC. Total soluble protein was extracted as per the manufacturer’s instructions then 
immediately diluted 1:3 and measured with the bicinchoninic acid (BCA) assay kit (Bio-
Rad). A standard curve with eleven points ranging from 0.0 – 2.0 mg/mL was created using 
bovine serum albumin (BSA) (Thermo Scientific) and the absorbance at 570nm was 
determined with a Multiskan Microplate Photometer (Thermo Scientific). 
Western blot  
25µg of cell protein was mixed with 5% β-Mercaptoethanol (Sigma Aldrich) in Laemelli 
Sample Buffer (Bio-Rad) then denatured at 100°C for 5 minutes. Samples were resolved on a 
4–15% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad) at 80 volts for around 90 minutes 
at room temperature then electroblotted on to a Nitrocellulose Membrane (Thermo Scientific) 
at 100 volts for one hour at 4°C. The membrane was blocked for one hour at room 
temperature using 5% skim milk in TBS-Tween 20 before poly (ADP-ribose) polymerase 
(PARP) (Cell signalling #9542) 1:2500 was applied overnight at 4ºC. PARP binds double 
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stranded DNA to mediate chromosomal stability (66) and becomes cleaved in cells 
undergoing apoptosis (69). The next morning, four 15-minute washes in TBS-Tween 20 were 
performed followed by the application of anti-rabbit (Cell signalling #7074) 1:5000 in a 0.5% 
skim milk in TBS-Tween 20 solution for 1 hour at room temperature. The wash steps were 
then repeated before detection using enhanced chemiluminescence SuperSignal West Pico 
Substrate (Thermo Scientific). Images were captured with a UVITEC Alliance digital 
imaging system (Thermo Scientific). The membrane was stripped for 15 minutes at room 
temperature using RestoreTM Western Blot Stripping Buffer (Thermo Scientific) then blocked 
in 5% skim milk in TBS-Tween 20. Cleaved PARP (Cell signalling #5625) (1:2500) was then 
applied and treated identically to PARP. 
Reactive oxygen species  
Oxidative stress was measured in live HPCs using the Image-iT LIVE Green Reactive 
Oxygen Species (ROS) Detection Kit (Life Technologies) and HPC reagents (Promo Cell) 
according to the manufacture’s protocol. For a positive control, 100μM of tert-butyl hydrogen 
peroxide (TBHP), an inducer of ROS production (Life Technologies), was added to subset of 
cells for 2 hours. Single images were taken to avoid photobleaching on a Nikon Eclipse Ti-E 
confocal microscope system with a 37°C chamber. Total fluorescence was determined using 
ImageJ and a minimum of 25 cells were analysed per group.  
Data Analysis 
Statistical tests and data transformation were performed in Microsoft Excel and PRISM was 
used to create the graphs. For confocal microscopy and gene expression experiments, 
statistical analyses were performed on the least transformed relative data (the integrated 
density and delta Ct values, respectively) but graphed as a fold change for meaningful 
representation. Although all groups are displayed together for simplicity, with one graph per 
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dependent variable, each treatment group was compared to its control only using the 
appropriate t-test. The control for the TERT and TRF2 knockdowns was the scramble siRNA 
and BIBR1532 was compared to a no treatment control group. Data are presented as means 
(M) ± the standard deviation (SD) with P<0.05 regarded as significant. 
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Results 
Telomere length  
48 hours of TERT, TRF2, or combined TERT and TRF2 knockdown did not change HPC 
telomere length (all P>0.05) (Figure 1A). Similarly, BIBR1532 did not influence telomere 
length after 48 hours (P=0.561); however, there was a significant reduction in telomere 
length following 10 days of telomerase inhibition with BIBR1532 (P=0.016) (Figure 1B). 
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Figure 1. Telomere length. (A) HPC telomere length was unchanged after 48 hours but (B) 
shorter after 10 days of telomerase inhibition. Data are presented as mean ± SD (n=3). * 
indicates P<0.05 compared to 48-hour Cont. # indicates P<0.05 compared to 10-day Cont. 
Scram, Scramble siRNA; TERT, siRNA-TERT; TRF2, siRNA-TRF2; T + T, siRNA-TERT 
and siRNA-TRF2; Cont., no treatment control; BIBR, BIBR1532. 
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Validation of knockdowns  
TERT-siRNA knockdown significantly decreased TERT mRNA levels (P=0.039) but not 
when used in conjunction with the TRF2-siRNA (P=0.638) (Figure 2A). TRF2 knockdown 
produced a significant decrease in TRF2 expression when used independently (P=0.011) and 
combined with the TERT-siRNA (P=0.010) (Figure 2B). BIBR1532 treatment did not alter 
TERT or TRF2 mRNA levels (both P>0.05) (Figure 2A and B, respectively). 
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Figure 2. Validation of knockdowns. (A) TERT and (B) TRF2 mRNA levels were 
decreased by targeted siRNA knockdown but not telomerase inhibition in HPCs. Data are 
presented as mean ± SD (n=3) with Scram normalised to 1. * indicates P<0.05 compared to 
Scram. * indicates P<0.05 compared to Scram. ** indicates P<0.01 compared to Scram. 
Scram, Scramble siRNA; TERT, siRNA-TERT; TRF2, siRNA-TRF2; T + T, siRNA-TERT 
and siRNA-TRF2; Cont., no treatment control; BIBR, BIBR1532. 
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Cell size 
Targeted siRNA-knockdown of TERT, TRF2, and TERT and TRF2 combined, all 
significantly increased HPC size relative to the scramble control (P<0.001) (Figure 3). 
Treatment with the telomerase inhibitor BIBR1532 also significantly increased HPC size 
compared to untreated control cells (P<0.001) (Figure 3).  
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Figure 3. Cell size. (A) Anti-α-sarcomeric actin immunocytochemistry; (B) inhibiting 
telomere maintenance increased HPC size. Data are presented as mean ± SD (n=25) with 
Scram and Cont normalised to 1. *** indicates P<0.001 compared to Scram or Cont.  Scram, 
Scramble siRNA; TERT, siRNA-TERT; TRF2, siRNA-TRF2; T + T, siRNA-TERT and 
siRNA-TRF2; Cont., no treatment control; BIBR, BIBR1532.  
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Telomeric gene expression 
siRNA inhibition of TERT caused a significant reduction in TERC expression, independently 
(P=0.019) and in conjunction with TRF2 (P<0.001) (Figure 4A). Telomerase inhibition 
decreased mRNA levels of two key shelterin components, telomere repeat-binding factor 1 
(TRF1) (P=0.015) (Figure 4B), and TRF1 interacting nuclear factor 2 (TINF2) (P=0.016) 
(Figure 4C). None of the treatments influenced the expression of the genes for the shelterin 
proteins TRF2-interacting protein (TERF2IP) (Figure 4D) or protection of telomeres 1 
(POT1) (both P>0.05) (Figure 4E). Combined TERT and TRF2 knockdown decreased mRNA 
levels of Tripeptidyl-peptidase 1 (TPP1), another shelterin component, (P=0.014) (Figure 4F) 
and protein phosphatase 1 regulatory subunit 10 (also known, and hereafter referred to, as 
PNUTS), a telomeric gene involved in TRF2 binding (P=0.032) (Figure 4G). No treatments 
altered the expression of the lifespan modulator and telomere-associate gene Sirtuin 1 
(SIRT1) (all P=0.05) (Figure 4H). TRF2 knockdown had no effect on any of the above genes 
(all P>0.05). 
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Figure 4. Telomeric gene expression. (A) TERT knockdown and BIBR1532 treatment 
reduced TERC mRNA levels; (B) BIBR1532 treatment decreased TRF1 and (C) TINF2 
expression; (D) Inhibiting telomere maintenance did not affect TERF2IP or (E) POT1 mRNA 
expression; (F) Combined TERT and TRF2 knockdown decreased TPP1 and (G) PNUTS 
mRNA levels; (H) BIBR1532 treatment decreased SIRT1 expression. All HPCs. Data are 
presented as mean ± SD (n=3) with Scram and Cont normalised to 1. * indicates P<0.05 
compared to Scram or Cont. *** indicates P<0.001 compared to Scram or Cont. Scram, 
Scramble siRNA; TERT, siRNA-TERT; TRF2, siRNA-TRF2; T + T, siRNA-TERT and 
siRNA-TRF2; Cont., no treatment control; BIBR, BIBR1532. TRF1, telomere repeat-binding 
factor 1; TRF2, telomere repeat-binding factor 2; TINF2, TRF1 interacting nuclear factor 2; 
TERF2IP, TRF2-interacting protein; TPP1, tripeptidyl peptidase 1; POT1, protection of 
telomeres 1; PNUTS, phosphatase nuclear-targeting subunit 1; SIRT1, Sirtuin 1.   
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Markers of pathological and physiological cardiac hypertrophy  
TRF2 knockdown significantly increased expression of the fetal genes and markers of heart 
failure NPPA and NPPB, both independently, and in conjunction with TERT (all P<0.001) 
(Figure 5A and B respectively). mRNA levels of NF-kappa-B p105 subunit (NFKB1), a gene 
associated with pathological cardiac hypertrophy (40) were not changed in any of the groups 
(Figure 5C) (all P>0.05). Expression of phosphokinase C alpha (PKCα), another gene 
associated with pathological cardiac hypertrophy (45) increased as a result of TERT-siRNA 
treatment (P=0.048) (Figure 5D). Inhibition of telomerase activity with BIBR1532 had no 
effect on the expression of any of the above genes (all P>0.05). Similarly, no treatments 
altered the gene expression of protein kinase AMP-activated catalytic subunit alpha 2 
(PRKAA2), a gene associated with physiological cardiac growth (all P>0.05) (Figure 5E). In 
contrast, all treatments significantly decreased expression of the cardioprotective gene 
MAPK1 (all P<0.05) (Figure 5F).  
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Figure 5. Markers of pathological and physiological cardiac hypertrophy. (A) TRF2 
knockdown increased NPPA and (B) NPPB expression; (C) Inhibiting telomere maintenance 
did not affect NFKB1 mRNA levels; (D) TERT knockdown increased PKCα expression; (E) 
Inhibiting telomere maintenance did not affect PRKAA2 mRNA levels; (F) Inhibiting 
telomere maintenance decreased MAPK1 mRNA levels. All HPCs. Data are presented as 
mean ± SD (n=3) with Scram and Cont normalised to 1. * indicates P<0.05 compared to 
Scram or Cont. ** indicates P<0.01 compared to Scram or Cont. *** indicates P<0.001 
compared to Scram or Cont. Scram, Scramble siRNA; TERT, siRNA-TERT; TRF2, siRNA-
TRF2; T + T, siRNA-TERT and siRNA-TRF2; Cont, no treatment control; BIBR, 
BIBR1532. NPPA gene for atrial natriuretic peptide; NPPB, gene for brain natriuretic 
peptide; NFKB1, Nuclear factor NF-kappa-B p105 subunit; MAPK1, Mitogen-activated 
protein kinase 1; PRKAA2, Protein Kinase AMP-Activated Catalytic Subunit Alpha 2. 
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Inflammation and oxidative stress 
As inflammation is a suspected cause of cardiac hypertrophy, heart failure, and telomere 
attrition (42, 58, 75), markers of inflammation were assessed. No treatments altered 
expression of the inflammatory markers interleukin 6 (IL6) and 1beta (IL-β) (all P>0.05) 
(Figure 6A and B, respectively). TRF2 knockdown increased (P=0.027) and TERT-siRNA 
treatment decreased (P=0.029) expression of the marker of cardiomyocyte inflammation 
cyclooxygenase 2 (COX2) (Figure 6C).  
Another cause of telomere attrition and cardiomyocyte apoptosis is oxidative stress 
(53, 99). Levels of ROS significantly increased following TRF2-siRNA treatment (P=0.010) 
but not when used in conjunction with the TERT-siRNA (P>0.05) (Figure 6D and E). The 
influence of BIBR1532 treatment on ROS levels was not assessed. 
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Figure 6. Inflammation and oxidative stress. (A) Inhibiting telomere maintenance did not 
affect IL6 or (B) IL-1β mRNA levels; (C) TERT knockdown decreased and TRF2 knockdown 
increased COX2 expression; (D) TRF2 knockdown increased ROS levels; (E) 6-carboxy-
2',7'-dichlorodihydrofluorescein diacetate immunofluorescence for ROS. All HPCs.   Data are 
presented as mean ± SD (n=3 for gene expression and n=25 for ROS) with Scram and Cont. 
normalised to 1. * indicates P<0.05 compared to Scram or Cont. ** indicates P<0.01 
compared to Scram or Cont. Scram, Scramble siRNA; TERT, siRNA-TERT; TRF2, siRNA-
TRF2; T + T, siRNA-TERT and siRNA-TRF2; Cont., no treatment control; BIBR, 
BIBR1532. IL6, Interleukin 6; IL-1β, Interleukin-1β; COX2, cyclooxygenase-2; ROS, 
reactive oxygen species.   
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Proliferation and apoptosis  
All treatments significantly reduced the expression of Mi67 (P<0.05) (Figure 7A), the gene 
for Ki67, which is also a marker of cardiomyocyte proliferation (50). As such, 
immunocytochemistry and confocal microscopy (Figure 7B) was performed on siRNA-
treated cells and revealed that Ki67 was also decreased in these groups (all P<0.05) (Figure 
7C). Levels of Ki67 were not assessed following treatment with BIBR1532. 
To explore if apoptosis accompanied this decrease in proliferation, cleaved PARP 
western blotting was performed (74) but was only detected in the positive control cells 
(Figure 7D). In siRNA-treated cells, cleaved caspase 3 was also observed using 
immunocytochemistry and confocal microscopy (Figure 7E), and a significant increase was 
detected as a result of TRF2 knockdown both independently (P=0.001) and in conjunction 
with the TERT-siRNA (P=0.014) (Figure 7F).  
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Figure 7. Proliferation and apoptosis. (A) TRF2 knockdown and BIBR1532 treatment 
decreased Mi67 expression; (B) TERT and TRF2 knockdown decreased Ki67 levels; (C) 
Anti-Ki67 immunocytochemistry; (D) Western blot for PARP; (E) TRF2 knockdown 
increased expression of cleaved caspase 3; (F) Anti-cleaved caspase 3 immunocytochemistry. 
All HPCs. Data are presented as mean ± SD (n=3 for gene expression and n=7 for Ki67 
immunocytochemistry) with Scram and Cont. normalised to 1. * indicates P<0.05 compared 
to Scram or Cont. ** indicates P<0.01 compared to Scram or Cont. Scram, Scramble siRNA; 
TERT, siRNA-TERT; TRF2, siRNA-TRF2; T + T, siRNA-TERT and siRNA-TRF2; Cont., 
no treatment control; BIBR, BIBR1532. Mi67, gene for Ki67. 
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Discussion 
The present study is the first to determine the effects of inhibiting TERT, TRF2, and 
telomerase activity on human cardiomyocyte hypertrophy. Results demonstrate that each of 
these methods of inhibiting telomere maintenance is sufficient to increase HPC size, 
independently of changes in telomere length. In addition, all treatments produced a decrease 
in HPC proliferation and expression of MAPK1, a gene associated with adaptive or 
‘physiological’ cardiac growth. Furthermore, specific TRF2 knockdown in HPCs was shown 
to induce oxidative stress, inflammation, apoptosis, and re-expression of the fetal genes and 
markers of pathological cardiac growth NPPA and NPPB. These findings indicate that, in 
addition to the accelerated biological aging and cell loss, lack of telomere maintenance can 
also induce cardiomyocyte hypertrophy and other molecular and cellular features, such as 
decreased proliferation, that are characteristic of heart disease.  
Although there is little evidence to causally link telomere insufficiency and cardiac 
hypertrophy, it has been suggested that short telomeres and not defective telomerase 
determines disease phenotypes (90). To support this suggestion, telomerase-deficient mice 
are healthy in early generations (15) and humans with mutations in TERT are asymptomatic 
in childhood and sometimes into adulthood (72). Furthermore, genetic anticipation is 
paralleled by degenerative telomere shortening in both mice (15) and humans (1) with 
defective telomerase. Findings of the present study, however, suggest that impaired 
telomerase can cause cardiomyocyte hypertrophy independently of telomere length. More 
specifically, the ability of the telomerase inhibitor BIBR1532 to induce hypertrophy before 
decreasing telomere length indicates that HPC size is more effected by insufficient telomere 
maintenance than telomere length. Interestingly, telomerase-deficient mice present with 
cardiac hypertrophy in the second generation, before obvious signs of premature aging and 
disease occur (51). Similarly, cardiac Tert and telomerase expression were downregulated in 
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the hypertrophic heart rats used in Chapter 2 before the onset of cardiac hypertrophy. 
Moreover, TERT mutations in humans lead to dyskeratosis congenita, a bone marrow failure 
syndrome, usually by 30 years of age (2), potentially obscuring the identification of early-
stage cardiac hypertrophy. Therefore, previous findings do not contradict the results of the 
present study which suggest that telomerase insufficiency may cause cardiac hypertrophy 
with the subsequent loss of telomere length later coinciding with heart failure (Figure 8).  
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Figure 8. The possible involvement of TERT, TRF2, and telomerase activity in the 
development of cardiac hypertrophy and heart failure. TERT, telomerase reverse 
transcriptase; TRF2, telomere repeat-binding factor 2; ROS, reactive oxygen species. 
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Despite stable telomere length between groups suggesting an important role for 
telomere maintenance in regulating cardiomyocyte size, only one additional telomere-
associated gene was dysregulated as a result of TERT or TRF2 knockdown. The TERT-
siRNA, was found to inhibit both TERT and its substrate TERC. Interestingly, only TERT and 
not TERC knockdown inhibits telomerase activity in breast cancer cells (79), although this 
may not apply to non-cancerous cells (4). Indeed, Terc knockout or haploinsufficiency in 
mice inhibits telomerase activity and predisposes to cardiac hypertrophy to the same extent as 
Tert-/- and Tert+/- mutants (90). Furthermore, both Tert (67) and Terc (14) mRNA are rapidly 
downregulated in the mouse heart in early life, making it difficult to elucidate the effects of 
these genes on cardiac growth and disease. Despite the similar effects of Tert and Terc 
insufficiency, Terc mRNA levels are often not assessed following TERT-siRNA knockdown 
(47, 48, 52, 79), potentially underreporting the significant effects TERT suppression on TERC 
mRNA and its possible role on cell function. In the present study, however, TRF2 
knockdown increased TERT expression and, as a result, when TERT- and TRF2-siRNAs 
were used in conjunction, TERT levels were not different than the scramble control. This 
suggests the stimulatory effects of the TRF2-siRNA on TERT expression cancelled out the 
inhibitory effects of the TERT-siRNA. In contrast to the stable TERT expression in the 
double-knockdown group, TERC remained downregulated, suggesting that changes in TERC 
mRNA levels are not a by-product or compensatory mechanism of decreased TERT in HPCs. 
As such, these findings should be interpreted while considering the potential confounding 
effects of TERC knockdown. 
In humans and other large, long-lived mammals, TERT is located near the telomere, at 
the end of the chromosome 5. As such, cells with relatively long telomeres can form a 
chromatin loop with the TERT locus and repress TERT expression (46). In addition, DNA 
methylation around the TERT region is significantly higher in cells with long telomeres (46). 
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Furthermore, there are almost 3000 interstitial TTAGGG repeats in the human genome (106) 
with several around the TERT gene (46). These combined mechanisms could explain why the 
down regulation of TERT in early passage cells was detrimental as TERT levels may already 
repressed due to relatively long telomeres. Importantly, TRF2 also interacts with interstitial 
TTAGGG repeats (76), and siRNA knockdown of TRF2 has been shown to reduce 
interactions between telomeres and the TERT locus (46). Therefore, the upregulation of TERT 
may be an inevitable consequence of TRF2 insufficiency. Interesting, Trf2 expression is 
increased in cardiac-specific Tert transgenic mice (67) (the opposite relationship observed in 
humans) and rodents lack the telomeric location (41) and interstitial TTAGGG repeats around 
the Tert locus (46). This suggests that TRF2-mediated chromatin looping is an important 
mechanism of TERT regulation in human cells. Like potential off-target effects of TERT 
knockdown, studies have not reported Tert or Terc mRNA or protein levels following TRF2 
knockdown (17, 46, 68, 70) so similar changes may have occurred previously. Indeed, given 
the well-documented increase in TERT and telomerase at the onset of heart disease (50, 82, 
97), the pathogenic effects of TRF2 knockdown may cause a compensatory increase in TERT 
expression. 
As the possibility of telomere-independent effects of, and potential interactions 
between, TERT and TRF2 were anticipated, the telomerase inhibitor BIBR1532 was used to 
and assess the effects of telomere insufficiency without genetic interference. Although 
telomerase inhibition did not change TERT or TRF2 expression, it did cause a significant 
decrease in TERC, TRF1 and TINF2 mRNA levels. Despite an early report suggesting small 
molecule telomerase inhibition did not interfere with chromosomal structure (23), BIBR1532 
can decrease TERT mRNA (28, 47) and TRF2 protein (37) levels, as well increase TRF1 
expression (in contrast to the downregulation of TRF1 observed in the present study) (28). In 
this regard, TRF1 helps maintain cell viability after BIBR1532 treatment (104), highlighting 
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the importance of TRF1, and its interacting factor TINF2, when telomerase activity is 
impaired. All these changes, however, could be due to cell types, dose, or, in some cases, 
treatment duration. Nonetheless, BIBR1532 treatment in HPCs, along with the TERT and 
TRF2 knockdown findings, demonstrate that insufficient telomerase activity, TERT and 
TERC, or TRF2 can induce hypertrophy. Furthermore, as TERT expression was unaltered by 
BIBR1532, TRF2 was unchanged by the TERT-siRNA, and TERC was not affected by TRF2 
knockdown, changes in HPC size can also occur independently of alterations in these genes. 
Interestingly, however, there was at least one downregulated telomeric gene in the presence 
of hypertrophy, suggesting that telomere integrity in general influences cardiomyocyte size. 
This could be due to the complex and precisely regulated interactions that are required for 
successful telomere maintenance (88).  
Changes in chromatin structure can also regulate non-telomeric gene expression in 
muscle cells (76). Indeed, Robin and colleagues found three genes that changed with 
decreases in telomere length and one of these, interferon-stimulated gene 15kd, was on 
chromosome 1p36.22 (76). Interestingly, NPPA and NPPB also occupy this region but their 
expression in relation to telomere length and structure has not been determined. In this 
regard, the decrease in TRF2 may have prevented the interaction of telomeres with these 
genes, explaining, at least in part, the upregulation of NPPA and NPPB following TRF2 
knockdown. Another factor to consider in the context of these findings is that the normal 
suppression of the fetal gene program coincides with the sharp reduction in Tert, Terc and 
telomerase in the perinatal period (19, 96). Although telomere length was unchanged 
following 48 hours of inhibiting telomere maintenance, it is reasonable to assume that the 
HPCs used in the present study have shorter telomeres than fetal cardiomyocytes (94, 96). 
Moreover, if chromosome looping can interact with NPPA and NPPB then these genes may 
be more susceptible to re-expression in cells with defective TRF2 or short telomeres. 
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Therefore, the transcription of NPPA and NPPB in the presence of short telomeres and other 
epigenetic changes associated with aging could explain why these genes are maladaptive 
upon adult re-expression.  
In addition to the upregulation of fetal genes, there was also a decrease in MAPK1 
expression, a gene associated with adaptive cardiac growth (21), in all treatment groups. 
Importantly, MAPK signalling pathways can protect cardiomyocytes (32, 83) and other cells 
(71) from apoptosis in vitro. As a decrease in MAPK1 mRNA levels was consistent across all 
treatment groups, this suggests there may be a link between telomere maintenance and 
MAPK1 in HPCs. Interestingly, estrogen-induced transcription of telomerase is mediated 
through MAPK signalling pathways (111). In addition, MAPK1 expression is associated with 
the differential expression of microRNAs determined by TERT genotype in colon cancer 
(86). Furthermore, MAPK1 was upregulated in agonist-treated groups in the previous 
Chapter, along with increased TERC mRNA levels. Taken together, these findings suggest 
that telomere maintenance could influence MAPK signalling and hence whether cardiac 
growth is adaptive or harmful.  
Another consistent feature of cardiomyocyte hypertrophy observed in this Chapter 
was a decrease in HPC proliferation. Similarly, previous research has shown that 
cardiomyocyte size is inversely correlated with proliferative ability and telomere length (78) 
– both of which can be caused by TERT-siRNA (52), TRF2-siRNA (70), or BIBR1532 (47) 
treatment. Furthermore, the decrease in proliferation shortly after birth is believed to be the 
mechanism responsible for restricting the majority of cardiac growth throughout life to 
hypertrophy (92). In this regard, adult cardiomyocytes may retain this signalling mechanism 
which would explain the increase in cell size detected in these treatment groups. In addition 
to decreasing proliferation, inhibiting TERT or telomerase seems to have an overall inhibitory 
effect on cells. Indeed, there were no stimulatory effects on any of the genes measured as a 
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result of BIBR1532 treatment, with similar findings in the TERT-siRNA group. In previous 
studies, siRNA inhibition of TERT (34) and treatment with BIBR1532 (84) has been shown 
to increase the cardiotoxicity of doxorubicin as well as other chemotherapy agents (62, 100). 
Similarly, wild type mice, if supplied with running wheels, are immune from the apoptotic 
effects of doxorubicin but Terc-/- mice are not (185). Despite the decrease in proliferation and 
expression of some protective genes, however, there were no signs of apoptosis as a result of 
TERT knockdown or telomerase inhibition with BIBR1532 in HPCs. Importantly, like the 
telomere shortening observed following ten days of BIBR1532 treatment, apoptosis is also an 
inevitable consequence of insufficient telomere maintenance (13, 16) and hence would occur 
with longer treatments.  
Unlike the acute knockdown of TERT or suppression of telomerase activity, the 
TRF2-siRNA induced apoptosis in HPCs after only 48 hours of treatment. This is consistent 
with the effects of TRF2 knockdown in renal carcinoma cells (70) and could be considered a 
result of chromosomal instability that accompanies TRF2 insufficiency and not necessarily 
short telomere length (57). For instance, enhanced TRF2 protein levels but not alterations in 
telomere length are associated with endothelial cell viability (89). In addition, long telomeres 
lacking TRF2 can still signal apoptosis, probably due to resembling damaged DNA (56) and 
it has been suggested that this may occur in cardiomyocytes (68). Interestingly, oxidative 
stress and inflammation, two established causes of cardiomyocyte apoptosis (60, 99), were 
both observed in the TRF2-siRNA group only. In this regard, TRF2 protein levels increase 
(and telomeres shorten) in response to oxidative stress in mouse skeletal muscle (53), 
suggesting that cells lacking TRF2 are less equipped to counteract normal levels of 
endogenous oxidative stress. Similarly, loss of TRF2 induces inflammation in arteries (64) 
which can lead to DNA damage and senescence associated inflammatory cytokine secretion 
(77) and Trf2 deficiency in mouse embryos causes inflammation and apoptosis (57). These 
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findings highlight the ability of short-term TRF2 knockdown in HPCs to simulate many of 
the molecular and cellular characteristics of pathological cardiac hypertrophy and hence its 
potential utility as a model of human cardiac disease.  
The present study also had some limitations which could be addressed with future 
research. Firstly, more time points could be used to assess possible transient changes in gene 
expression (24) and if other factors, such as decreased proliferation, precede increases in cell 
size. Secondly, telomere length measurements using quantitative fluorescent in situ 
hybridisation or a similar technique could further elucidate the role of telomeres in the 
development of cardiac hypertrophy by providing more sensitive and cell-specific 
measurements of telomere length (37). This could also be used to correlate telomere length 
and proliferation with cardiomyocyte size in individual cells (78). Further to this, markers of 
cytokinesis could be used to more accurately measure proliferation as Ki67 is also associated 
with changes in DNA content that may not result in cell division (98). In addition, the 
potential ability of TRF2, telomerase activity, and telomere length to regulate cell-specific 
genes is an important area for future research. Indeed, it would be useful to determine the 
mechanism through which TRF2 knockdown induced NPPA and NPPB expression. It also 
needs to be noted that all cells used in this study came from one individual and are not true 
primary cardiomyocytes but rather a population of replicating cardiac progenitor cells. As 
such, these findings need to be validated in other models. 
In conclusion, the findings of the present study demonstrate that disruptions in 
telomere maintenance are sufficient to induce cardiomyocyte hypertrophy independently of 
changes telomere length. Given the presence of short telomeres and cardiac hypertrophy in 
diabetes, smoking, alcoholism, chemotherapy treatment, and other risk factors for heart 
failure (18), inhibiting telomere maintenance could be a useful model of cardiac hypertrophy 
and early stage heart disease. TERT-siRNA and BIBR1532 may have contributed to HPC 
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hypertrophy through decreasing proliferation whereas TRF2-siRNA could have additional 
mechanisms such as increased NPPA and NPPB, oxidative stress, and apoptosis. The role of 
TRF2 in maintaining telomere loops suggests an important function for telomere structure in 
regulating cardiomyocyte size and hypertrophic gene expression. This study provides new 
evidence and elucidates the role telomeres can play in the development of cardiac 
hypertrophy and hence heart failure.  
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Recap and summary 
As discussed in Chapter 1, there are currently no effective strategies to prevent the 
degenerative cardiomyocyte loss that leads to heart failure (34, 82). Association studies have 
shown that short telomere length (TL) is a molecular feature of heart failure (14, 53) but the 
contribution of telomere insufficiency in the pathogenesis of this disease is unknown. In this 
regard, cardiac hypertrophy precedes heart failure (35, 54) and is also associated with 
changes in cardiomyocyte TL (52, 63) and maintenance (65, 73). Therefore, telomeric 
aberrations in cardiac hypertrophy could explain the cell loss that is characteristic of 
subsequent heart failure as well as identify therapeutic targets and guide preventative 
interventions. As such, the overall aim of this thesis was to determine the role of telomeres in 
the development of cardiac hypertrophy using a combination of in vivo and in vitro models. 
 To formally test the possibility of a causal role for telomeres in the development of 
cardiac hypertrophy, it was hypothesised that decreases in TL and/or maintenance would 
increase cardiomyocyte size. In Chapters 2 and 3, polygenic and environmental rat models of 
cardiac hypertrophy were used, respectively. In Chapters 4 and 5, human primary 
cardiomyocytes (HPCs) were grown in vitro and treated with hypertrophic agonists or 
inhibitors of telomere maintenance. Although these research designs differ, Tert, Terc, and 
Ppp1r10 (also known, and hereafter referred to, as Pnuts) mRNA levels, TL, as well as 
measures of cardiac or cardiomyocyte hypertrophy were determined in all these Chapters. 
These results are summarised in Figure 1 and then discussed in more detail below, along with 
other key findings from this Thesis.  
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Figure 1. A summary of comparable findings between Chapters. Tert was upregulated at 2 days but reduced at 4 weeks of age along with 
telomere length, Terc, and Pnuts. Reduced rats had increased Tert expression relative to Control rats, Pnuts was increased in Restricted rats but 
there were no changes in Terc mRNA levels in either group (not shown). Adrenergic and endothelin receptor activation in HPCs increased TERC 
mRNA levels, which paralleled increases in cell size, but had no effect on TERT or PNUTS expression. Inhibiting telomere maintenance in HPCs 
involved changes in TERT and TERC but not PNUTS expression although hypertrophy also occurred without the involvement of these genes. 
Telomere length in the HHR was longer at 2 days but shorter by 13 weeks of age. Telomeres were shorter in Restricted rats but longer after early 
exercise treatment in all groups.  ET-1 reduced cardiomyocyte telomere length after 48 hours, 10 days, and 16 days of treatment. BIBR1532 
shortened HPC telomeres after 10 days. Cardiac hypertrophy occurred in the HHR by 13 weeks of age. Unlike previous cohorts, Restricted and 
Reduced rats did not present with cardiac hypertrophy, although exercise increased cardiac weight index in all groups. Endothelin and adrenergic 
receptor activation, TERT-siRNA and TRF2-siRNA knockdown, and inhibiting telomerase with BIBR1532 induced HPC hypertrophy. *with the 
exception of adrenaline treatment. AR, adrenergic receptor; BIBR1532, 2-((E)-3-naphthalen-2-yl-but-2-enoylamino)-benzoic acid; ET-1, 
endothelin-1; HHR, hypertrophic heart rat; HPCs, human primary cardiomyocytes; Pnuts, protein phosphatase 1 regulatory subunit 10. 
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Cardiac telomeres in rat models of human disease 
In Chapter 2, cardiac and cardiomyocyte TL was determined in the hypertrophic heart rat 
(HHR) before, during, and after the development of cardiac hypertrophy. This work revealed 
vastly different patterns of telomere attrition and telomeric gene regulation between the HHR 
and its control strain. In the HHR, cardiac TL was longer at birth and 38 weeks of age but 
shorter at 13 weeks of age (the onset of cardiac hypertrophy). Somewhat surprisingly, there 
was no difference in cardiac TL at 52 weeks of age, around the time the HHR suffers from 
heart failure (57). Importantly, telomere shortening paralleled increases in cardiac weight 
index (CWI) in both strains, providing some evidence in support of the hypothesis that 
telomere attrition increases cardiac mass. As both cardiac growth (25, 50) and telomere 
shortening (9, 42) are normal features of aging, however, these findings do not preclude a 
consequential or confounding role for telomeres in the development of cardiac hypertrophy.  
One limitation of many studies on telomeres in heart disease is the use of circulating 
leukocyte TL as it may not reflect cardiac TL (23) or contribute to the pathogenesis of heart 
failure (64). To address this, Chapter 2 determined TL in circulating leukocytes at the onset 
of cardiac hypertrophy and in the presence of shorter cardiac TL (13 weeks of age). In 
accordance with the heart, leukocyte TL was shorter in the HHR and there was significant 
correlation between these two variables. In the NHR, however, leukocyte TL was not 
significantly correlated with cardiac TL, demonstrating that leukocyte telomere length is not 
always representative of the heart. Indeed, previous studies have reported significantly longer 
leukocyte telomeres in the presence of cardiac hypertrophy (37, 76) in contrast to the short 
leukocyte telomeres found in heart failure (75). While this could be due, at least in part, to 
physiological cardiac hypertrophy, which is associated with longer telomeres (46), or the 
upregulation of TERT that has been found in early-stage heart failure (65, 73), it is also 
possible that TL was shorter in hypertrophic hearts and that this was not reflected in 
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leukocytes. Furthermore, if short telomeres determine disease phenotypes as suggested (69), 
then leukocyte TL is unlikely to be a useful biomarker as it would not be detectable in the 
early and reversible stages of disease. In this regard, a telomeric variable such as Tert 
(discussed below) could be a more useful target for disease identification and prevention.    
Following on from the investigation into polygenic cardiac hypertrophy, the aim of 
Chapter 3 was to determine if changes in cardiac telomeres were present in an environmental 
model of cardiac hypertrophy caused by growth restriction in early life. Unlike previous 
research using Restricted and Reduced rats (78), cardiac hypertrophy was not present at 24 
weeks of age in the cohorts used in this Chapter. While this prevented the testing of the main 
hypothesis of this Thesis, it did not preclude the investigation of growth-restriction and 
exercise effects on cardiac telomeres. Indeed, a major finding of Chapter 3 was that 
Restricted rats had shorter cardiac telomeres than Reduced and Control rats in all exercise 
groups. Furthermore, cardiac telomere length was positively correlated with body weight and 
heart weight but not CWI. Interestingly, the HHR is also born small and remains lighter 
throughout life, suggesting low bodyweight could influence cardiac TL. If longer cardiac 
telomeres were detected in other low birthweight individuals this would favour the suggestion 
put forth in Chapter 2 that fewer cardiomyocyte divisions in early life delays cardiac growth, 
prevents proper maturation of the heart, and predisposes to cardiac hypertrophy in later life. 
This would be interesting to determine as long cardiac telomeres at birth may be a genetic 
trait of the HHR that is unrelated to the development of cardiac hypertrophy.  
Significant evidence is accumulating that highlights the effects of adverse events in 
early life on adult TL and disease risk. For instance, recent meta-analyses have demonstrated 
that stress (18), separation (40), abuse, neglect, and other traumas (62) in childhood are 
associated with short leukocyte telomere length in adulthood. In addition to expanding this 
phenomenon to telomeres in the heart, Chapter 3 demonstrated that exercise training in 
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adolescence can attenuate the cardiac telomere shortening caused by fetal growth restriction. 
Although the importance of genetic predisposition or early environmental effects on later 
cardiac disease is becoming obvious, the relevance of animal models needs to be continually 
validated to ensure studies are representative of human disease. The absence of cardiac 
hypertrophy in Restricted and Reduced rats demonstrates that animal models do not always 
present with the same characteristics across cohorts. Nonetheless, early exercise training 
attenuated cardiac telomere attrition even in normal birth weight Reduced and Control rats, 
highlighting the potential of exercise treatment in the prevention of heart failure.  
Levels of the proapoptotic and hypertrophic miR-34a were assessed in Chapter 2 and 
found to be significantly overexpressed in the HHR in early life only. As such, miR-34a 
expression was not determined in the 24-week old Restricted and Reduced rats used in 
Chapter 3. However, Trf2, Pnuts, and Sirt1 were all positively correlated with one another, 
suggesting that they may be controlled by a master regulatory agent such as miR34a. In 
support of this suggestion, these genes are all direct or indirect targets of miR-34a (10, 80). In 
Chapter 2, however, Pnuts was only weakly correlated with miR-34a expression at any of the 
ages and neither Pnuts or Sirt1 were found to reflect changes in telomere length or 
cardiomyocyte/cardiac size in any of the Studies in this Thesis. An important factor to 
consider, however, is that telomeric genes (13) and miR-34a expression (21) are transiently 
upregulated shortly after exercise and thus may not be dysregulated under normal conditions. 
With this in mind, the anti-hypertrophic and cardio-protective effects of miR-34a inhibition 
in mice (10, 21) may also maintain cardiac function in humans. 
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Telomeres in human and rat in vitro models of cardiac hypertrophy  
Given the recent evidence of differences in telomere regulation between species (36) and the 
absence of cardiac hypertrophy in Restricted and Reduced rats, Chapter 4 of this Thesis 
focused on adult human primary cardiomyocytes (HPCs) in vitro. The common rat 
embryonic cardiomyoblast (H9c2) cell line was also used for comparison. Both HPCs and 
H9c2 cells were treated with the hypertrophic agonists adrenaline (Adren), angiotensin-II 
(Ang II), endothelin-1 (ET-1), isoproterenol (ISO), and phenylephrine (PE) to induce 
hypertrophy. All five agonists significantly increased HPC and H9c2 cell size, however only 
two out of eight selected genes that showed patterns of differential expression in the HPCs 
were detected in H9c2 cells (IL-6 and Mi67, markers of inflammation and proliferation, 
respectively). This further demonstrates that key differences exist between primary and 
immortalised, human and rat, and/or adult and embryonic cell types. Interestingly, in both 
HPCs and H9c2 cells, there were no differences in TERT mRNA levels and, with the 
exception of ISO-treated HPCs, very few alterations in the genes encoding the protective 
(shelterin) proteins. This demonstrates that changes in telomere length or telomeric gene 
expression are not required for cardiomyocyte hypertrophy. Another key finding of Chapter 4 
was the reduction in TL after only 48 hours of ET-1 treatment. Follow up research confirmed 
that ET-1 shortened HPC telomeres in a time dependent manner, highlighting a novel 
pathophysiological role in the heart that is independent of the vasoconstrictive and 
hypertensive effects of this agonist.  
In Chapter 5, HPCs were grown in vitro and treated with TERT- and TRF2-siRNAs 
and the small molecule telomerase inhibitor BIBR1532 to determine if aberrations in 
telomere maintenance could induce hypertrophy (the inverse design of Chapter 4). 
Interestingly, all three of these treatments significantly increased HPC size, demonstrating 
that inhibiting telomere maintenance is sufficient to cause cardiomyocyte growth, 
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independently of changes in TL. Although cell-specific and non-telomeric functions have 
been reported for TERT, telomerase (15), and TRF2 (36), this is the first research to 
demonstrate that these telomeric regulators may have hypertrophic roles in human 
cardiomyocytes. Consistent with the stable TLs in hypertrophic HPCs, Terai and colleagues 
found only a 3bp decrease in TL with each one gram increase in heart weight (70). In this 
regard, if cardiac hypertrophy is viewed as an asymptomatic and reversible condition in its 
early stages (24, 25), then the suggestion that telomere shortening determines disease is not 
contradicted by these findings. Indeed, telomere shortening is a necessary consequence of 
insufficient telomere maintenance (2, 8). Furthermore, a causal role for telomerase and/or 
TRF2 in the development of cardiac hypertrophy could potentially be used to identify and 
treat cardiac hypertrophy before the onset of heart failure and telomere shortening. As the 
preservation of telomeres is a necessary step in oncogenic transformation (9), such treatments 
would have to be targeted specifically to cardiomyocytes to avoid an increased risk of cancer.  
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Telomeric regulators as hypertrophic and cardiac risk factors 
When the findings of Chapter 2 are considered from the perspective of telomere regulation 
and not length, the rapid decrease in telomerase activity in the HHR early in life also offers 
an explanation for the development of cardiac hypertrophy in this model. Similarly, TERT 
knockdown HPC hypertrophy in Chapter 5. Cardiac and cardiomyocyte hypertrophy, 
however, was also associated with increased TERT expression in both the HHR and HPCs. 
This is consistent with the literature, where studies have found that mice lacking (39) or 
overexpressing (5, 52) Tert develop cardiac hypertrophy. In addition to fluctuations in TERT, 
significant increases and decreases in TERC were also detected in hypertrophic hearts or 
cardiomyocytes in this Thesis. Moreover, Trf2 expression is increased in cardiac-specific Tert 
transgenic mice (52) which is the opposite of what was observed in the HPCs. Therefore, 
despite the importance in TERT, TERC, and TRF2 in maintaining cardiac size, hypertrophy 
can occur in the presence of increased, decrease or stable levels of these genes (Table 1). This 
suggests that there is more than one telomeric pathway that can influence cardiomyocyte size 
in both rodents and humans. In this regard, these findings also demonstrate that changes in 
telomeric gene expression are sufficient but not necessary for the development of cardiac 
hypertrophy in rodents and humans. Although this does not take into account the enzymatic 
activity of TERT and TRF2, short telomere length is the inevitable consequence of 
insufficient telomere maintenance, even at the level of gene expression (2, 8). Therefore, this 
still has important consequences as short telomere length is a universal feature of poor 
cardiac health (14, 27, 53).  
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Table 1. Cardiac TERT, TERC, and TRF2 mRNA levels in models of cardiac 
hypertrophy.  
Model/treatment Cardiac TERT Cardiac TERC Cardiac TRF2 
HHRs* Unchanged Unchanged Not determined 
Tert and Terc-/- mice Absent Absent Not determined 
Tert and Terc+/- mice Decreased Decreased Not determined 
Tert transgenic mice Increased Not determined Increased 
Agonist-treated HPCs# Unchanged Increased Unchanged 
TERT-siRNA HPCs# Decreased Decreased Unchanged 
TRF2-siRNA HPCs# Increased Unchanged Decreased 
TERT- and TRF2-siRNA HPCs# Unchanged Decreased Decreased 
BIBR1532 HPCs# Unchanged Decreased Unchanged 
*at the onset of hypertrophy (13-weeks of age). #after 48 hours of treatment. HHRs, 
hypertrophic heart rats; HPCs, human primary cardiomyocytes; Tert, telomerase reverse 
transcriptase; Terc, telomerase RNA component; Trf2, telomere repeat-binding factor 2; 
BIBR1532, 2-((E)-3-naphthalen-2-yl-but-2-enoylamino)-benzoic acid. 
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Like telomeric gene expression, significant increases as well as decreases in 
cardiomyocyte proliferation were detected in the presence of hypertrophy. It should be noted 
that proliferation was measured using Ki67 antigen expression (as performed previously (7, 
43)), which is also associated with changes in cardiomyocyte ploidy and not necessarily 
completed cell division (74). Interestingly, however, there were clear trends within groups 
with all agonist treatments increasing proliferation (Chapter 4) and all telomere-inhibiting 
treatments decreasing proliferation (Chapter 5). As cardiomyocyte proliferation is the driving 
feature of cardiac repair (58, 59), inhibiting telomere maintenance may better reflect the 
phenotype of pathological cardiac hypertrophy that leads to degenerative heart failure. 
Furthermore, inhibiting telomere maintenance, particularly with TRF2 knockdown, caused a 
much greater increase in HPC size than any of the agonists (~3 compared to ~1.5-fold, 
respectively). As only small cardiomyocytes are capable of undergoing replication in both 
human and animals (14, 39, 72), greater increases in cell size may lead to decreased 
proliferation. Moreover, as increased proliferation decreases human cardiomyocyte TL (6) 
agonist stimulation could cause telomeres to shorten through repeated cell divisions. This is 
one possible explanation of the early events leading to the telomere attrition and replicative 
senescence characteristic of heart failure (14, 53, 63, 71). In this regard, Restricted rats 
(Chapter3) have upregulated expression of the angiotensin-II type 1 receptor (AT1) (78) 
which may also be involved in the pathophysiology of cardiac telomere attrition following 
growth restriction. Similarly, the decrease in telomere length, Tert, and Pnuts expression 
observed in young HHRs (Chapter 2) may reduce cardiomyocyte proliferative ability and 
predispose to cardiac hypertrophy.  
Corresponding to changes in proliferation, mRNA levels of the cardioprotective gene 
mitogen activated protein kinase 1 (MAPK1) were also higher in all agonist-treated HPCs 
(Chapter 4) and downregulated after inhibiting telomere maintenance (Chapter 5). 
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Interestingly, research suggests MAPK1 may also be involved in telomere maintenance. For 
instance, estrogen can stimulate telomerase activity through mitogen activated protein kinase 
(MAPK) pathways (84) and MAPK1 expression in colon cancer is associated with TERT 
genotype (67). Similarly, decreased Mapk1 expression from siRNA knockdown decreased 
proliferation in H9c2 cells (83), potentially predisposing to hypertrophy. In regard to heart 
function, Mapk1 overexpression in mice leads to cardiac hypertrophy while 
haploinsufficiency or knockout of Mapk1 decreases cardiac performance (60). As with 
telomerase insufficiency in mice, cardiac-specific inhibition of Mapk1 is required to rule out 
potential confounding effects of systemic gene deletion. In contrast to some telomeric 
proteins, evidence suggests that the function of MAPK1 is evolutionarily conserved. For 
instance, specific Thr188 phosphorylation of MAPK1 has been detected in hypertrophic and 
failing human hearts (44) and mutations at these sites in mice prevented the development of 
cardiac hypertrophy (44). Findings from the HPCs in Chapters 4 and 5 also suggest a 
dynamic role for MAPK1 in the development of human cardiac hypertrophy but the 
mechanisms involved are beyond the scope of this Thesis. Nonetheless, the decrease in 
MAPK1 expression, in addition to the pronounced hypertrophy and decreased proliferation, 
further suggests that inhibiting telomere maintenance better reflects the molecular phenotype 
of pathological cardiac hypertrophy than agonist stimulation (Figure 2).  
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Figure 2. Telomere inhibition induces a more pathological phenotype overall than 
agonist stimulation. *TRF2 knockdown only. **with the exception of ET-1. 
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Another key finding of Chapter 5 was the increase in the fetal genes and markers of 
heart failure NPPA and NPPB caused by TRF2 knockdown. This could be due to a decrease 
in chromatin looping with 1p36.22 locus where these genes are located. For instance, cells 
with long telomeres can regulate the expression of genes positioned near the ends of 
chromosomes, including the 1p36.22 locus (36). Importantly, TRF2 is crucial in facilitating 
these interactions by maintaining telomere structure and interacting with TTAGGG repeats 
throughout the genome (36). Although no changes in NPPA or NPPB were detected after 
telomerase inhibition in HPCs, previous research has indicated that telomerase may also be 
able to regulate hypertrophic gene expression. For instance, endothelin-converting enzyme 
(ECE-1) mRNA expression and circulating ET-1 levels are higher in telomerase-deficient 
mice, which is considered the cause of hypertension in these animals (55). Interestingly, 
significant decreases in TL occur only after the development of hypertension in 
spontaneously hypertensive mice (16), further suggesting a role for telomere maintenance and 
not length in disease onset. Taken together these findings demonstrate that telomeric factors 
can regulate hypertrophic genes and that loss of telomere function could directly influence 
the pathogenesis of cardiac hypertrophy.  
Although fetal genes are still considered key biomarkers of pathological cardiac 
hypertrophy and heart failure (17), inflammatory markers were the most dysregulated genes 
detected in explanted human hearts (12). Indeed, interleukin-6 (IL6) and interleukin-1β (IL-
1β) were upregulated 11.54- and 8.23-fold, respectively while NPPA or NPPB were not listed 
as having a fold change >1.8. Other studies have also demonstrated that NPPA and NPPB 
expression in adulthood does not always reflect pathological cardiac hypertrophy (1, 66, 79). 
In this regard, the agonist-treated cells (Chapter 4) accurately modelled pathological cardiac 
hypertrophy, causing the upregulation of at least one inflammatory marker in all groups. 
Furthermore, inflammation can illicit reactive oxygen species (ROS) production (30) a potent 
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cause of telomere attrition (19) and cardiomyocyte apoptosis (77). In this regard, ROS was 
only induced by Ang II, ET-1, TRF2-siRNA treatments, all of which caused (or, in the case 
of Ang-II, are known to cause (20)) profound, age-associated changes in cardiomyocytes. 
Interestingly, ROS activity is also increased in cultured embryonic Terc-/- deficient cells, but 
treatment with antioxidants can reduce ECE-1 promoter activity, potentially preventing the 
short-term consequences of telomerase insufficiency (55). Taken together, these findings 
demonstrate that, in addition to telomere shortening and cardiomyocyte apoptosis, ROS may 
be linked to hypertrophic gene expression and thereby contribute to the development of 
cardiac hypertrophy.  
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Future research 
Animal models 
There are several questions raised from the findings of this thesis which could be addressed 
in future studies. Firstly, Trf2 levels, along with other important regulators of TL, such as 
inflammation (33, 41, 49) and oxidative stress (45, 77), could be determined in HHR and 
other animal models to elucidate the interactions between hypertrophic and telomeric risk 
factors. Secondly, determining the efficacy of interventions to reduce the severity of genetic 
predispositions or environmental insults to disease, is an important area of future research. In 
this regard, exercise treatments could be performed on the HHR as well as dietary 
interventions, such as calorie restriction and antioxidant treatment, which have all 
demonstrated utility in preserving telomeres, heart function, and longevity (29, 47, 48). 
Thirdly, cardiac telomeres could be measured in young animals predisposed to disease, such 
as Restricted rats, to determine if they suffer from rapid telomere attrition during early life or 
in utero and if this is involved in the pathogenesis of heart disease. To confirm this, it would 
also be necessary to house a subset of animals until death and perform post-mortem 
examinations to ensure the disease being studied is accurately reflected in the model. In this 
regard, the differences in telomeres and heart function between animals and humans should 
be carefully considered when designing future studies. 
Human in vitro models  
To elucidate the pathophysiology of human cardiomyocyte growth, more timepoints during 
the development hypertrophy are required. For instance, the 48-hour treatments used in 
Chapters 4 and 5 could have missed transient changes in gene expression, particularly genes 
involved in telomere maintenance (13) and the hypertrophic response (32). Earlier 
timepoints, such as 6-hours after treatment, would minimise this possibility as well as 
investigate if the changes in proliferation, inflammation, TERC or MAPK1 expression 
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reported in Chapters 4 and 5 occur before or after increases in cell size. Similarly, longer 
treatments lasting several days or weeks could be performed to determine when significant 
telomere shortening occurs after the development of hypertrophy. In this regard, the 
increasingly-available CRISPR-Cas9 technology could be used to create useful models of 
telomere insufficiency and thus cardiac hypertrophy in vitro. As ET-1 is produced by 
cardiomyocytes (81) and upregulated in Terc-/- mice (55), ET-1 levels could be determined in 
human models of telomere insufficiency in search for hypertrophic pathways common to 
agonist stimulation and telomere maintenance. In contrast, it would also be useful to 
determine the effects of cardiomyocyte-specific TRF2 overexpression in human cells and if 
this could rescue or prevent hypertrophy. Results from this Thesis have also provided the 
foundation and rationale to pursue more detailed analyses on factors implicated in changes to 
HPC size, such as specific phosphorylation of MAPKs. 
Given the inconsistent changes in TERT, TERC, and TRF2 expression (Table 1) in the 
presence of hypertrophy, future studies could search for novel telomeric factors whose 
expression reliably reflects cell size. One such factor could be Telomere Repeat-Containing 
RNA (TERRA), a long noncoding RNA transcribed from subtelomeric promoters. In support 
of this suggestion, TERRA has been shown to directly interact with TRF2 (22), inhibit 
telomerase (61), facilitate telomere looping, and regulate gene expression (36). Furthermore, 
TERRA levels are cell-specific (68) but have not been assessed in cardiomyocytes. As such, I 
also treated the HPCs in Chapter 5 with a custom TERRA-siRNA but this was defective and 
hence had to be excluded. Nonetheless, as findings from this Thesis suggest that aberrations 
in telomere maintenance are sufficient for the development of HPC hypertrophy, the role of 
other telomeric regulators, such as TERRA telomere repeat-binding factor 1 (TRF1), or 
tripeptidyl-peptidase 1 (TPP1), in regulating human cardiomyocyte size could be addressed in 
future knockdown or overexpression studies. As cardiac hypertrophy can occur in response to 
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hypertension, atherosclerosis, and aortic stenosis (35), elucidating the regulation of 
cardiomyocyte telomeres could provide insights into the development of heart disease more 
generally. 
Methodological considerations 
The use of different methods to measure TL could be necessary in the study of cardiac 
hypertrophy and the testing of causal hypotheses. For instance, Flow fluorescent in situ 
hybridization (Flow FISH) uses labelled peptide nucleic acid (PNA) probes specific for 
telomere repeats and fluorescence generated by flow cytometry (4). The benefits of Flow 
FISH for the measurement of telomeres in cardiomyocytes is that cell size is also determined 
allowing for telomere length to be quantified in subsets of cells of based on size. 
Furthermore, these single-cell measurements provide a population distribution rather than a 
measure of the average TL for the population, like the T/S ratio method used in this Thesis 
(11). A population distribution allows for the quantification of short telomeres and minimises 
the possibility of type 2 errors if changes in TL are present only in a subset of cells (4). Given 
these benefits, Flow FISH was used in Chapter 4 to determine TL in HPCs with untreated 
H9c2 cells as the internal controls. Unfortunately, the H9c2 cell line was not a suitable 
internal control due to the difference in DNA content between rat and human 
cardiomyocytes. As the recommended internal cell line control was not available due the high 
cost, this method had to be abandoned. 
Telomere-specific PNA probes are also used for quantitative fluorescent in situ 
hybridization FISH (qFISH) with confocal microscopy (3). Although Flow FISH is highly 
quantitative and prevents biased sampling, qFISH is considered more sensitive to detect small 
changes in TL (26, 31) which could be particularly useful in short-term studies where 
changes in TL are likely to be small. Furthermore, other cell-specific variables, such as 
surface area (cell size) and proliferative ability, can be detected in conjunction with TL (63), 
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providing insights into the relationships between telomeres and other cardiac risk factors. As 
such, Chapter 5 also used qFISH to determine TL in HPCs but the transfer of adherent cells 
to appropriate slides and obtaining sufficient number of metaphase spreads required for 
analysis was not possible with the available resources. Indeed, cells with low mitotic indices 
may not be amenable to the qFISH method (3) and other studies have reported significant 
reductions in the number of metaphase spreads following BIBR1532 treatment even in 
rapidly dividing cancer cells (26). Furthermore, inducing mitosis and metaphase arrest can 
potentially confound experimental treatments as well as bias the results if senescent cells are 
excluded from analysis (38, 56). Similarly, Flow FISH requires cells to be grown in 
suspension and in the present Thesis all in vitro experiments were performed using adherent 
cells. In this regard, adherent cells may grow and respond differently to treatments, making it 
difficult to compare findings from adherent cells. The T/S ratio method, however, does not 
require additional treatments or specific cell preparations and has been shown to strongly and 
reliably correlate with TL measurement generated from qFISH (51) and Flow FISH (28).  
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Conclusions 
The Studies undertaken in this Thesis provide new evidence implicating telomeres in the 
development of cardiac hypertrophy. Decreases in Tert expression and telomere length in the 
heart were found to parallel the development of cardiac hypertrophy in the HHR. TL in 
circulating leukocytes was also shown to strongly correlate with cardiac TL but only in 
hypertrophic rat hearts. In addition to the well-established propensity to heart disease, fetal 
growth restriction and low birthweight reduced cardiac TL in later life in rats. The ability of 
short-term exercise interventions in adolescence to attenuate cardiac telomere attrition in 
older rats highlights new ways of approaching cardiac aging and disease prevention. 
 Of all the methods of inducing hypertrophy in HPCs, only ET-1 shortened HPC 
telomeres, highlighting a novel role for this agonist in human cardiomyocyte aging. 
Interestingly, inhibiting telomere maintenance had an even more severe effect on HPC 
hypertrophy than agonist stimulation. In particular, TRF2 knockdown induced a molecular 
and cellular phenotype that closely reflected changes observed in human heart failure (17, 
53). In conclusion, the findings from this Thesis suggest an important role for the structure 
and maintenance of telomeres in regulating cardiomyocyte growth, paving the way for further 
research in this promising field.  
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